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Summary of the Thesis 
 
 
Neurostimulation in the form of sacral nerve stimulation has been used in the treatment of 
bowel dysfunction since the past 17-18 years. However, our knowledge on the alternative 
forms of neurostimulation such as pudendal nerve stimulation and posterior tibial nerve 
stimulation are limited. In addition, there exist several patient groups where sacral nerve 
stimulation is not effective. This thesis incorporates a series of studies done with the aim 
of expanding our existing knowledge on neurostimulation as well as exploring alternate 
forms of neurostimulation in treating bowel dysfunction.  
 
The role of pudendal nerve stimulation in faecal incontinence and the steps in the 
development of a new technique including cadaveric dissection, for stimulating the 
pudendal nerve are discussed. The new technique developed is subsequently used to 
successfully stimulate the pudendal nerve in two specific subgroups of patients where 
sacral nerve stimulation has not been effective in: patients with complete cauda equina 
syndrome and those who failed to improve with sacral nerve stimulation. 
 
The thesis explores additional routes of neurostimulation using the posterior tibial nerve 
and discusses the findings of a single blinded randomised placebo controlled clinical trial 
of percutaneous, transcutaneous and sham posterior tibial nerve stimulation in a group of 
faecal incontinent patients. 
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Our knowledge on the effects of sacral nerve stimulation in constipation is relatively new. 
The results of a double blinded crossover study of sacral nerve stimulation in constipation 
sheds more light on the possible actions and effects of sacral nerve stimulation in this 
group of patients. 
 
The effects of sacral nerve stimulation in the elderly is discussed in the subsequent 
chapter through the presentation of the findings of a single center retrospective analysis 
on the safety and long term efficacy of sacral nerve stimulation in the elderly subgroup. 
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Chapter 1 
 
Faecal Incontinence 
 
1.1 - Introduction 
 
1.1.1 - Definition of Faecal Incontinence 
 
The International Consultation on Incontinence (1) defines faecal incontinence (FI) to be 
the involuntary loss of liquid or solid stool that causes a social or hygienic problem and 
anal incontinence to additionally include the loss of flatus.  
 
1.1.2 - Historical References and Backdating the Problem 
No data are available regarding the first description of FI whereas the first description of 
constipation and urine incontinence dates back to 1550 BC in the George Ebers 
Papyrus(2). 
The Egyptians record the need to regularly cleanse the intestinal tract to maintain 
health. Early Egyptian surgeons placed great value on hygiene and personal 
cleanliness and the anus was a prime target for medical treatment as it was the meeting 
point of different channels or ‘metu’ carrying urine, sperm and faeces. Treatments 
favoured by the Egyptians to cleanse the anus included purges, enemas and emetics. 
Though there were several hundreds of physicians in the Egyptian courts 
subspecialisation of medicine led to the king having a prominent physician royally titled 
as the “Shepherd of the anus of the Pharaoh” (3) or the “the keeper of the royal anus” 
(4) -probably, the first evidence of the Coloproctology subspecialisation.  
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There are random references to FI throughout history with the risks of vaginal delivery 
and complications of sphincter damage being mentioned during the time of the 
Romans(5).The first formal report of anal sphincter repair was in 1957(6) though brief 
mentions of surgical attempts of anal sphincter repairs go back to the late 1800’s. 
 
1.1.3 - Incidence of the Problem 
 
FI today continues to remain as a ‘silent affliction’ although awareness about the 
condition has improved along with the treatment options available. While the prevalence 
of faecal incontinence is estimated to be 2-10% of the general population, the real 
magnitude of the problem is difficult to determine because many affected persons do 
not voluntarily report their symptoms (7-10). FI occurs more frequently in the elderly 
affecting up to 10% of people over the age of 65 years living at home and 
approximately 50% of nursing home residents over 65 years (11).  
People with FI live in a confined world with restricted social contact and poor quality of life 
and often describing it as being in prison (12). FI continues to be associated with a social 
stigma and patients remain hesitant to discuss the issues - hence the true incidence of 
this condition may never be known (13). 
 
 
 1.1.4 - Treatment  
 
Conservative therapy is the first line treatment for FI. It includes dietary adjustment, 
antidiarrhoeal medication and behavioural therapy including biofeedback (14, 15). 
For patients who fail to achieve satisfactory relief despite maximal conservative treatment 
neurostimulation in the form of sacral nerve stimulation (SNS) is the present first line  
treatment (16-18). 
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 1.2 - Neurostimulation 
 
1.2.1 - History of Neurostimulation 
 
The earliest therapeutic attempt at neurostimulation appears to have been that of the 
Mesopotamian healer Scribonius Largus who used electrical currents to produce 
transient pain relief.  By either the direct application of electrical torpedo fish to the 
human body or by placing painful extremities into a pool of water containing torpedo 
fish the resulting electrical shocks stunned the nervous system allowing an immediate 
and residual numbness in the extremity (19). The diagnostic use of electrical stimulation 
in patients with denervated muscle has been in use for over a century (20). The first 
attempt at electrical stimulation of the lower urinary tract dates back to 1878, when the 
Danish surgeon Saxtorph treated patients with urinary retention by intravesical 
stimulation, in which he inserted a special catheter with a metal electrode 
transurethrally (21). 
 Application of electrical stimulation in FI was first attempted by Caldwell in 1963 who 
restored continence in a patient who had suffered FI for over 30 years (22). The 
instruments in that era were rudimentary and technical failures and lead breakages 
reduced the effectiveness of this treatment. Further improvements in equipment and 
technique by Caldwell (23) and by Hopkinson (24, 25) enhanced the effectiveness of 
this treatment but it was only with advances in cardiac pacing and pain management 
that research into neuromodulation of bladder and bowel function was again 
undertaken. Electrical stimulation upto the 1990s was focussed on stimulation of the 
distal nerve endings and the pelvic floor. From the 1990s interest developed into the 
concept of improving organ function and incontinence by electro stimulation of 
peripheral nerves supplying the incontinence organs. 
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 The concept of recruiting the unutilized residual function of an inadequate urinary 
continence organ by electro stimulation of its peripheral nerve supply using the sacral 
nerves had been used in urology by Prof Tanagho et al during the 1980s (26, 27).  
This concept was used experimentally in FI using direct stimulation of the dorsal penile 
branch of the pudendal nerve (28, 29) – however, this never progressed further for 
obvious reasons. 
Though the credit for laying the foundation of neuromodulation as it is performed today 
goes to Drs Schmidt and Tanagho (30)  Matzel et al was the first to use 
neurostimulation of the sacral nerve roots for FI (31). The first publication in 1995 
reported the use of SNS in patients with functional deficits but no morphological defects 
of the anal sphincter (31, 32).  
Since then the spectrum of indications for neurostimulation of the sacral nerves has 
expanded tremendously and the original technique has undergone several 
modifications and improvements.  
 
1.2.2 - Nerves that have been used for neurostimulation for bowel dysfunction 
 
Several nerves including the sacral nerves (31),pudendal nerves (33, 34) and their 
branches (28, 29)  and the posterior tibial nerves - both the percutaneous and 
transcutaneous routes (35, 36) have been used for neurostimulation in an attempt to 
treat faecal incontinence. Neurostimulation of the sacral nerves - though only nearly two 
decades old – remains the most favoured route of neurostimulation today with this 
being a NICE approved treatment for faecal incontinence in the United Kingdom (16). 
The sacral area can be regarded as the crossroads of vesical-sphincteric, anorectal, 
and sexual function. 
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The S2–S4 nerve roots provide the primary autonomic and somatic innervation to the 
lower urinary tract, including the pelvic floor, urethra, and bladder. The rationale for 
using the sacral nerves was based on both physiological and anatomical 
considerations. Physiologically, faecal continence depends in part, on the anorectal 
angulation and the closing pressure of the anal canal and augmenting these two 
parameters can lead to improved continence (37). The fibres of the right and left 
puborectalis muscle decussate in the midline and form a sling behind the rectum. 
Contraction of this conjoined muscle increases the angulation at the anorectal junction 
and is one of the factors in maintaining faecal continence (38, 39).  
The striated muscle of the external anal sphincter contributes to the anal high pressure 
zone (40) which contributes to maintaining faecal continence. Anatomically, the S3 
sacral nerve with contributions from the S2 and S4 nerve roots supply both the 
puborectalis and the external anal sphincter though the supply to both are distinctly 
separate(38-40). The puborectalis is supplied by direct branches splitting from the 
sacral nerves proximal to the sacral plexus (38) and running on the inner surface; the 
external anal sphincter is supplied by mainly the S3 sacral nerve fibres travelling along 
with the pudendal nerve on the levator's under surface (38, 40).  
Neurostimulation of the pudendal and sacral nerves has been performed in patients 
with lower urinary tract dysfunction. Stimulation of the pudendal nerve was shown to 
increase the anal pressure, whereas stimulation of S3 nerve increased it only slightly 
but caused an augmentation of the anorectal angle. When the S3  nerve was stimulated 
after bilateral pudendal block, the anal pressure did not change but the change in the 
anorectal angulation persisted (40) . 
This formed the basis for using the sacral nerves, specifically the S3 nerve for sacral 
nerve stimulation.  
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1.3 - Sacral Nerve Stimulation  
 
 1.3.1 - Approaches to the Sacral Nerve 
 
SNS represents a relatively safe procedure compared with more invasive surgical 
procedures available for treating FI. Patients undergo a trial phase with a temporary 
stimulation wire (Figure 1) in order to assess whether patients will benefit from the 
permanent neurostimulator implant. The trial phase may represent (Figure 2) a 
convenient method to identify patients who may not benefit from a permanent 
neurostimulator implant. Although initial studies suggested that the trial phase had a 
100% positive predictive value (41) recently concerns have been raised in that the 2 to 
3 week temporary percutaneous test stimulation may not always successfully predict 
those for whom a permanent SNS implant will be beneficial (42).  
 
Figure 1: Temporary Stimulation Lead 
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Figure 2: Temporary Stimulation lead and circuits 
 
 
 
 
The precise placement of the stimulating electrode is crucial for the success of SNS. 
Before 2002, the permanent lead was implanted using an open surgical technique 
where an incision was made in the midline over the sacrum and the lead placed under 
direct vision into the sacral foramen (43). The lead models used (Medtronic Model 
3886; Medtronic, Minneapolis, MN) had no mechanism to hold them in place and the 
resulting high incidence of lead migration caused loss of efficacy and required further 
surgical procedures to relocate the lead. The next generation of leads had an additional 
plastic anchor (Medtronic Model 3080), which was sutured to the periostium of the 
sacrum in an attempt to reduce lead migration(44). In 2002, a new ‘‘tined’’ lead 
(Medtronic Interstim A Model 3889 / 3093) was introduced which further reduced the 
incidence of lead migration (Figure 3). A simultaneous refinement in lead placement 
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techniques was also introduced whereby the lead was placed using a percutaneous 
technique under radiologic guidance (45). At present, the tined lead (Medtronic 
Interstim A Model 3889/3093) and the percutaneous placement of the stimulating lead 
remain the most widely used approach for SNS (45).  However, in about 10% of the 
patients who undergo PNE, electrode placement using the percutaneous technique 
proves impossible due to anatomical variations of the sacral foramina (46). 
 
Figure 3 : The new ‘tined’ Model 3889 lead 
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A laparoscopic approach for placement of the stimulating electrode may overcome this 
shortcoming (47) and the LION procedure (Laparoscopic Implantation Of 
Neuroprothesis) described by Professor Marc Possover was used for lead placement in 
13 patients who had previously failed transforaminal percutaneous attempts at SNS 
lead placement (48). The advantage of this approach is in that the implantation of the 
stimulating electrode occurs under direct visual control while in the percutaneous 
technique, even when the position of the electrode is radio graphically controlled, a 
“non-response” can be due to a “non-response” to the stimulation or to a “non-optimal” 
implantation of the electrode (48). 
A small single centre, single surgeon study examining a non-invasive transcutaneous 
approach to sacral nerve stimulation reported a 31% improvements in bowel continence 
of the 32 patients recruited at the 3 month follow-up (49). Though larger multicentre 
studies are required to confirm its efficacy, this new approach to SNS may hold 
promise. 
 
1.3.2 - Complications  
 
Reports of complications regarding SNS are relatively scarce and the safety profile of 
SNS has been based on pooled data (50). As the urological use of SNS has preceded 
its use in FI, most of the information regarding complications comes from its use in 
urology. A review of SNS for faecal incontinence revealed an adverse event rate of 0.04 
per patient for test stimulation and 0.12 adverse events per patient for permanent 
implantation (51). 
The various complications have been tabulated to illustrate the range of data: 
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Table 1: Complications of Sacral Nerve Stimulation reported in Literature 
Study Pain Infection 
Loss of 
Efficacy 
Lead 
Migration 
Lead 
Breakage 
Kenefick 
BJS 2002(52) 
3/15 
(20%) 
0/15 
(0%) 
- 
2/15 
(13%) 
- 
Matzel K 
Lancet 2004(53) 
9/37 
(24.3%) 
1/37 
(3%) 
- - 
1/37 
(3%) 
Leroi A M(54) 
Annals of Surgery 2005 
3/27 
(11%) 
1/27 
(3.7%) 
1/27 
(3.7%) 
- - 
Miriam B 
Urology 2006(50) 
162/653 
(25%) 
35/727 
(5%) 
282/855 
(33%) 
129/785 
(16%) 
- 
Deng D Y 
Urology 2006(55) 
- - - 
5/235 
(2%) 
- 
Melenhorst J(56) 
Colorectal Disease 2008 
- 
3/14 
(23%) 
- 
0/100 
(0%) 
- 
Hetzer(57) 
Archives of Surgery 2007 
4/37 
(10.8%) 
3/37 
(8%) 
2/37 
(5.4%) 
- - 
Tjandra JJ 
DCR 2008(58) 
3/53 
(6%) 
0/53 
(0%) 
- - - 
Altomere 
DCR 2009(59) 
6/52 
(11.5%) 
- - 
8/52 
(15.4%) 
- 
Koch S M (51) 
Colorectal Disease 2010 
3/19 
(15.7%) 
2/19 
(10.5%) 
- 
4/34 
(11.7%) 
1/34 
(2.9%) 
Gallas (60) 
Colorectal Disease 2010 
43/200 
(21.5%) 
3/200 
(1.5%) 
- - 
3/200 
(1.5%) 
Wexner 
GI Surgery 2010 (61) 
- 
13/120 
(10.8%) 
- - - 
Maeda Y 
BJS 2010(62) 
67/176 
(38.1%) 
5/176 
(2.8%) 
87/176 
(49.4%) 
- - 
Medtronic 
2010(63) 
- - - - 
45 /4482 
(1%) 
Faucheron F 
DCR 2010(64) 
2/87 
(2.2%) 
4/87 
(4.5%) 
9/87 
(10.3%) 
2/87 
(2.2%) 
2/87 
(2.2%) 
Boyle D 
DCR 2011(65) 
2/33 
(6%) 
1/33 
(3%) 
2/33 
(6%) 
4/33 
(12%) 
- 
Maeda 
DCR 2011(66) 
208/1600 
(13%) 
62/1600 
(3.9%) 
194/1600 
(12.1%) 
85/1600 
(5.3%) 
- 
Mellgren A 
DCR 2011(67) 
34/120 
(28%) 
12/120 
(10%) 
- - - 
Lim J T 
DCR 2011(68) 
2/41 
(4.9%) 
- - 
2/41 
(4.9%) 
2/41 
(4.9%) 
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Pain remains the most common complication for patients with 9-26% of patients 
reporting discomfort either at the lead implant site, lead tunnelled site or at the site of 
the permanent implant placement (41, 50, 52, 60).  
Infection of the implant is the most serious complication though reports of infection of 
the implant are scanty. The peripheral nerve evaluation (PNE) phase which is the test 
stimulation phase has a very low complication rate with <1% developing minor 
superficial wound infections (52). Infection rates following implantation of the permanent 
SNS following the percutaneous technique of lead implantation have been reported to 
vary from 3% to 20% (51, 57, 64, 69) though the overall risk of postoperative infection 
after SNS is estimated to be 5 % (50). The incidence of infection is less using the 
percutaneous lead introduction technique compared to the open technique for lead 
introduction (44). Although most studies fail to define the site and severity (44) the 
majority of infections reported tend to be superficial which settle with antibiotics (41, 
51). (Figure 4) 
Loss of efficacy is another common complication though the reported rates for loss of 
efficacy post permanent SNS are highly varied (Table 1). 
This can be secondary to lead migration or due to unknown reasons in the long term 
(70).The position and orientation of the electrode in relation to the sacral nerve root and 
achievement of a low motor stimulation threshold during permanent lead placement has 
the greatest impact on subsequent treatment efficacy (71).  
Lead migration refers to the migration of the permanent or temporary stimulation wire 
electrode leading to a poor study outcome (18, 41). The theoretical risk of lead 
migration is higher when the percutaneous technique of lead insertion is used 
compared to the open technique where the Model 3080 lead is placed under direct 
vision, parallel to the nerve root and as the lead is physically anchored into position and 
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is less likely to migrate. However, the majority of the studies report on the lead 
migration rates subsequent to 2002 when the new tined leads were introduced (18, 45, 
55, 59). Although the tines of the new lead design seem sufficient to fix the electrodes 
in the short and medium term, there is still concern with regard to anterior lead 
migration (55). Reported lead migration rates tend to be around 2% (55) but the actual 
incidence may be underreported, so the true incidences may be higher (72) (Figure 5). 
Inadvertent lead breakage (51) or damage is rare and may occur during surgery for 
unrelated pathologies especially when monopolar diathermy is used during a surgical 
procedure (73) (Figure 6).  
Lead breakage incidents or lead remnants being left behind in the patient during 
attempts at removing the tined lead have been reported. There are 45 reports out of an 
estimated 4,482 leads explanted (63).(Figure 7) 
Incidences of minor localised electrical shocks while passing through ambient electrical 
or magnetic fields (52) and lead breakages in-situ (18, 64) have been reported.  
Increased impedance in-situ possibly due to fibrosis surrounding the tip of the 
stimulating electrode has also been reported (64). 
Current advice from the manufacturer is that MRI is contraindicated in patients with a 
previously implanted stimulator and electrode even if the device is switched off. There 
are reports of neurostimulator failure in 2 patients following an MRI scan (64). 
Interestingly, a small group of patients who meet the criteria to progress from temporary 
to permanent stimulation then go on to experience an increase rather than a reduction 
in episodes of faecal incontinence (42). 
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Figure 4:  Infection post permanent SNS implant
 
 
Figure 5: Anterior migration of the permanent stimulating lead 
 
 
 
 
Infected wound 
post permanent 
SNS placement 
39 
 
Figure 6: Breakage of the permanent stimulating lead 
 
 
 
 
Figure 7: Lead remnants left in situ following lead removal 
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1.3.3 - Results and Long Term Outcomes 
 
The first SNS was performed in 1995 (32) and it is only within the past decade that the 
potential for SNS to treat faecal incontinence has been realised (16, 31). 
Two double blinded placebo controlled trials - one with two patients and another with 27 
patients, confirmed the efficacy of SNS in FI (54, 74). There are no questions about the 
short-term efficacy of SNS and numerous studies have confirmed this (51, 61, 62, 
64).The long term efficacy is less clear with only a small number of studies commenting 
on the 10 year follow-up (59, 75, 76). 
 
1.3.4 - Present and Expanding Indications for Sacral Nerve Stimulation 
 
The indications for SNS are yet to be clearly defined. Currently an accepted indication 
is  FI, with at least one episode per week of leakage of solid or liquid stool after failure 
of conservative treatment (16). SNS was first attempted in patients who had evidence of 
pelvic floor muscle dysfunction without any  structural sphincter injury (31). With less 
rigid inclusion criteria SNS was found to be of benefit in patients with FI secondary to 
idiopathic weakness of the pelvic floor (77),due to iatrogenic injury  to the internal 
sphincter (46),neurological causes including incomplete spinal cord lesions (77-79) , 
scleroderma (80), rectal prolapse (46, 81) anal fissure (82)  and  FI secondary to low 
anterior resection (83, 84). SNS has also been used  for anal pain (85, 86) though in 
our experience it  was effective in one of the 10  patients studied  (87). SNS has been 
used successfully in constipation (88, 89) although some remain sceptical (90). More 
recent reports of SNS for constipation suggest a high incidence of loss of efficacy and 
requirement for repeated surgical interventions or discontinuation of therapy (91, 92). 
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1.4 - Opening New Horizons in Neurostimulation and its Applications 
 
1.4.1 - Looking beyond Sacral Nerve Stimulation- Pudendal Nerve Stimulation 
 
The pudendal nerve is formed from the sacral plexus including the sacral nerve (S2-S4) 
just proximal to the sacrospinous ligament (93). Stimulation of the pudendal nerve 
would hypothetically offer a better option than SNS as it should be equivalent to  
stimulating the S 2, 3 and S4 nerve roots (94, 95). In theory, during SNS only one of the 
three afferent pathways of the pudendal nerve is stimulated. Lead placement is usually 
into the third sacral foramen as this correlates with the position of the S3 nerve root, 
which is believed to offer the best efficacy.  Unlike the pudendal nerve, the sacral nerve 
is not an isolated nerve and at higher levels of stimulation amplitude adjacent  nerve 
roots  are also stimulated (96) leading to  undesirable side effects such as  buttock pain, 
leg pain and occasional  neuropathy (55, 96, 97).  
 
1.4.2 - Developing a New Technique for Pudendal Nerve Stimulation 
 
Approaches to the pudendal nerve can be either anterior or a posterior. The initial nerve 
localisation techniques were complex (98, 99) and have now been replaced by 
minimally invasive transgluteal, posterior or ischiorectal approaches (100-102) of which 
the technique of Spinelli et al is the most preferred. These authors (100) describe a 
transgluteal approach where the correct positioning of the stimulating electrode requires 
neurophysiologic confirmation through the measurement of anal sphincter 
electromyography (EMG) amplitude and latency.  
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Though they (100) describe only a mean duration of 45 minutes for the procedure, in 
our experience, we have found this procedure to be time-consuming with difficulties in 
accurate lead positioning and in obtaining EMG recordings.  
There remains a need to develop simpler techniques for stimulating the pudendal nerve. 
 
1.5 - Scope for Improvements in Neuromodulation 
 
1.5.1 - Neurological Bowel Dysfunction 
 
1.5.2 - Existing Knowledge 
The role of SNS in treating patients with bowel dysfunction secondary to underlying 
neurological conditions remains poorly defined. Until recently, the majority of the  
information that we had about the role of SNS in such patients still came  from  treating 
urological dysfunction  (103). Faucheron et al (64) assessed the effectiveness of SNS in 
a group of 104 patients with bowel dysfunction secondary to underlying neurological 
conditions. A 41% loss of efficacy was reported in these patients over a mean follow-up 
time of 32.8 months. However, the exact group which failed  this treatment was not 
clearly defined (64). Although SNS has had good results in FI in the general population 
this procedure seems to have a low success and high complication rate in the specific 
subgroup with neurological conditions. 
It could be that the central sacral nerve roots are more susceptible to ischaemia and are 
damaged following the precipitating injury in patients with patients with cauda equina 
injury or spinal cord injury at the sacral or lower lumbar levels (104, 105). The more 
peripheral  pudendal nerve which is directly linked to the sacral nerve roots ,is less 
sensitive to ischemia and is more likely to survive an ischemic insult (106).  
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1.5.3 - Room for Improvement 
Stimulating the pudendal nerve could be a better choice for successful neurostimulation 
compared with SNS in such patients.  
 
1.5.4 - Patients who fail Sacral Nerve Stimulation 
 
Treatments for FI patients who fail SNS are limited. Patients who progress to SNS are 
usually those who have failed all methods of conservative treatment and further re-
attempts at conservative measures may not prove beneficial. Surgical procedures in the 
form of neosphincters remain an option for such patients though they are associated with 
considerable morbidity and low  success rates (107).Formation of a stoma remains the 
only viable option for such patients today.  
Alternate routes of neurostimulation have been relatively unexplored in such patients. 
The pudendal nerve has an inherent anatomical and physiological advantage over the 
sacral nerve roots (94-96, 108) and a comparative study in urology found that the majority 
of patients found a better response in PNS compared to SNS (101).Stimulation of the 
pudendal nerve has been reported to have a success rate of 94%  in the treatment of 
urological dysfunction in patients who have failed SNS (109). Though PNS has been 
used in urology, its  use in FI is relatively new (34). It has not been reported to date in 
patients who have failed SNS. 
 
.  
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1.6 - Stretching the Frontiers – Tibial Nerve Stimulation 
 
1.6.1 - Available Evidence 
 
SNS and PNS require invasive surgical procedures along with the need for anaesthesia. 
This poses an additional risk for patients with a pre-existing co-morbidity.  
Posterior tibial nerve stimulation (PTNS) can be applied via the percutaneous and 
transcutaneous approaches and is technically easier to perform than SNS or PNS. 
Patients have the treatment as an outpatient and given twice weekly with no need for 
anaesthesia. PTNS for detrusor instability was first described in 1983 (110). Both 
percutaneous and transcutaneous routes have been more recently used in FI with 
success rates appearing to be comparable to those for SNS (35, 111-113).  
 
1.6.2 - Scope for Improvement 
 
No study so far has compared the percutaneous and transcutaneous neurostimulation 
and there is a need for a blinded placebo controlled randomised clinical trial into the 
efficacy of PTNS. 
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1.7 - Identifying New Roles for Sacral Nerve Stimulation 
 
1.7.1 - Sacral Nerve Stimulation in Constipation 
 
1.7.2 - Existing Knowledge 
 
SNS for constipation is a relatively new indication for this form of neuromodulation (88, 
89, 114-116). Though the short term results suggest good efficacy (88, 115, 117) 
reports of poor outcome and adverse events of patients having SNS for constipation are 
beginning to emerge (90-92). Randomised controlled trials of SNS for faecal 
incontinence have reported good efficacy (54, 74), but to date there has only been one 
such study of SNS for constipation.(118). This contained only two patients however, 
and the duration of each arm of the study was only two  weeks, unlike other studies in 
which  patients were followed up  for a period of 1 month (54).  
 
 
1.7.3 - Room for Improvement 
 
There is therefore, a need for a double blinded placebo controlled study of SNS for 
constipation using sufficient patient numbers and with a longer duration. 
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1.7.4 - Sacral Nerve Stimulation in the Elderly 
 
FI occurs more frequently in the elderly affecting up to 10% of people over the 
age of 65 years living at home and approximately 50% of nursing home 
residents over 65 years (11). It  can severely impair an elderly person’s activity 
and may be the main reason for his or her institutionalisation (119). With the 
proportion of the general population over 65 years estimated to increase to 23% 
from its present 16% over the next 30 years (120), the prevalence of FI will also 
rise. 
Conservative therapy including dietary adjustment, antidiarrheal medication and 
biofeedback remains the first line treatment for FI (14, 15). For patients who fail to 
achieve satisfactory relief despite maximal conservative treatment, SNS is the 
present first line treatment (16-18). Although there is much information on the long 
term safety and efficacy of SNS (59, 76, 121) there have been no reports 
assessing it in elderly patients. 
 
. 
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Chapter  2 
 
Statement of aims of the thesis 
 
 
This thesis aims to add to the existing knowledge of neuromodulation by the following: 
 
1) Developing a new, simple and easily reproducible technique for stimulating the 
pudendal nerve. 
 
2)  Evaluating the effect of pudendal nerve stimulation on bowel dysfunction in: 
                         -- Patients with complete cauda equina syndrome (CES) who fail conservative 
treatment  
                         -- Patients who have failed to respond to SNS 
                           
3) Assessing the efficacy of percutaneous and transcutaneous posterior tibial nerve 
stimulation for faecal incontinence – by a blinded placebo controlled randomised clinical 
trial. 
 
4) Evaluating the efficacy of SNS in constipation by a double blinded placebo controlled 
study. 
 
5) Evaluating the effectiveness of SNS for FI in the elderly. 
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Chapter 3 
 
Introduction to the Thesis 
 
3.1 - Overview of the Chapter 
 
Neurostimulation has been used for many years in treating urological disorders but it is 
only in the last 17 years that it has been applied to the intestine. There is much 
information on sacral nerve stimulation (SNS) and modulation with this treatment has 
been an important part in the management of faecal incontinence in recent years. 
There are circumstances, however, in which SNS is ineffective. Either it is shown to fail 
on peripheral nerve evaluation (PNE) or it ceases to be effective over time or will be 
ineffective in spinal or cauda equina lesions. New forms of neurostimulation are being 
developed which may have advantages over SNS in certain circumstances. 
This thesis is largely a study investigating some of these including pudendal nerve 
stimulation and posterior tibial nerve stimulation. In addition, attention has been turned 
to specific patient groups in which there is little information on the value of SNS for 
example in constipation and in the elderly.  
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3.2 - Pudendal Nerve Stimulation 
 
3.2.1 - Anatomic Considerations 
3.2.2 - Enteric Anatomy  
The large intestine has intrinsic nerves which forms the enteric nervous system. The 
myenteric plexus is a mesh like structure lying in the intermuscular plane made up of 
autonomic axons and ganglia that passes among the muscle fibres. Meissner’s plexus 
lies between the muscularis mucosa and circular muscle layers with the Auerbach’s 
plexus lying between the longitudinal and circular muscles. The enteric nervous system 
is responsible for co-ordination and integration of muscular and glandular functions. 
Short reflexes within the enteric plexus, which do not involve the central nervous 
system, enable segmentation and peristalsis on stimulation by distension of the bowel 
(122). 
 
 
 3.2.3 - Somatic Motor Pathways  
Somatic motor pathways to the external sphincter originate from the Onuf nucleus in the 
S2-S4 anterior horn of the spinal cord. The somatic motor fibres travel in the cauda 
equina prior dividing into dorsal and ventral rami that contributes to the sacral plexus 
(123). The sacral plexus is formed from the lumbosacral trunk (L4, L5) and the anterior 
primary rami from S1 through to S5. The fibres run in the plane between the intrapelvic 
fascia and the levator muscles. Levator ani and coccygeus muscles are innervated 
directly by branches which split off proximal to formation of the plexus. The external 
anal sphincter is supplied indirectly from roots S2-S4 through the pudendal nerve and 
through additional branches from the coccygeal plexus.  
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3.2.4 - Somatic Sensory Pathways  
Somatic afferent fibres that transmit pain and sexual sensation from the external 
urethral sphincter, distal vaginal mucosa and ano-genital region, accompany the 
pudendal nerves and somatic motor branches of the sacral plexus. They synapse with 
cell bodies in spinal ganglia located in the sacral segments of the spinal cord. Anal 
somatic afferents contribute asymmetrically primarily to S2 and S3 roots. Visceral 
afferents transmitting innocuous sensations from the pelvic floor muscles also exist and 
travel with autonomic efferent fibres. Those accompanying sympathetic fibres synapse 
in the T11- L2 dorsal root ganglia and those accompanying parasympathetic fibres in 
the sacral segments S1/S2-S4 (123).  
3.2.5 - Anatomy of the Pudendal Nerve 
 
The pudendal nerve is formed from the sacral plexus (S2-S4) just proximal to the 
sacrospinous ligament (93). It passes out of the pelvis briefly travelling between piriformis 
and coccygeus through the greater sciatic foramen. It then hooks around the sacrospinous 
ligament and ischial spine to re-enter the pelvis through the lesser sciatic foramen. From 
here it runs with the internal pudendal vessels on the medial surface of obturator internus 
in the pudendal (Alcock’s) canal, which is situated in the lateral wall of the ischio-anal fossa 
between the lesser sciatic notch and deep perineal pouch (93). It branches to give off the 
inferior rectal, perineal and dorsal nerve of the penis/clitoris (123). The inferior rectal nerve 
is responsible for the innervation of the external anal sphincter along with additional 
branches from the coccygeal plexus (S4, S5). It also provides sensation to the anal canal 
below the level of the pectinate line. Above the pectinate line only autonomic fibres from 
the inferior hypogastric plexus supply the canal. This part of the sphincter is only sensitive 
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to stretch. Parasympathetic fibres that travel via the pelvic splanchnic nerves innervate the 
internal anal sphincter (123, 124).  
The pudendal nerve can be reached percutaneously through the perineum using the 
ischial spine felt per rectum or it can be reached by a posterior approach at the transection 
of a horizontal line marked from the superior aspect of the greater trochanter of the femur 
and a vertical line marked from the mid-point of the ischial tuberosity. This point denotes 
the level of the ischial spine at which the pudendal nerve lies dorsal to the sacrospinous 
ligament and ventral to the sacrotuberous ligament. The pudendal nerve is a mixed 
somatic and autonomic nerve that derives its fibres from the ventral rami of the second, 
third and fourth sacral nerve roots. Studies on human cadavers have shown  that 50% of 
subjects have nerve fibres originating from the roots of S2, S3, and S4, 40% of subjects 
from only S2 and S3 and 10% of subjects from S3 and S4 only (125) . 
Hamdy has demonstrated that there may be a dominant pudendal nerve with 75% of 
subjects demonstrating a dominant response on one side (50% right, 25% left and 25% 
equal responses). This would suggest that unilateral stimulation as used in sacral nerve 
stimulation is adequate in the majority of patients (126)
 
.  
 
3.2.6 - Is Stimulating the Pudendal Nerve is better than the Sacral Nerve? 
 
Stimulation of the pudendal nerve may be a better option than sacral nerve simulation 
for several theoretical reasons including: 
1) Stimulation of the pudendal nerve should be equivalent to stimulating the S 2, 3 
and S4 nerve roots (94, 95). In contrast, in SNS only one of the three afferent 
pathways of the pudendal nerve may be stimulated. The third sacral foramen is 
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usually entered as this correlates with the position of the S3 nerve root, which is 
believed to offer the best efficacy of stimulation.    
2) At higher levels of amplitude or with poor electrode selection in SNS neighbouring 
nerve roots or adjacent nerves are also stimulated (96). This often leads to 
undesirable side effects including buttock pain, leg pain and occasionally neuropathy 
(55, 96, 97).  Raynaud’s syndrome has also been reported following SNS (55) . 
3) Identifying the correct nerve root in SNS relies on biological responses such as 
contraction of the pelvic floor and toe flexion as a response to stimulation. This can 
be unreliable and more importantly could reflect indirect reflex motor activity that is 
unlikely to be the mechanism by which the therapy works. In addition, many patients 
have unquantifiable, unreliable sensory perception and find it hard to localize a 
stimulus. This causes difficulty in using sensation for electrode placement under local 
anaesthetic (108). In pudendal nerve stimulation (PNS), EMG has been objectively to 
assess correct lead placement (100) . 
4) The ischial spine is a very consistent marker for the objective assessment of the 
pudendal nerve in both sexes as it re-enters the pelvis through Alcock's canal. The  
nerve is a relatively isolated structure at the ischial spine  and the implanted electrode 
is protected in this area by the sacral tuberous and sacrospinous ligaments (95).  
 
3.2.7 - Approaches for Pudendal Nerve Stimulation 
 
 
Pudendal nerve stimulation (PNS) and its effects on the bladder have been studied in 
detail over the past 30 years (33, 99, 102). Early attempts to stimulate reflexly  the 
pudendal afferent nerve fibres were based on direct pelvic floor stimulation using penile 
squeeze (127) and anal stretch (128). Subsequently, electrical stimulation of the 
terminal fibres of the pudendal nerve was attempted through stimulating the pelvic floor 
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and this led on to the development of anal plug stimulators (24, 25) and intravaginal 
pessary stimulators (129, 130). Further progress led to localisation of the pudendal 
nerve and new techniques for continuous electrical stimulation of the main trunk of the 
pudendal nerve (98, 99, 102). Approaches to the pudendal nerve became minimally 
invasive using a new posterior approach (100).Recently a new transobturator approach 
for the pudendal nerve has been patented though no reports of the results for this new 
approach are yet available (131).  
PNS has mainly been used to modify urological function (94, 132) and its application  in 
FI is relatively new (34). In 2005, Matzel et al reported successful PNS in a patient with 
faecal and urinary incontinence using the now unavailable Bion
® 
system stimulator 
(Bion, Advanced Bionic Corp.) (33). The neurostimulator measured only 28 mm in 
length and 3.2 mm in diameter and weighed less than 1 gram (Figure 8).  Insertion of 
the stimulating electrode for this new system was using a perineal approach (Figure 9 
& 10). Post implant, the patient had a reduction in the number of weekly incontinent 
episodes and the time spent per day on bowel management. However an equivalent 
time was required for recharging the implant which was a major drawback. 
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Figure 8: The Bion
® 
neurostimulator                                           
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Figure 9 : Implanted Bion
® 
System 
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Figure 10: Post-operative X ray with Bion
® 
System 
 
 
 
 
 
3.2.8 - Background of Existing Techniques  
 
Conventionally the pudendal nerve is approached by a trans-vaginal or a trans-gluteal 
approach. Both these approaches have been described previously for the administration 
of local anaesthetic pudendal nerve blockade (98, 133). Pudendal nerve stimulation 
(PNS) depends on the proximity of the stimulating electrode to the nerve (134) and 
therefore, unlike the administration of a local anaesthetic, lead placement needs to be 
more precise. Currently this is achieved by recording the neuro-physiological responses 
during stimulation.   
The original pudendal nerve localisation techniques used were complex (98, 99). These 
were replaced by minimally invasive transgluteal, posterior or ischiorectal approaches 
(100-102) of which the technique of Spinelli et al was the most preferred. These authors 
(100) described a transgluteal approach in which the correct positioning of the 
stimulating electrode required neurophysiologic confirmation through the measurement 
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of anal sphincter electromyography (EMG) amplitude and latency. Recently a new 
transobturator approach to  the pudendal nerve has also been described although no 
reports are yet available (131). 
 
3.2.9 - Requirement for a New Technique 
 
Spinelli et al (100) described a mean duration of 45 minutes for his minimally invasive 
transgluteal approach. However, in our experience, we have found this procedure to be 
more time-consuming and laborious with difficulty in obtaining accurate EMG 
recordings. In the three patients in whom we attempted this technique, the operation 
time was around 180 minutes. 
Thus there was a need to develop a simpler and more user friendly technique for 
stimulating the pudendal nerve. 
 
3.2.10 - Developing a New Technique for Pudendal Nerve Stimulation  
 
In our experience, the time consuming part of the procedure described by Spinelli et al 
(100) was in identifying the correct lead position based on EMG recordings.  We 
therefore modified their technique (100) to allow successful lead placement in the 
absence of any specialist electro-physiology equipment or knowledge. In addition we 
hoped to identify, through cadaveric studies that the surface markings used for 
pudendal nerve localisation at the ischial spine were applicable to pudendal nerve 
electrode lead placement.  
This new technique is discussed in detail in the next chapter. 
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3.3 - Potential Roles for Pudendal Nerve Stimulation 
 
3.3.1 - Pudendal Nerve Stimulation in Complete Cauda Equina Patients 
 
3.3.1.1 - Cauda equina Syndrome and its Symptoms 
 
Cauda equina syndrome (CES) is a peripheral nerve lesion and results from the 
damage of multiple sacral and lumbar nerve roots in the lumbar vertebral canal. It was  
first reported in 1934 by Mixter and Barr (135) as a rare consequence of lumbar disc 
prolapse. Its incidence is thought to be 1 in 33,000 to 100,000 of the population, and is 
a significant indication for surgery in around 2-3% of all operations for lumbar disc 
prolapse (136, 137). Classically it is characterized by the presence of one or more of 
the following  symptoms (138): 
1. Lower back pain 
2. Bilateral radicular sciatic pain into both legs 
3. Saddle anaesthesia +/- genital sensory deficit 
4. Bladder dysfunction (retention or incontinence) 
5. Bowel dysfunction (constipation or incontinence) 
6. Sexual dysfunction                                                                                            
Bladder symptoms are one of the most consistent symptoms in patients with CES(139). 
The sudden onset of urinary symptoms, which are the most distressing for the patient, 
can vary from complete urinary retention (either acute or chronic) to incontinence (both 
urge and stress incontinence). Sudden onset of significant and predominant bladder 
symptoms may result in CES patients being referred to a urological surgeon and a 
subsequent urological investigation or a surgical intervention before the correct 
neurological diagnosis is made (140).                                                                              
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Bowel dysfunction is common. It includes constipation to faecal incontinence (141). 
Typically patients with cauda equina injury develop parasympathetic denervation of the 
sigmoid and rectum (142) which can manifest as an atonic bowel and severe 
constipation. Faecal incontinence is due to a  denervated anal sphincter (142). . About 
ninety-five percent of patients with spinal cord injury (SCI) require assistance for 
defecation and half are fully dependent on others for toileting. In the majority, bowel 
evacuation takes more than 30 minutes and the time taken correlates with measures of 
distress and depression (141). Male subjects may present with erectile dysfunction 
although they may report a decreased penile tactile sensation and ejaculatory 
dysfunction. Women may report loss of erotic sensation in the perineal region and an 
inability to appreciate sexual stimuli. Somatic dysfunction is usually confined to the 
lower limbs and the peri-sacral region. Patients can develop a paraesthesia or a 
sensory deficit in the sacral, perianal, perineal or scrotal area. Bowel, bladder, and 
sexual function is the least likely to return fully and take the longest time to show any 
sign of recovery.  This is because of the anterior wallerian degeneration of the sacral 
parasympathetic neurons and the relative sensitivity of un-myelinated parasympathetic 
fibres to compression compared with myelinated sensory and motor nerves. 
3.3.1.2 - Classification of Cauda Equina 
 
Though there are several classifications for CES, the clinically and medico-legally 
relevant classification of complete and incomplete CES (136, 140) is based on the degree 
of disturbance of urinary function: 
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1) Incomplete CES 
This is partial damage to the cauda equina nerve fibres. Patients with incomplete CES 
can present with altered urinary sensations which may include an altered sensation 
when passing urine or a loss of the desire to void or a poor urinary stream.  However, 
the patients still retains full bladder control. Saddle and genital anaesthesia is partial 
and incomplete. These patients may have a loss of bowel function and can present with 
faecal incontinence. 
 
2) Complete CES 
Complete CES arises from a complete disruption of the cauda equina nerve fibres. 
Patients classically present with painless urinary retention or with overflow 
incontinence.  Patients typically describe complete saddle anaesthesia (140). Bowel 
dysfunction, though less pronounced, can vary from constipation to faecal incontinence. 
 
3.3.1.3 - Rationale for using Cauda Equina Patients in this Study 
 
Complete cauda equina patients were selected for this study due to four reasons: 
1) To provide a uniform consistency of aetiology across the study population and to 
avoid inter- and intra- group variations in baseline symptoms. 
2) The available treatment for the bowel and bladder dysfunction in these patients  are 
limited with little  role for surgery (143). No definitive strategy other than conservative 
treatment or a stoma (144) is presently available to manage their symptoms.  
3) The effectiveness of SNS in this group depends on an intact sacral nerve root and 
this is less likely in patients with a complete CES (145) where there is a more or less 
complete disruption of the cauda equina roots.  
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4) Bladder and bowel dysfunction - once developed as secondary to complete cauda 
equina syndrome - is unlikely to progress and deteriorate as the maximum damage has 
already been sustained. 
 
3.3.1.4 - Available Treatments for Bowel Dysfunction in this Group 
 
Management of bowel symptoms in this group of patients is difficult. Patients can have 
a range of symptoms including abdominal pain, sense of incomplete evacuation, 
numerous unsuccessful visits to the toilet, abdominal distension, constipation, faecal 
incontinence, prolonged duration of bowel management and the need for digitation to 
assist evacuation. The sudden onset of these symptoms can result in a diminution of 
the patient’s self-confidence and independence. Treatment should be aimed at the 
attainment of self-management of daily care tasks. 
Though establishment of a bowel program should be individualized, a conservative 
approach including transanal irrigation is the most common and effective method of 
managing neurogenic bowel dysfunction (141, 146).  
There are only limited alternative treatments when conservative care has failed. These 
include nerve stimulation techniques and stoma formation. 
 
3.3.1.5 - Results of SNS  
 
CES causes a simultaneous compression of  eventually all lumbo-sacral spinal nerve 
roots (147). An intact sacral nerve root pathway which is essential for a successful SNS 
is less likely to be found in complete CES than in  incomplete CES where at least one 
sacral nerve root may be spared (141, 145).  
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Though the position statement on SNS (148) recommends that SNS should be 
attempted in patients with incomplete medullary or cauda equina lesion, there are only 
a few reports of use of SNS in cauda equina syndrome (145, 149, 150). This could be 
due to the relative rarity of this condition combined with hesitancy on the part of patients 
to seek medical help.  
SNS has been attempted in 11 patients with incomplete cauda equina and faecal 
incontinence (145). It was found to be effective in five (<50%). SNS has also been 
attempted for urinary dysfunction secondary to cauda equina syndrome (149) with only 
one out of the three patients recruited showing sufficient improvement to proceed to a 
permanent neurostimulator implantation. 
No study, so far, has studied cauda equina patients with constipation, which is by far 
the major symptom of patients with this condition (142).  
Important observations regarding SNS in patients with bowel dysfunction secondary to 
a neurological cause include: 
1) The patient needs to be  neurologically intact for the best outcome (151). 
2) If neurogenic defects are present incomplete lesions fare better than complete or 
near-complete spinal lesions (151). Studies on SNS in such patients have reported that 
none of the patients with complete spinal injury benefited (151, 152).  
3) The success rates for peripheral nerve evaluation and successful trial stimulation in 
such patients (excluding multiple sclerosis) are less than 50% (145, 151) and are in 
general far less than in non-neurogenic patients. A significant number  with urge urinary 
incontinence secondary to refractory detrusor over activity, fail to benefit from sacral 
neuromodulation in comparison to non-neurogenic subjects (151). However, studies of 
SNS for FI in multiple sclerosis patients have consistently shown good results with high 
success rates for the PNE phase (80, 103, 153, 154). 
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4) Patients with bowel dysfunction secondary to a neurological cause form a small but 
diverse group of patients with causes varying from injury to an inherent neurological 
disorder. 
5) Complication rates following permanent neurostimulator implant including chronic 
pain and discomfort, infection and loss of efficacy have been reported to be higher in 
patients with neurological disease (151, 155). 
6) Patients with neurological disease who have initial symptom improvement  with SNS 
appear to lose this with time (151). Patients experience deterioration in the efficacy due 
to indefinable reasons. Possible explanations for this include low-pressure compression 
trauma of the spinal nerve resulting in a conduction block because of nutritional 
impairment, fibrosis between the electrode and target nerve, electrode dislocation, and 
the  natural plasticity of the nervous system leading to reactivation of the pathologic 
reflex arcs (156). 
7) Autonomic dysreflexia can occur in patients with complete spinal lesions following 
neurostimulation of the sacral nerve roots (151, 155).  
8) It is generally felt that if the patient is unable to walk and requires a wheelchair the 
success of neuromodulation is likely to be lessened (151). 
Although SNS has had good results in FI in the general population it seems to have had a 
low success and high complication rate in this specific subgroup of patients. 
 
3.3.1.6 - Why is PNS a better option than SNS in these Patients? 
 
The central sacral nerve roots are thought to be more susceptible to ischaemia and 
damage following the precipitating injury in patients with patients with cauda equina 
injury or spinal cord injury at the sacral or lower lumbar levels (104, 105). The 
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peripheral pudendal nerve which is directly linked to the sacral nerve roots is thought to 
be less sensitive to ischemia and is more likely to survive an ischemic insult (106) 
Several reasons have been postulated for this increased resilience of the peripheral 
pudendal nerve compared to the central sacral nerve roots: 
1) The peripheral nerves have a much more developed network of arterioles and 
venules than the central nerve roots and are better able to withstand ischemia (104). 
2) The main blood vessels of the cauda equina and nerve roots are always located 
superficially and might therefore easily be exposed to mechanical deformation 
compared to the vessels of the peripheral nerves which are located between the 
fascicles, in the epineurium, and may thereby be better protected from mechanical 
deformation (104). 
3) The peripheral nerves have a regional blood supply compared to the nerve roots 
which have only a central arteriolar blood supply (104, 105). This increases the 
susceptibility of the latter to ischemia particularly if there is more than one site for 
compression. 
4) Unlike peripheral nerves, the spinal roots do not possess a thick epineurium and 
perineurium, but are bound in much thinner extensions of the spinal pia-arachnoid 
which increases its susceptibility to ischemia (157). 
5) The nerve roots have a less developed blood-nerve barrier of the endo-neurial 
capillaries compared to peripheral nerves and are more susceptible to a compression-
induced oedema (158). 
The pudendal nerve is therefore more likely to be intact compared to the sacral nerve 
roots in patients with cauda equina injury or spinal cord injury at the sacral or lower 
lumbar levels. Stimulating the pudendal nerve could be a better choice for a successful 
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neurostimulation compared to SNS. However pudendal nerve stimulation has not been 
attempted to date in such patients. 
In subsequent chapters the findings of stimulating the pudendal nerve in patients with 
complete CES are discussed. 
 
3.3.2 – Pudendal nerve stimulation in patients who have failed SNS 
 
3.3.2.1 - Limitations of Sacral Nerve Stimulation 
 
As SNS is  a minimally invasive technique and because it has  a preliminary testing 
phase before permanent insertion of the device (17) has led to a revolution in  the 
treatment for FI. However, it has its limitations.  
Results of the temporary testing phase for SNS are varied with success rates of 50 - 
90% (51, 61, 62, 64, 159). This might point to a lack of adherence to the strict criteria of 
> 50% improvement in the episodes of FI during the trial phase to define a successful 
stimulation. Even when the trial phase is successful, upto one third of patients may lose 
efficacy following the permanent implant (159) suggesting that the 2-3 week temporary 
testing phase may not always successfully predict those for whom a permanent implant 
will be beneficial (42). The short-term efficacy of SNS has been confirmed by several 
studies. However, in the medium and long term the results of SNS are unclear with 
studies suggesting that only about 60% of patients have long term efficacy  for reasons 
yet unknown (59, 75, 76). Thus though SNS is effective in majority of the patients, there 
remains a small proportion of the patients with faecal incontinence who do not benefit 
from SNS. 
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3.3.2.2 - Available treatments in this Group 
 
Further available treatments for patients with faecal incontinence who fail SNS are 
limited. Colonic irrigation is suitable for some. Repeated attempts at temporary SNS 
screening is  a poor prognostic factor for successful stimulation (71) .Implantation of an 
artificial bowel sphincter or a dynamic graciloplasty is an option although the morbidity is 
considerable, the reoperation rates high and the success and long term efficacy is low 
(107). Formation of a stoma remains the only practical option for most patients today.  
 
3.3.2.3 - Rationale of Stimulating the Pudendal Nerve in these Patients 
 
Stimulation of the pudendal nerve is a viable treatment in patients who fail SNS due 
to certain inherent anatomical and physiological advantages (94-96, 108): 
1) During SNS only one of the three afferent pathways (usually of the S 3 root) of the 
pudendal nerve may be stimulated. In contrast PNS should achieve synchronous 
stimulation of the nerve roots of sacral segments of S 2, S 3 and S4 (94, 95). 
2) At the sacral foramen, adjacent nerves lie in close proximity to the sacral nerve 
roots and poor electrode positioning or higher amplitudes can stimulate them causing 
undesirable side effects including  buttock pain, leg pain and in occasionally 
neuropathy (55, 96, 97). Anatomically at the ischial spine the pudendal nerve is a 
relatively isolated structure and the implanted electrode is protected in this area by 
the sacrotuberous and sacrospinous ligaments (95).The possibility of undesirable 
effects due to adjacent nerve root stimulation is therefore  less. 
3) PNS has been used in  urology and a comparative study found that the majority of 
patients found a better response in PNS compared to SNS (101). 
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Stimulation of the pudendal nerve has been used successfully with 94% success rates, 
for treating urological dysfunction in patients who had failed attempts at SNS (109). The 
use of PNS in FI is relatively new (34) and has not been attempted to date in patients 
who have failed SNS. 
In subsequent chapters we discuss our results of stimulating the pudendal nerve in a 
small group of patients who had failed to have symptomatic improvement following 
SNS. 
 
3.4 - Posterior Tibial Nerve Stimulation 
 
 3.4.1 - Anatomy 
 
Faecal incontinence affects approximately 2 - 10% of the adult general population (7-10). 
In those who failed conservative treatments sacral nerve stimulation (SNS) is now 
regarded as a first line surgical treatment owing to its low morbidity and high success rate 
(16). SNS stimulates the third sacral nerve root which is part of the sacral plexus. 
The sacral plexus also provides connections with the pelvic floor, bladder, bowel, urethral 
and anal sphincters. In addition it contributes fibres to the sciatic nerve, which carry 
information to and from the leg. The sciatic nerve gives rise to the anterior and posterior 
tibial nerves. It has been hypothesised that bowel function can be modified by stimulating 
sensory fibres of these due to their proximal connections with fibres supplying the pelvic 
floor. The posterior tibial nerve is easily accessible at the medial aspect of the ankle and 
contains fibres arising from both the second and third sacral nerve roots.  An acupuncture 
point called ‘sanyinjiao’’ or ‘‘spleen-6’’ (SP-6) overlies the posterior tibial nerve close to the 
medial malleolus and stimulation of this point has shown improvement in urinary symptoms 
and increase in myoelectrical activity of the bowel (160, 161). (Figure 11) 
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Figure 11: Position of the ‘sanyinjiao’’ or ‘‘spleen-6’’ (SP-6) acupuncture point 
 
 
 
 
 
The idea of stimulating the posterior tibial nerve for urological dysfunction comes from 
the  traditional Chinese practice of using these acupuncture points over the common 
peroneal or posterior tibial nerves to affect bladder activity (110).  
 
 
3.4.2 - Physiological considerations 
 
Unlike SNS which uses continuous or cycling stimulation, PTNS uses intermittent 
stimulation.  Studies of PTNS in patients with urinary symptoms have shown efficacy with 
stimulation as infrequently as once a week, with less frequent stimulation showing similar 
efficacy, but taking longer to reach full effect (162). It has been shown that repetitive tibial 
nerve stimulation powerfully inhibits spinothalamic tract cells through A-δ fibres (163). It 
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is postulated that inhibition of pathological afferent information from the bladder to supra-
spinal centres occurs at the spinal cord level, resulting in a decreased awareness of 
pathological sensations such as urgency and blocking of reflex pathways which 
pathologically cause detrusor instability (164). Studies on spinothalamic tract cells 
demonstrate inhibition continuing for over 30 minutes after the cessation of stimulation 
(165). This may possibly explain how PTNS could have a long-lasting effect from 
intermittent stimulation (164).  
Activation of the pudendal nerve reflex loop secondary to stimulation of the posterior 
tibial nerve at frequencies of 35 to 40 Hz may cause re-innervation of end organs with 
conversion of fast twitch fibres into slow twitch fibres (166). At lower frequencies of 2 to 
10Hz reflex inhibition may occur (167). Fixed stimulation at 20Hz could target both 
mechanisms of action (166). 
 
3.4.3 - Techniques for PTNS 
 
Posterior tibial nerve stimulation (PTNS) can be performed using  a percutaneous (168) 
or a transcutaneous (36) approach. The former is carried out by the insertion of a 34-
gauge stainless steel needle adjacent to the tibial nerve whilst the latter uses a surface 
electrode placed on the skin over the nerve.  
The effects of PTNS have mainly been studied in the treatment of urological dysfunction.  
In 1983 two studies reported by Nakamura et al (169) and McGuire et al (110) showed 
that transcutaneous stimulation of the posterior tibial nerve was effective in the control of 
urinary urge incontinence and overactive bladder. This has since been confirmed by 
other independent studies (170, 171).  
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The percutaneous route for PTNS was popularised by Stoller et al in 1999 who described 
a new technique for needle placement (172);the Stoller Afferent Nerve Stimulator SANS 
protocol. Subsequently, there have been several other studies of both percutaneous and 
transcutaneous PTNS. Percutaneous PTNS has been found to be more effective than 
the transcutaneous route for bladder control and several studies have been published on 
percutaneous PTNS for urological dysfunction (168, 173-175). 
A detailed description of the various techniques used for PTNS has been discussed in 
the relevant chapter. 
 
3.4.4 - PTNS in Faecal Incontinence 
 
The role of PTNS in FI has been relatively unexplored with only a few studies which have 
commented on the improvements following both the percutaneous and the 
transcutaneous routes. Shafik et al first reported  PTNS for fecal incontinence (FI) with a 
78% improvement among 32 patients (35). Several subsequent studies including a 
multicentre study have demonstrated the efficacy of percutaneous and transcutaneous 
stimulation with improvements of 50- 80% (35, 36, 111-113, 176, 177).  
 
3.4.5 - Benefits of PTNS 
 
SNS and PNS require invasive surgical procedures along with the need for anaesthesia. 
This poses an additional risk for patients with comorbidity. PTNS using the percutaneous 
or the transcutaneous route is easier for the patient than SNS and PNS. In addition, 
patients have the PTNS treatment on an outpatient basis and require only twice weekly 
sessions of treatment for six weeks with no requirement for anaesthesia. 
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SNS is an effective treatment for FI but it is expensive and can be associated with some 
morbidity and limited adaptability once in situ (178). Early results of PTNS show it to be 
simpler, less invasive and better tolerated. In addition, it also has the  benefit that it could 
be safely administered in a nurse-led outpatient clinic (179). PTNS offers a potential for 
self-administered treatment although some patients may have difficulty with or reluctance 
to perform needle insertion. The direct medical costs of PTNS are substantially lower 
than that for SNS (179) . Though indirect non-medical costs can be high due to repeated 
clinic visits for top-up stimulations, a two-year follow up of percutaneous PTNS patients 
reported that PTNS became highly cost effective after the first year of treatment (179). 
 
 
3.4.6 - Lacking Data on PTNS 
 
The true efficacy of PTNS can be demonstrated if PTNS is compared with a placebo 
treatment through a blinded study. To date, there have been no prospective studies 
comparing the PTNS with a placebo arm. 
We describe in a subsequent chapter, a randomised prospective, single-blinded placebo 
controlled study with patients being given either percutaneous or transcutaneous PTNS 
or sham stimulation. 
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3.5 - Identifying New Roles for Sacral Nerve Stimulation 
 
3.5.1 - Sacral Nerve Stimulation in Constipation 
 
3.5.1.1 - Background  
 
Constipation is common, affecting between 3 and 15% of the general population at any 
one time (180, 181).While organic and drug associated causes account for a minority of 
cases, the majority of patients have functional idiopathic constipation. These patients can 
experience a combination of decreased bowel frequency, difficulty in evacuation, 
abdominal pain and bloating. Symptoms may be severe and can often result in a 
significantly impaired quality of life for these patients.  
 
3.5.1.2 - Treatments 
Initial treatment involves dietary modifications and pharmacological therapies. These can 
be unsuccessful, particular in the long-term and are not without side effects (182). 
Behavioural therapy (biofeedback), available in some specialist centres, can improve a 
proportion of patients, however a minority remain symptomatic (183). When conservative 
treatment fails and symptoms are severe surgery remains the only option. The current 
options include either a bowel resection or the formation of a stoma. Subtotal colectomy 
and ileorectal anastomosis is the most widely performed procedure, however it has a high 
failure rate and significant morbidity (184). While a stoma may relieve some of the 
symptoms of constipation it is not an attractive option for most patients, and symptoms of 
abdominal pain and bloating may persist (185).  
An alternative approach would be to attempt to modify the neural control of the lower 
bowel and pelvic floor, in order to produce a physiological alteration in function. This would 
72 
 
seem a more logical treatment of a functional condition where there is no associated 
structural abnormality. Lower bowel motility and sensation, anal sphincter function and 
pelvic floor function are controlled predominantly through the nerves of the sacral plexus.  
 
3.5.1.3 - Role of Sacral Nerve Stimulation (SNS) 
SNS is a surgical technique that applies temporary, or permanent, low-level chronic 
electrical stimulation, via electrodes placed through the sacral foramina, to these nerves. 
This technique has been established in the treatment of detrusor irritability and urinary 
retention with good long-term results (30). More recently it has been used in the treatment 
of faecal incontinence, when other therapies have failed, with similarly excellent results 
(54, 77, 148, 186, 187). As well as producing an unequivocal clinical benefit, a few studies 
suggested that SNS improved anal sphincter function (186, 188) and altered rectal 
sensation and motility (186, 187, 189) – which raises the potential for SNS to be used in 
patients with constipation.  
Though SNS in constipation is relatively new, early reports suggest a good efficacy for this 
procedure (88, 89, 114-117). However, recent reports describe suboptimal outcomes and 
adverse events occurring in a high proportion of implanted patients (90-92). The clinical 
and physiological changes reported so far vary both between studies and within individual 
studies. In addition there may be a significant placebo effect. 
The best tool to assess the efficacy of neurostimulation remains a double blinded placebo 
controlled study. Similar studies done for SNS for faecal incontinence reported its efficacy 
(54, 74). 
To date there has been only one  double blinded placebo controlled study into the efficacy 
of SNS for  constipation (118), but it contained only two patients and the duration of each 
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arm of the study was only two weeks unlike other studies where the patients were followed 
up in each arm for a period of one month (54).   
We describe in subsequent chapter, a double blinded placebo controlled study into the 
role of SNS in constipation using sufficient patient numbers and with a longer duration of 
the study arm period. 
 
 
3.5.2 - Sacral Nerve Stimulation in the Elderly 
 
3.5.2.1 - Introduction 
Faecal incontinence (FI) affects approximately 2% of the adult general population 
(7). However, the incidence of FI is more in the elderly (> 65 year age group) and 
can affect up to 10% of people over the age of 65 years living at home and 
approximately 50% of nursing home residents over 65 years (11). Faecal 
incontinence in the elderly is a marker for poor general health and mortality and can 
severely impair an elderly person’s activity and may be the main reason for his or 
her institutionalisation (119, 190, 191).Control of the excretory functions is the most 
likely single factor that determines a patient’s admission to hospital (192) .  
 
 
3.5.2.2 – Relevance of Faecal Incontinence in the Elderly 
Over the next half century, around the world, the proportion of people aged more 
than 65 years is expected to more than double and the costs of looking after an 
increasingly old and frail population is also set to soar (193). With the proportion of 
the general population over 65 years estimated to increase to 23% from its present 
16% over the next 30 years (120), the prevalence of FI will also rise. With one out 
of every seven >65 year olds projected to have some level of faecal incontinence 
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(194) the additional costs involved in their care will also increase. Estimates of the 
cost of managing faecal incontinence alone, through the additional health 
expenditure were estimated to be around $9000 per patient-year of incontinence in 
an American study (195). 
 
3.5.2.3 - Available Treatments 
Conservative therapy is the first line treatment for FI. It includes dietary adjustment, 
antidiarrheal medication and behavioural therapy including biofeedback (14, 15). For 
patients who fail to achieve satisfactory relief despite maximal conservative treatment, 
sacral nerve stimulation (SNS) is the next treatment (16-18).  Although there is much 
information on the use, efficacy and safety of SNS in the general population (59, 76, 
121) there have been no published reports looking at effects of SNS specifically in 
elderly patients. 
 
 
3.5.2.4 - Attractiveness of SNS in the Elderly 
 
 
SNS which is usually done as a day-case procedure has the advantages of being a 
minimally invasive technique coupled with its ability to offer a preliminary testing 
phase before permanent insertion of the device (17). SNS is therefore more 
acceptable than the artificial bowel sphincter or dynamic graciloplasty both of which 
are associated with considerable morbidity and less satisfactory function. 
 
We describe in a subsequent chapter, a study focussed on the role of SNS 
exclusively in the elderly population aimed to assess the risks and benefits of SNS as 
a treatment for FI in the elderly. 
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Chapter 4 
 
Developing a New Technique for Pudendal Nerve Stimulation 
 
4.1 - Overview of the Chapter 
 
This chapter describes a new technique for stimulation of the pudendal nerve which we 
developed in the operating theatre and in the dissection rooms with anatomical 
dissections of cadaveric specimens. 
 
4.2 - Background of Existing Techniques  
 
Access to the pudendal nerve is usually by a trans-vaginal or a trans-gluteal approach. 
Both have been described previously for pudendal nerve local anaesthetic blocks (98, 
133). The outcome of pudendal nerve stimulation (PNS) depends on the proximity of the 
stimulating electrode to the nerve (134) and therefore, unlike the administration of a 
local anaesthetic, lead placement needs to be more precise. Currently this is achieved 
by recording the neuro-physiological responses during stimulation.   
The original pudendal nerve localisation techniques used were complex (98, 99) and 
have been replaced by minimally invasive transgluteal, posterior or ischiorectal 
approaches (100-102) of which the technique of Spinelli et al was the most preferred. 
These authors (100) describe a transgluteal approach where the correct positioning of 
the stimulating electrode required neurophysiologic confirmation through the 
measurement of anal sphincter electromyography (EMG) amplitude and latency. 
Recently a new transobturator approach to  the pudendal nerve has also been 
described although no reports of its use are yet available (131). 
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4.3 - Developing a New Technique for Pudendal Nerve Stimulation  
 
In our experience, the time consuming part of the procedure described by Spinelli et al 
(100) was in identifying the correct lead position based on EMG recordings.  We 
therefore modified their technique (100) to allow lead insertion in the absence of any 
specialist electro-physiological equipment. In addition we hoped to confirm through 
cadaveric dissection that the surface markings used for pudendal nerve localization over 
the ischial spine were applicable to lead placement.  
 
4.4 - Outline of the Study 
 
The study was carried out in two parts. 
 In the first, a 20G 9 cm foramen needle (Model 041828) was introduced using the 
modified technique in three human cadavers followed by a dissection of its track to 
identify the final position of the needle tip.                                                                        
In the second part, percutaneous placement of the stimulating electrode using the 
modified technique was undertaken in 20 patients with bowel dysfunction (13 patients 
secondary to a complete cauda equina lesion and seven with faecal incontinence who 
had failed sacral nerve stimulation).  
 
 
4.5 - Cadaveric Dissections  
 
4.5.1 - Location/ Supervision 
 
Cadaveric dissection was carried out at the Guy’s and St Thomas Dissection hall 
under the supervision of Dr Alistair Hunter (Senior lecturer and academic manager of 
the Guy's dissecting rooms). All prosections were carried out by Mr Anil George.  
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4.5.2 - Dissection Details 
 
All dissections were carried out on a hemi-pelvis that had been divided in the midline 
sagittal plane. With the hemi-pelvis in the prone position, the surface marking of the 
ischial spine (98) was determined by the intersection of two straight lines (Figure 12). 
These included a transverse line along the upper margin of the ipsilateral greater 
trochanter and a vertical line through the centre of the ipsilateral ischial tuberosity. 
 
Figure 12: Anatomical surface marking of the pudendal nerve 
 
 
 
The ischial spine was palpated by the index finger inserted per anum (Figure 13) and 
a 20 Gauge insulated stimulating needle (Medtronic 041828) was inserted through 
the skin at the surface marking of the pudendal nerve (Figure 14) and advanced 
Line at the level of the greater trochanter 
Line through the centre 
of the ischial tuberosity 
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towards the ischial spine to the tip of the finger and then left in this position (Figure 
15).  
A similar 20 Gauge insulated stimulating needle (Medtronic 041828) needle was also 
inserted through the S 3 foramen to compare with SNS (Figure 16). 
A dissection of the side-wall of the pelvis was then carried out to determine the route 
taken by the needle. The dissection was started from the lateral border of the rectum 
and was continued laterally until the ischial spine was reached.  
 
 
Figure 13: Palpating and marking the ischial spine 
 
 
 
 
 
 
 
 
 
 
Finger on the ischial 
spine 
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Figure 14: Needle insertion through the surface marking point 
 
 
 
 
Figure 15: Final resting point of the needle 
 
 
Needle insertion 
through the surface 
marking point 
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Figure 16: Needle through the S3 foramen 
 
 
 
 
 
Figure 17 : Dissection of the Pudendal nerve and internal pudendal artery 
(Left hemi-pelvis dissected) 
 
 
 
S 3 Main trunk of the 
pudendal nerve  
Needle at the ischial spine 
Internal pudendal artery 
Needle through S3 for 
comparison 
Coccyx 
Needle insertion 
through the S 3 
foramen 
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4.5.3 – Findings 
 
In all three cadaveric specimens dissected, the terminal part of the needle was found 
to be in close proximity to the pudendal nerve before it entered Alcock’s canal 
(Figure 17).The main trunk of the pudendal nerve was found to be medial to the 
internal pudendal artery at the level of the ischial spine in all the three cadaveric 
specimens dissected, as described in other cadaveric dissection studies (196, 197).  
 
4.6 - In-vivo Usage of the New Technique  
 
4.6.1 - Ethical Permission 
 
Ethical permission to proceed with the study of pudendal nerve stimulation was granted 
by the Harrow Research Ethics Committee. Written informed consent was obtained from 
all patients after a detailed discussion of the procedure involved.  
 
4.6.2 - Operative Procedure 
 
For the purpose of pudendal nerve stimulation in vivo, we decided to use a blunt lead 
introducer, comprising a plastic sheath and rigid metal obturator for peripheral nerve 
evaluation (Medtronic model 3550-18). We hypothesized that this would be associated 
with a lower risk of vascular, rectal or needle-stick injury when compared with the sharper 
stimulation needle that we had used in the cadaveric study. All temporary testing is done 
as a day case procedure under general anaesthesia. The surface marking of each ischial 
spine was identified by palpation of the greater trochanter and ischial tuberosity as 
performed in the cadaveric study (Figure 18). In addition, the position of these landmarks 
was also confirmed by anterior-posterior fluoroscopic screening (Figure 19).  
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Figure 18: Anatomical surface marking of the pudendal nerve 
 
 
 
 
Figure 19: Radiological identification of the ischial spine 
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4.6.2.1 - Localisation of the Pudendal Nerve 
 
 
A small 5 mm skin incision was made at the point of the surface marking of the ischial 
spine through which the lead introducer (Model 3550-18, Medtronic) was advanced. A 
gloved index finger, positioned per anum, allowed internal palpation of the ipsilateral 
ischial spine. The sheathed introducer was then advanced, using the finger per anum to 
guide the introducer towards the ischial spine (Figure 20). By aiming slightly lateral to the 
index finger the introducer was felt to come in contact with the bony ischial spine. Fine 
adjustment of the introducer tip to the correct position was then performed by 'walking' 
the tip medially.  
 
Figure 20: Finger per anum to guide the introducer towards the ischial spine 
 
 
 
 
 
 
               
  
Finger per anum guiding the 
introducer towards the ischial 
spine 
Introducer being guided towards 
the ischial spine 
Position of the 
ischial spine 
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4.6.2.2 - Testing the position of the stimulating electrode 
 
 
A stimulation wire (Medtronic, Inc. 041831) was then connected to the metal obturator of 
the sheathed introducer and to an external neurostimulator (Medtronic™ Model 3625 
Screener) (Figure 21). This was set to a standard sacral nerve stimulation pulse width of 
210 microseconds and frequency of 14 Hertz and initially at amplitude of 5 volts. 
Activation of the stimulator was followed by a palpable contraction of the anal sphincter if 
the electrode was in contact with the nerve (198). If no contraction was felt or observed, 
the finger per anum was used to reposition the sheathed introducer until a palpable 
contraction was felt in the anal sphincter on stimulation. If a simultaneous contraction of 
the gluteal muscles or hip movements was also felt, the position of the sheathed 
introducer was adjusted using the finger per anum until only the contraction of the anal 
sphincter was felt.  The stimulation voltage was then gradually reduced by decrements of 
1 volt until the position of best contraction with the lowest stimulation voltage was found. 
During stimulation the index finger was withdrawn from the ischial spine as direct 
pressure on the lead against the spine could lead to a false evaluation of the true resting 
position.  Once the final ‘best’ position of the introducer has been determined, the position 
was reconfirmed using fluoroscopy. 
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Figure 21: Model 3625 External Neurostimulator 
 
 
 
 
 
 
4.6.2.3 - Insertion of the permanent electrode 
 
Once the ‘best’ position of the introducer had been confirmed radiologically, the metal 
obturator was removed and a barbed quadripolar ‘tined’ lead (Medtronic 3093-28 cm) 
was introduced through the sheath. By consecutively stimulating the four poles on the 
electrode, the one closest to the nerve was identified. The lead was then repositioned so 
that the best response was obtained with the extended electrode (electrode 1) which had 
the greatest surface area -allowing for continued stimulation even in the presence of 
small movements of the electrode.  The final position of the stimulating electrode was 
confirmed by observation and palpation of sphincter contraction and radiological 
screening (Figure 22). 
The stimulating lead was then connected to an extension lead (Medtronic 3093- 
extension kit), subcutaneously tunnelled to cross the midline, and brought out through the 
contra-lateral buttock (Figure 23) and connected to a pulse generator (Model 362, 
Medtronic).  
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Figure 22: Final resting position of the permanent stimulating electrode 
 
 
 
 
Figure 23: Tunnelling of the extension lead to the contra lateral buttock 
 
 
 
 
 
 
Permanent stimulating 
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4.6.2.4 - Intra-operative Anorectal Manometry  
 
 
In addition in our study, intra-operative anorectal manometry was also performed to confirm 
contraction of the sphincter using a stationary pull through technique with an eight-channel 
water-perfused system (MMS, Enschede, The Netherlands).The resting and squeeze anal 
pressures generated during the pudendal nerve stimulation with the electrode in the optimal 
position were recorded. Intra-operative anorectal manometry showed a mean increase of 25 
+/- 2.3 cm of water during stimulation compared to baseline. 
Single fibre electromyography (EMG) of the external anal sphincter was also recorded in the 
first two patients in an attempt to optimize lead position using the amplitude and latency of the 
EMG response. It was found however that this added little to inspection and palpation of the 
sphincter response to stimulation under general anaesthetic. Use of EMG recording was 
therefore discontinued in further patients. 
The time taken for the procedure was a mean of 23 +/- 4.2 minutes. 
All patients had the stimulation switched on, once they were fully awake and felt the 
stimulation in the perineal region.  
 
4.6.2.5 - Medication Usage 
In those patients with no contra-indications the following medications were used:  
Antibiotic usage:  
Pre-procedure: Augmentin 1.2 gm / Metronidazole 500 mg IVI 
All implanted materials soaked in Amikacin solution (160mg in 50mls 0.9% saline)  
Post procedure: Augmentin 625 mg / Metronidazole 400 mg three times daily for 5 
days.  
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Analgesic regimen:  
Paracetamol 500mg four times a day for 5 days. 
Oral non-steroidal analgesia as required in the absence of any contra-indications.  
 
4.6.3 - Results of Lead Placement 
 
Percutaneous placement of the stimulating electrode using the modified technique  was 
undertaken in 20 patients with bowel dysfunction (13 patients secondary to a complete 
cauda equina syndrome and seven with faecal incontinence who had failed to respond 
to sacral nerve stimulation).  Successful on-table stimulation and placement of the 
stimulating electrode was achieved in all 20 patients. The lowest voltages required for 
eliciting a motor response during intra-operative testing, once the stimulating lead was 
inserted was a mean of 2.6 +/- 1.3 volts. All patients had the temporary and permanent 
stimulation switched on once they were fully awake. All patients felt the stimulation in 
the perineal region. The lowest voltages required for a sensory response when the 
temporary external test stimulator was switched on was 3.6 +/- 2.4 volts.  
The lowest voltages required for a sensory response when the permanent stimulator 
was switched on was 2.9 +/- 1.3 volts.  
Fourteen of the 20 patients implanted found a > 50% improvement in their symptoms 
during the 3 week trial phase and proceeded to permanent neurostimulator implant. 
The details of each group are discussed in detail in the further chapters.  
 
 
 
 
 
89 
 
4.6.4 - Complications 
 
4.6.4.1 - Infection 
2 patients developed infection following permanent neurostimulator implantation.  
The 1st patient developed only a superficial wound infection over the site, 4 weeks after 
insertion of the permanent neurostimulator. The infection responded to conservative 
treatment with antibiotics. 
The 2nd patient developed a deep seated infection at the site of the permanent 
neurostimulator implant, one month after its insertion. The entire implant and the 
stimulating wire were removed and the infection was allowed to settle. Six months 
following the removal of the device, re-stimulation of the pudendal nerve was attempted 
successfully and another permanent neurostimulator was implanted at a different site. 
 
4.6.4.2 - Lead Migration 
1 patient developed loss of efficacy after the 3 month follow-up due to migration of the 
permanent stimulating lead. This patient is presently awaiting restimulation of the 
pudendal nerve. 
 
4.6.5 - Potential Complications of the New Technique 
 
1) Lead migration 
There was one case of lead migration (5%) in the 20 patients. This is  comparable with 
other reports of PNS lead migration (199). Lead migration for sacral nerve stimulation 
electrodes is rare and occurs in about 2% of patients (55, 200). 
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The reasons for a higher incidence of lead migration for PNS compared to SNS may 
include: 
a) Sacral nerve stimulation electrodes are inserted through the sacral foramina and the 
transforaminal approach may provide a bony buttress to support the lead and reduce 
lead migration. Insertion of the PNS stimulating electrode is lateral to the sacral bone 
and lacks the additional bony support to provide stability for the lead. The new 
transobturator approach (131) may circumvent this as the approach is through the bony 
obturator foramen although there are no reports of this new approach. 
b) The acute holding strength of the tined lead used in SNS and PNS lies in the 
engagement of the tines with the musculofascial tissue (55). The approach that we 
used required the lead to be introduced through the buttock fat and it could be possible 
that the musculofascial support provided to the lead and the fibrosis that the lead 
produced was less than when the lead is introduced through the sacral foramina for 
SNS, thus accounting for higher lead migration.  
 
2) Risk of Rectal perforation 
There exists a risk of inadvertent rectal perforation by the stimulating electrode. The 
examining finger is essential to guide the electrode and localise it to the best position.. 
We reduced this risk by the use of the blunt lead introducer in localising the position of 
the nerve. There were no cases of perforation in the twenty patients. 
 
4.6.6 - Use of Anorectal Manometry 
 
We performed intra-operative anorectal manometry to confirm sphincter contraction during 
stimulation. Though no muscle relaxants were used during the procedure, the validity of 
quantifying such data is not proven as there are no published data on anorectal manometry 
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done under general anaesthesia. Thus, interpretation of our manometry findings is at best 
qualitative and not quantitative.     
 
4.7 - Discussion / New knowledge from this study 
 
Although it is more than 15 years since Matzel et al (31) first reported the application of 
sacral nerve stimulation to faecal incontinence, pudendal nerve stimulation has been 
relatively unexplored. The anatomical integrity of the pudendal nerve at the level of the 
ischial spine as a single structure containing contributions from all the nerve roots of S2-
4, should allow stimulation to be more efficient than it is with a conventional sacral nerve 
root approach (101). 
 Our modification of the technique described by Spinelli includes using index finger 
guidance of the stimulating lead as it advanced towards the ischial spine. This allowed 
lead placement based on evidence of visible and palpable sphincter contraction. This 
method of nerve localisation also has the advantages of simplicity and not having to 
assess EMG recordings for ensuring correct placement. The technique that we have 
developed appears to be reproducible and takes only about half an hour. The key to the 
procedure is the accurate identification of the surface marking of the ischial spine. Once 
this has been made, the rest of the procedure is straightforward.   
Although not used in other studies (34), we found fluoroscopy useful as it was the only 
objective assessment of the correct location of the electrode at the ischial spine where 
the main trunk of the pudendal nerve is located.   The standard 20 gauge insulated 
stimulating needle (model 041828, or 041829 Medtronic) used by others for pudendal 
nerve stimulation (34, 100), was replaced by the blunt sheathed introducer (model 3550-
18, Medtronic) to avoid injury to the examining finger or the bowel wall.  
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The bony support of the sacral foramen to the sacral nerve stimulation lead is lacking for 
pudendal nerve stimulation and this could make the electrode prone to migration. In the 
present group of 20 patients there has, however, been only one case of this so far during 
a mean follow up period of 12 (+/-2.3) months. This rate is slightly higher than the lead 
migration rates for SNS (18, 59). Laparoscopic placement of the stimulating lead 
represents a future option that could be explored for lead placement. This new approach 
has been attempted only for SNS so far (47) . 
4.8 - Role for further research 
 
Our study showed PNS to be effective in only 14 out of the 20 patients attempted. A 
lack of response following lead placement could be due to either a true “non-response” 
or due to a lack of response due to a “non-optimal” implantation of the electrode as the 
percutaneous technique that we used is a blind method of implantation, even when the 
position of the electrode is radio-graphically controlled. Laparoscopic placement of the 
stimulating lead is where the lead is placed adjacent to the nerve under direct visual 
guidance and this route of lead placement for SNS has been found to be effective in 
patients who have failed the percutaneous approach to SNS (48). Developing a new 
laparoscopic technique for PNS lead placement may improve the success rates for 
PNS. The mean stimulation voltages required for initial response in our study was 3.6 
volts for sensory response during the temporary testing phase and 2.9 volts during the 
permanent implant phase. The voltages required are directly linked to the distance of 
the stimulating lead from the nerve (201) and a higher voltage could indicate that there 
remains scope for improvement in lead placement closer to the target nerve reflected 
by a lowering of voltages required for initial response. 
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4.9 - Summary  
 
We have described a new technique of pudendal nerve stimulation which can be 
assessed both subjectively and objectively. Successful insertion was achieved in 14 
(70%) out of the 20 patients with only one lead displacement over a 12 month follow-up 
period. 
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Chapter 5 
 
Pudendal Nerve Stimulation 
 
 
5.1 - Overview of the chapter 
 
This chapter describes our experience of pudendal nerve stimulation (PNS) in patients 
with bowel dysfunction secondary to complete cauda equina syndrome (CES) and in 
those patients with faecal incontinence (FI) who had failed to improve with sacral nerve 
stimulation (SNS). 
 
5.2 - Aims of the Study 
The aim of this pilot study was to assess the efficacy of PNS in patients with bowel 
dysfunction secondary to complete CES and also in those patients with faecal 
incontinence who had failed to improve with SNS.   
 
5.3 - Hypothesis 
The working hypothesis was that stimulation of the pudendal nerve would cause 
improvement in symptoms of FI in the stimulated patients while the null hypothesis was 
that there would be no improvement in symptoms of FI in the stimulated patients.  
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5.4 - Study protocol 
5.4.1 - Patient Selection 
Patients were selected after individual assessments from clinics based at St Mark’s 
Hospital or identified from the existing database of patients with bowel dysfunction of 
failed SNS or a documented complete CES. 
All patients had attempted and failed conservative treatment and biofeedback therapy 
and were awaiting further treatment options. Patients were placed into one of the three 
groups based on their predominant bowel symptom. Urological dysfunction were also be 
documented and measured by validated questionnaires as a secondary outcome of 
stimulation.  
Group 1: Patients with complete CES with predominant symptoms of constipation.  
Group 2: Patients with complete CES with predominant symptoms of faecal incontinence. 
Group 3: Patients with FI who have failed to respond to SNS. 
 
5.4.2 - Pre-entry Evaluation 
Prior to consideration of enrolment in the study, all subjects underwent a thorough 
evaluation including clinical assessment, anorectal physiological testing and an endoanal 
ultrasound. In addition, a transit study and proctogram were performed in those with 
constipation (Group 1). Neurophysiologic assessment was performed using pudendal 
nerve terminal motor nerve latencies to assess neuropathy and preferential side for 
stimulation. Prior to temporary stimulation informed consent was obtained and all 
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patients completed a detailed three-week bowel diary documenting bowel activity. 
Patients with constipation (Group 1) completed the Wexner Constipation Score (206) and 
the PACQOL constipation questionnaire (204) along with the SF-36 quality of life 
questionnaires (202). In addition they recorded: 
       -- Frequency of attempts to defecate 
       -- Time spent on the toilet 
       -- Average number of motions per week 
       -- Time spent straining 
       -- Use of laxatives, suppositories and enemas 
       -- Frequency of anal digitations 
       -- Feelings of incomplete evacuation 
 
 For those with faecal incontinence (Group 2 and 3), all episodes of incontinence to 
flatus, liquid and solid stool were recorded in addition to the St Mark’s Incontinence 
scores (207), Rockwood quality of life in faecal incontinence (203) and the SF-36 quality 
of life questionnaires (202). In addition, the sense of incomplete evacuation and the time 
spent straining to open bowels were also recorded for the incontinence group. Though no 
formal neurological assessments were carried out, patients were asked about their 
perianal numbness and saddle anaesthesia and whether any improvements were 
observed following neurostimulation. 
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5.4.3 - Post-operative Period 
 All patients were observed for at least two hours after the procedure to exclude bleeding 
or haematoma formation at the site of insertion of the temporary wire. The patients were 
provided with full instructions as soon as they are fully recovered from the anaesthesia.  
5.4.4 - Post Procedure Evaluation 
Following successful temporary lead placement, patients were asked to keep a detailed 
21 consecutive day bowel diary documenting bowel activity during the temporary testing 
phase. Patients also completed relevant constipation or incontinence questionnaires at 
the end of the 3 week test evaluation.  
Based on the 3 week assessment, patients were assessed for suitability for permanent 
implantation. If the patient had no benefit from stimulation then at the discretion of the 
investigator and willingness of the patient a further wire was re-inserted. Otherwise the 
patient was exited from the study and the wire removed along with the extension cable. 
The 21 day test stimulation bowel habit diary was used to ascertain if an adequate 
response was obtained with the PNE with subjective improvement in symptoms 
compared to baseline. 
5.4.5 - Follow-up Assessments 
Patients who had a successful temporary stimulation phase and proceeded to permanent 
stimulation were assessed at 1 month, 3 month, 6 month and 1 year and then yearly after 
implantation of the permanent neurostimulator. 
Patients kept a detailed 21 consecutive day bowel diary to document their bowel activity 
prior to their follow-up visit. Patients also completed relevant constipation or incontinence 
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questionnaires. Patients had an anorectal manometry testing done at each visit. 
Together with this constipation predominant patients had a colonic transit study done just 
prior to their 6 month follow-up visit. All the patients who were due to have colonic transit 
studies were asked to defer taking laxatives and to defer using digital evacuation during 
the 5 days required for the transit study. 
 
5.4.6 - Method of stimulation 
Stimulation of the pudendal nerve was carried out using the new technique described in 
the previous chapter  
 
5.4.7 - Inclusion and Exclusion Criteria 
 
Inclusion Criteria 
1 Signed informed consent  
2 Age 18-75 years  
3 Group 1: constipation defined as two or fewer bowel movements per week on 
average over a three week diary card  period (86)   
And/or straining to evacuate on >25% of attempts to evacuate 
And/or sensation of incomplete evacuation after defaecation on >25% of occasions 
4 Group 2 & 3: Faecal incontinence defined as two or more episodes a week assessed 
by a three-week diary card.  
5 Circumferential intact external sphincter (including previous repair).  
6 Failed conservative and medical therapy  
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7 Competent and willing to fill in questionnaires and attend clinics throughout the 
duration of the study. 
8 At least one year after the precipitating injury.  
 
Exclusion Criteria  
1 Complete spinal cord injury due to the risk of autonomic dysreflexia (205)  
2 Congenital anorectal malformations  
3 Previous rectal surgery (rectopexy / resection) within the past one year   
4 Current full-thickness rectal prolapse  
5 Chronic bowel diseases such as inflammatory bowel disease  
6 Chronic diarrhoea, unmanageable by drugs or diet.  
7 Presence of perianal sepsis (including pilonidal sinus)  
8 Stoma in situ  
9 Neurological diseases, such  as diabetic neuropathy and multiple sclerosis  
10 Haematological disorders that could predispose to excessive bleeding  
11 Pregnancy  
12 Anatomical limitations that would prevent successful placement of an electrode  
13 Psychiatric or physical inability to comply with the study protocol 
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5.4.8 - Study Endpoints 
 
Primary Endpoint 
 
The primary end point of the 3 week trial phase was to assess the efficacy of PNS in 
complete CES patients and this was by grouping patients into responders and non-
responders on intent to treat analysis.  
A responder to the intervention was defined as: 
-- Patients with faecal incontinence who had a ≥50% reduction in incontinence episodes 
per week over a 3 week period. 
-- Patients with constipation who had any of the following per week over a 3 week period:  
≥ 50% improvement in the frequency of defaecation  
≥ 50% reduction in amount of times needed to strain   
≥ 50% reduction in amount of time with feeling of incomplete evacuation post defaecation.  
 
Secondary Endpoints                             
Secondary end points included changes in continence scores (St Mark’s Score for FI 
and Wexner Scores for constipation), urgency and quality of life (QOL) scores as 
recorded by the generic SF36 (202) QOL and the FI specific Rockwood (203) QOL and 
constipation specific PAC-QOL (204). 
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5.5 - Ethical permissions 
 
Ethical permission to proceed with the study of pudendal nerve stimulation was granted 
by the Harrow Research Ethics Committee. Written informed consent was obtained from 
all patients after a detailed discussion of the procedure involved and before any 
investigation and treatment. 
 
5.6 - Statistical Analysis 
 
All patients were measured at baseline, during the temporary phase and then again 
during the permanent phase at 1, 3, 6 months and 1 year follow-ups. The aim of all 
analysis was to compare the baseline results with each subsequent time point. 
Statistical analysis was done only when there were four or more patients. All outcomes 
were measured on a continuous scale, and the paired t-test was used for the majority of 
analyses. For variables where the differences between time points had a highly skewed 
distribution, the Wilcoxon matched-pairs test was used for the analysis. 
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5.7 - Results of PNS in Cauda Equina Patients with Faecal Incontinence 
 
5.7.1 - Vital Parameters 
Five patients (4 female, 1 male, mean age: 47 +/- 13.3 years) underwent temporary 
PNE. The median duration of incontinence was 48 months (18-168 months; IQR 150). 
Four patients had both urge and passive FI while one patient had passive FI only. The 
mean BMI was 31.6 +/- 7.1.  
Three had had children, all by normal vaginal delivery with no associated perianal tear. 
No patient had any sphincter defect on endoanal USS. Three patients had a history of 
previous surgical procedures including an ileo-cystoplasty, a right hemicolectomy and 
an abdominal hysterectomy. Two patients had hypertension and one had asthma and 
diabetes mellitus. Only one patient was healthy with no co-morbidity.  Two patients had 
previously undergone temporary SNS but did not proceed to permanent implant due to 
lack of efficacy.  
All five patients underwent temporary screening for three weeks, showing a > 50% 
improvement in their symptoms during the 3 week trial phase. They all received a 
permanent implant. 
 
5.7.2 - Follow up and Complications 
The median period of follow up was 12 (9 - 20) months. All patients had successful 
stimulation on the first attempt at stimulation. There was no loss of efficacy or case 
of lead migration during the follow-up period. One patient developed an infection in 
the battery insertion site one month after insertion of the permanent implant. The 
stimulation wire and the battery were removed and re-inserted after a period of six 
months once the infection had settled.  
103 
 
5.7.3 - Stimulation Parameters 
 
The lowest voltage required for obtaining a motor response during the procedure was 4 
+/- 1.3 volts. The lowest voltage required for a sensory response when the temporary 
stimulator was switched on was 3.1 +/- 1.2 volts and 3.6 +/- 1.7 volts when the 
permanent stimulator was switched on. All the implanted permanent neurostimulators 
were set on a frequency of 14 Hz and a pulse width of 210 microseconds.  
 
 
5.7.4 - Continence (Table 2) 
 
 
The St. Mark's score (205) was significantly reduced from baseline to each of the 
subsequent phases. The biggest reduction was from baseline to the temporary 
phase, with a mean reduction of 14 units over this time. There was no real 
evidence of a change in the number of bowel movements per 24 hours from 
baseline to any of the subsequent time points. The number of incontinence 
episodes was found to significantly reduce from baseline to the temporary phase 
and the improvement was maintained over each of the subsequent time points. 
The ability to defer was significantly increased from baseline to each subsequent 
point. There was an increase of 9 minutes from baseline to the temporary phase, 
and an increase of 11 minutes from baseline to each of the permanent phases. A 
sense of incomplete evacuation has been observed in FI (206) and this was 
measured subjectively in all the patients studied. The sense of incomplete 
evacuation improved from baseline to each of the subsequent times. There was a 
reduction of 80 units from baseline to the temporary phase, and a similar 
reduction at 3 months.  
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Straining was significantly reduced from baseline to the temporary phase, with a 
mean reduction of over 70 units. There was also some evidence that straining 
changed from baseline to each of the permanent phases, but these results were 
not of any statistical significance. 
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Table 2: Continence Parameters 
 
Variable Time Baseline     
Mean (SD) 
Subsequent 
Mean (SD) 
Change            
Mean (95% CI) 
P-value * 
St. Mark's score 
(0- full continence       
24- full incontinence) 
Temporary (n=5) 18.0 (1.0) 3.8 (2.5) -14.2 (-18.0, -10.4) <0.001 
1 month (n=5) 18.0 (1.0) 4.2 (4.6) -13.8 (-20.0, -7.6) 0.003 
3 months (n=5) 18.0 (1.0) 6.0 (3.3) -12.0 (-15.8, -8.2) 0.001 
6 months (n=5) 18.0 (1.0) 7.0 (3.7) -10.8 (-15.8, -5.7) 0.007 
 1 year  (n=3)  18.3 (1.0)    6.3 (2.1) NA 
Ability to defer         
(in minutes) 
Temporary (n=5) 2.2 (1.8) 11.0 (5.5) 8.8 (1.9, 15.7) 0.02 
1 month (n=5) 2.2 (1.8) 14.5 (1.1) 12.3 (9.4, 15.2) <0.001 
3 months (n=5) 2.2 (1.8) 13.5 (2.2) 11.3 (8.2, 14.4) <0.001 
6 months (n=5) 2.2 (1.8) 14.4 (1.3) 11.2 (8.0, 15.8) 0.002 
1 year (n=3) 1.6 (1.0) 15 (0) NA 
Incontinence 
Episodes           
 (per week) 
Temporary (n=5) 9.4 (10.7) 0.4 (0.5) -9.0 (-22.3, 4.3) 0.04 ** 
1 month (n=5) 9.4 (10.7) 0.2 (0.4) -9.2 (-22.4, 4.0) 0.04 ** 
3 months (n=5) 9.4 (10.7) 0.2 (0.4) -9.2 (-22.4, 4.0) 0.04 ** 
6 months (n=5) 9.4 (10.7) 0.8 (1.0) -4.0 (-5.3, -2.7) 0.002 ** 
1 year (n=3) 13.3(10.4) 0.2 (0.2) NA 
Bowel   movements/ 
24 hours 
Temporary (n=5) 1.7 (0.5) 1.2 (0.5) -0.5 (-1.1, 0.1) 0.09 
1 month (n=5) 1.7 (0.5) 1.7 (0.8) 0.0 (-1.2, 1.2) 1.00 
3 months (n=5) 1.7 (0.5) 1.4 (0.7) -0.3 -1.3, 0.7) 0.47 
6 months (n=5) 1.7 (0.5) 1.1 (0.6) -0.6 (-2.0, 0.7) 0.24 
1 year (n=3) 1.5  (0) 1.0 (0.4) NA  
Straining              
(% of time) 
Temporary (n=5) 76 (34) 0 (0) -76 (-100, -35) 0.007 
1 month (n=5) 76 (34) 20 (45) -56 (-100, -1) 0.05 
3 months (n=5) 76 (34) 20 (45) -56 (-100, -1) 0.05 
6 months (n=5) 76 (34) 20 (45) -56 (-100, -1) 0.05 
1 year (n=3)   76 (33) 33 (47) NA 
Sense of incomplete 
evacuation                    
(% of time) 
Temporary (n=5) 80 (27) 0 (0) -80 (-100, -46) 0.003 
1 month (n=5) 80 (27) 10 (22) -70 (-100, -36) 0.005 
3 months (n=5) 80 (27) 0 (0) -80 (-100, -46) 0.003 
6 months (n=5) 80 (27) 20 (45) -60 (-100, -8) 0.03 
1 year (n=3)   83 (24)   33 (47) NA 
* P value calculated using the paired t-test 
** P-values calculated using Wilcoxon matched-pairs test  
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5.7.5 - Anorectal Physiology  
 
5.7.5.1 - Intraoperative Anorectal Manometry  
 
The pudendal nerve supplies the external anal sphincter and stimulation of the 
nerve should produce an increase in the squeeze pressures (38). Intra-operative 
anal manometry was performed to confirm contraction of the sphincter using a 
stationary pull through technique with an eight-channel water-perfused system 
(MMS, Enschede, Netherlands). The resting and squeeze anal pressures 
generated during the pudendal nerve stimulation with the electrode in the optimal 
position were recorded. The mean resting pressures on ano-rectal manometry 
testing during stimulation was 13.2 +/- 5.4 cm of water. This increased to a 
maximal squeeze pressure of 37.7 +/- 15.6 cm of water during PNS. 
 
 
5.7.5.2 – Before and after PNS Anorectal Physiology Testing 
 
Routine pre-operative and post procedure anorectal physiology measurements were 
performed using the stationary pull through technique using an eight-channel water-
perfused system.  
The manometry and rectal capacity assessments showed variations though no 
significance in the changes could be inferred. All the patients had a high anal and 
rectal sensory threshold at baseline.  Following PNS sustained reductions in the anal 
and rectal sensory thresholds were observed. (Table 3) 
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Table 3: Pre and Post Stimulation Anorectal Physiology Assessments 
 
 
Variable Time 
Baseline     
Mean (SD) 
Subsequent 
Mean (SD) 
Change            
Mean (95% CI) 
P-value * 
Anorectal Manometry Assessments (cm of water) 
Resting Pressure 
1 month (n=5) 82 (40) 69 (21) -13 (-36, 10) 0.19 
3 months (n=5) 82 (40) 86 (24) 3 (-28, 35) 0.79 
6 months (n=5) 82 (40) 75 (25) -7 (-38, 24) 0.55 
1 year  (n=3) 57 (27) 75 (42) NA 
Peak Squeeze 
1 month (n=5) 51 (26) 80 (54) 29 (-14, 73) 0.14 
3 months (n=5) 51 (26) 90 (53) 39 (-6, 85) 0.07 
6 months (n=5) 51 (26) 92 (82) 26 (-32, 114) 0.20 
1 year  (n=3) 53 (36) 114 (95) NA 
5 second Squeeze 
1 month (n=5) 19 (12) 48 (46) 29 (-19, 77) 0.16 
3 months (n=5) 19 (12) 48 (65) 29 (-21, 80) 0.18 
6 months (n=5) 19 (12) 54 (49) 35 (-18, 87) 0.14 
1 year  (n=3) 12 (20) 61 (51) NA 
 
Involuntary 
Squeeze Pressure 
1 month (n=5) 56 (29) 54 (31) -1 (-42, 39) 0.94 
3 months (n=5) 56 (29) 64 (28) 9 (-24, 41) 0.50 
6 months (n=5) 56 (29) 59 (23) 3 (-23, 30) 0.74 
1 year  (n=3) 50 (33) 78 (40) NA 
Rectal Capacity Assessments (Ml of air) 
 
Threshold 
Volume 
1 month (n=5) 82 (65) 83 (27) 1 (-58, 60) 0.97 
3 months (n=5) 82 (65) 93 (49) 11 (-62, 84) 0.70 
6 months (n=5) 82 (65) 148 (66) 66 (-13, 144) 0.08 
1 year  (n=3) 60(79) 83(58) NA 
Urge Volume 
1 month (n=5) 176 (75) 171 (49) -5 (-128, 118) 0.92 
3 months (n=5) 176 (75) 166 (48) -10 (-129, 109) 0.83 
6 months (n=5) 176 (75) 196 (51) 20 (-47, 87) 0.47 
1 year  (n=3) 150 (87) 147 (50) NA 
 
Maximal Tolerated 
Volumes 
1 month (n=5) 234 (96) 226 (75) -8 (-124, 108) 0.86 
3 months (n=5) 234 (96) 211 (46) -23 (-139, 93) 0.61 
6 months (n=5) 234 (96) 254 (27) 20 (-82, 122) 0.61 
1 year  (n=3) 200 (100) 200(50) NA 
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Anal and Rectal Electro sensation (mA) 
Anal 
sensation ** 
1 month (n=5) 52 (44) 12 (10) -40 (-89, 10) 0.04  
3 months (n=5) 52 (44) 14 (15) -38 (-84, 9) 0.04 
6 months (n=5) 52 (44) 19 (5) -33 (-84, 18) 0.04 
1 year  (n=3) 76 (41) 23 (16) NA 
Rectal 
sensation 
1 month (n=5) 47 (32) 28 (26) -19 (-39, 0) 0.05 
3 months (n=5) 47 (32) 31 (12) -16 (-49, 17) 0.24 
6 months (n=5) 47 (32) 34 (28) -12 (-23, -1) 0.04 
1 year  (n=3) 54 (40) 31 (19) NA 
* p value calculated using the paired t test 
** P-values calculated using Wilcoxon matched-pairs test 
 
 
5.7.6 - Quality of Life Analysis 
 
Patients were assessed for changes in their quality of life and this was done using 
both a generalised SF-36 QOL (202) and the FI specific  Rockwood QOL (203) 
questionnaire.  
 
5.7.6.1 - Short Form 36 General Health Quality of Life Subset Scores 
 
The SF-36 questionnaire showed a sustained improvement in seven out of the 
eight subsets though statistical significance was not reached (Table 4).  
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Table 4: Short Form 36 general health quality of life subsets mean scores  
 
Variable Time 
Baseline 
Mean (SD) 
Subsequent 
Mean (SD) 
Change 
Mean (95% CI) 
P-value * 
Physical function Temporary (n=5) 44 (41) 56 (37) 8 (-11, 35) 0.23 
 1 month (n=5) 44 (41) 65 (32) 21 (-7, 49) 0.10 
 3 months (n=5) 44 (41) 66 (31) 22 (-8, 52) 0.11 
 6 months (n=5) 
1 year (n=3) 
54 (40) 
52 (45) 
70 (38) 
78 (21) 
16 (0, 33) 
NA 
0.05 
NA 
      
Role physical Temporary (n=5) 40 (45) 30 (41) -10 (-27, 7) 0.18 
 1 month (n=5) 40 (45) 25 (43) -15 (-62, 32) 0.43 
 3 months (n=5) 40 (45) 40 (42) 0 (-22, 22) 1.00 
 6 months (n=5) 
1 year (n=3) 
50 (45) 
58 (52) 
50 (35) 
50 (43) 
0 (-56, 56) 
NA 
1.00 
NA 
      
Bodily pain Temporary (n=5) 50 (33) 53 (30) 2 (-4, 9) 0.38 
 1 month (n=5) 50 (33) 65 (29) 15 (-26, 555) 0.36 
 3 months (n=5) 50 (33) 58 (35) 8 (-13, 29) 0.37 
 6 months (n=5) 
1 year (n=3) 
53 (38) 
67 (30) 
62 (29) 
81 (18) 
9 (-7, 25) 
NA 
0.16 
NA 
      
General health Temporary (n=5) 37 (27) 46 (27) 9 (-1, 20) 0.07 
 1 month (n=5) 37 (27) 53 (29) 16 (-2, 35) 0.07 
 3 months (n=5) 37 (27) 52 (28) 15 (4, 29) 0.02 
 6 months (n=5) 
1 year (n=3) 
39 (26) 
48 (22) 
59 (14) 
64 (26) 
20 (-2, 42) 
NA 
0.06 
NA 
      
Vitality Temporary (n=5) 35 (18) 41 (23) 6 (-13, 25) 0.44 
 1 month (n=5) 35 (18) 57 (14) 22 (1, 43) 0.04 
 3 months (n=5) 35 (18) 57 (13) 22 (-2, 46) 0.07 
 6 months (n=5) 
1 year (n=3) 
40 (16) 
30 (22) 
55 (17) 
48 (24) 
15 (-2, 32) 
18 (-11,11) 
0.07 
0.008 
      
Social function Temporary (n=5) 40 (16) 65 (33) 25 (-7, 57) 0.09 
 1 month (n=5) 40 (16) 75 (25) 35 (-5, 75) 0.07 
 3 months (n=5) 40 (16) 67 (21) 28 (-10, 65) 0.11 
 6 months (n=5) 
1 year (n=3) 
44 (16) 
41 (19) 
72 (21) 
83 (19) 
28 (-13, 70) 
NA 
0.12 
NA 
      
Role emotional Temporary (n=5) 33 (47) 40 (55) 7 (-12, 26) 0.38 
 1 month (n=5) 33 (47) 67 (47) 33 (-17, 84) 0.14 
 3 months (n=5) 33 (47) 40 (55) 7 (-83, 96) 0.84 
 6 months (n=5) 
1 year (n=3) 
42 (50) 
55 (51) 
 
42 (42) 
22 (19) 
0 (-75, 75) 
NA  
1.00 
NA  
Mental health Temporary (n=5) 50 (19) 62 (14) 12 (4, 19) 0.01 
 1 month (n=5) 50 (19) 63 (7) 13 (-3, 28) 0.08 
 3 months (n=5) 50 (19) 58 (14) 8 (-12, 28) 0.33 
 6 months (n=5) 
1 year (n=3) 
54 (20) 
56 (22) 
63 (7) 
60 (18) 
8 (-18, 34) 
NA 
0.40 
NA 
* P values calculated using paired t-test  
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5.7.6.2 - Rockwood Quality of Life Subset Scores 
 
The FI specific Rockwood QOL (203)  showed an improvement in all four subsets post 
stimulation which was maintained into the permanent phase as well (Table 5). 
 
Table 5: Rockwood Quality of Life Subset Scores  
 
Variable Time 
Baseline 
Mean (SD) 
Subsequent 
Mean (SD) 
Change 
Mean (95% CI) 
P-value* 
      
Lifestyle Temporary (n=5) 2.1 (1.0) 2.8 (1.2) 0.7 (0.0, 1.5) 0.06 
 1 month (n=5) 2.1 (1.0) 3.6 (0.4) 1.5 (0.5, 2.5) 0.01 
 3 months (n=5) 2.1 (1.0) 3.8 (0.3) 1.7 (0.7, 2.7) 0.009 
 
6 months (n=5) 
1 year (n=3) 
2.3 (0.9) 
2.4 (1.2) 
3.5 (0.5) 
3.9 (0.2) 
1.1 (-0.2, 2.5) 
NA 
0.08 
NA 
      
Coping/Behaviour Temporary (n=5) 1.5 (0.5) 2.3 (0.9) 0.8 (0.2, 1.4) 0.02 
 1 month (n=5) 1.5 (0.5) 3.0 (0.6) 1.5 (0.9, 2.1) 0.002 
 3 months (n=5) 1.5 (0.5) 3.2 (0.7) 1.7 (1.2, 2.2) <0.001 
 
6 months (n=5) 
1 year (n=3) 
1.6 (0.5) 
1.4 (0.7) 
2.9 (0.7) 
2.9 (0.9) 
1.3 (0.7, 1.9) 
NA 
0.005 
NA 
 
 
Depression/ 
 
 
Temporary (n=5) 
 
1.8 (0.8) 
 
2.6 (0.8) 
 
0.8 (0.3, 1.2) 
 
0.008 
Self-Perception 1 month (n=5) 1.8 (0.8) 3.1 (0.8) 1.6 (0.6, 2.7) 0.01 
 3 months (n=5) 1.8 (0.8) 3.2 (0.8) 1.7 (1.2, 2.1) <0.001 
 
6 months (n=5) 
1 year (n=3) 
1.6 (0.5) 
2.1 (1) 
3.3 (0.7) 
3.3 (0.3) 
1.6 (0.2, 3.1) 
NA 
0.04 
NA 
 
Embarrassment 
 
 
Temporary (n=5) 
 
1.4 (0.7) 
 
2.9 (1.2) 
 
1.5 (0.2, 2.7) 
 
0.03 
 1 month (n=5) 1.4 (0.7) 3.3 (0.5) 1.9 (1.2, 2.6) 0.002 
 3 months (n=5) 1.4 (0.7) 3.3 (1.2) 1.8 (0.5, 3.1) 0.02 
 
6 months (n=5) 
1 year (n=3) 
1.6 (0.8) 
1.4 (0.7) 
3.0 (0.9) 
3.0 (0.9) 
1.4 (-0.4, 3.2) 
NA 
0.09 
NA 
      
* P values calculated using paired t-test  
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5.7.7 - Urinary Function  
Urinary symptoms are one of the primary problems in patients with complete CES 
(139). Faecally incontinent CES patients recruited into this study had symptoms of 
associated urinary urge or stress incontinence. 
During the temporary testing phase four of the five patients showed improvements 
in the number of incontinence episodes per week (Table 6).  
One patient failed to show any improvements during the trial phase and there was 
no improvement observed post permanent implant as well. Four out of the five 
patients had improvements in their ability to defer urination which was sustained 
into the permanent phase and to the time of the latest follow-up. 
 
Table 6: Urinary symptoms pre and post PNS  
 
Variable Time 
Baseline 
Mean (SD) 
Subsequent 
Mean (SD) 
Change 
Mean (95% CI) 
P-value* 
      
Urinary accidents Temporary (n=5) 8 (11) 1 (1.3) 7.6 (7 ,22) 0.21 
per week 1 month (n=5) 8 (11) 1 (1.3) 7.6 (7, 22) 0.21 
 3 months (n=5) 8 (11) 1 (1.3) 7.6 (7, 22) 0.21 
 6 months (n=5) 
1 year (n=3) 
8 (11) 
3  (0) 
1 (1.3) 
1 (1.7) 
7.6 (7, 22) 
NA 
0.21 
NA 
      
Ability to defer Temporary (n=5) 4.6 (6) 12 (4.5) 7.4 (0.6, 3) 0.03 
urination 1 month (n=5) 4.6 (6) 12 (4.5) 7.4 (0.6, 3) 0.03 
 3 months (n=5) 4.6 (6) 13 (2.7) 8.4 (2, 3.7) 0.02 
 6 months (n=5) 
1 year (n=3) 
4.6 (6) 
5.7 (8) 
12 (4.5) 
15 (0) 
7.4 (0.6, 3) 
NA 
0.03 
NA 
* P values calculated using paired t-test  
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5.8 - Results of PNS in Cauda Equina Patients with Constipation 
 
5.8.1 - Vital Parameters 
Eight constipation predominant complete CES patients (7 female, 1 male, mean age: 48 
+/- 6.7 years) underwent temporary PNE. The mean BMI was 29.1 +/- 4. 
All the eight patients were healthy with no associated co-morbidity.   
All seven women were multiparous but had only normal deliveries without any perianal 
tears. No patient had any sphincter defect on endoanal USS. 
All eight patients underwent temporary screening for three weeks. Five showed a > 
50% improvement in their symptoms during the 3 week trial phase and proceeded 
onto permanent implantation. The remaining three patients showed an < 50% 
improvement in symptoms and hence did not qualify for permanent implantation. 
One patient in this group had a 2nd attempt at re-stimulation on the opposite side, 
which did not show any improvement during the 3 week trial phase. 
 
5.8.2 - Follow up and Complications 
The median period of follow up was 12 (12 - 22) months. 
One patient developed loss of efficacy after the 3 month follow-up period and is 
presently awaiting restimulation. One patient developed a superficial wound 
infection over the battery insertion site one month after insertion of the permanent 
implant, which settled with a course of antibiotics.  
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5.8.3 - Stimulation Parameters 
 
The lowest voltage required for obtaining a motor response during the procedure was 
2.5 +/- 1.1 volts.  
The lowest voltage required for eliciting a sensory response with the external temporary 
stimulator, once the patient was fully awake after surgery was 5.2 +/- 2.9 volts. It was 
2.5 +/- 0.7 volts for the permanent neurostimulator. 
The voltage for eliciting a sensory response with the external temporary stimulator in 
those patients who did not improve during the 3 week trial  was 8.7 +/- 1.1 volts  which 
was significantly higher than for patients whose symptoms improved (3.2 +/- 1.6 volts ) 
(p=0.002). All the permanent neurostimulators were set at standard settings a frequency 
of 14 Hz and a pulse width of 210 microseconds.  
 
 
5.8.4 - Continence  
 
 
All parameters of continence improved following stimulation (Table 7).  
 
The frequency of defecation rose from a mean of 3 bowel movements per week at baseline 
to 8 per week during the 3 week trial phase. This sustained improvement was observed at 
subsequent follow-up visits. 
At baseline patients felt a sense of incomplete evacuation 94% of the time they 
opened bowels and this caused them to strain 81% of the time to help evacuation. 
During the 3 week trial phase these rates fell to 30% (p=0.004) and 44% (p=0.03) 
respectively. There was a sustained reduction in the sense of incomplete 
evacuation and requirement to strain during defaecation in the post permanent 
implant phase. 
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The Wexner score (205) improved from a baseline score of 17 to 10 during the 3 
week trial phase (p=0.01)  which was maintained in the permanent phase.  
At baseline patients could defer defaecation for a mean of 1.8 minutes. This 
improved to 7.8 minutes during the 3 week trial phase and continued after 
permanent implantation.  
The sense of incomplete evacuation and the resultant constant desire to evacuate 
are a major complaint of CES patients with constipation. Patients had a mean of 
25 unsuccessful toilet visits per week to the lavatory at baseline. This improved 
following stimulation to 9 visits per week during the 3 week trial (p=0.07) and was 
sustained after permanent implantation. 
At baseline, patients had episodes of abdominal pain and bloating respectively 
58% and 56% of the time. These improved to 22% (p=0.01) and 28% (p=0.06) 
respectively during the 3 week trial phase. Patients suffered less episodes of 
abdominal pain and bloating once the permanent implant was placed as well. 
Patients spent nearly 10 minutes less in the lavatory during each visit following 
stimulation compared with the baseline of 17 minutes per visit.  
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Table 7: Continence Parameters 
Variable Time 
Baseline     
Mean (SD) 
Subsequent 
Mean (SD) 
Change            
Mean (95% CI) 
P-value * 
 
Bowel 
movements /week 
Temporary (n=8) 3 (0.4) 8 (1.0) 5 (-0.2, 1.6) 0.11 
1 month (n=5) 3 (0.4) 7 (0.6) 4 (-0.3, 1.6) 0.12 
3 months (n=5) 3 (0.4) 8 (0.8) 5 (0.2, 1.4) 0.02 
6 months (n=5) 3 (0.4) 8 (1.0) 5 (0.0, 1.7) 0.05 
 
1 year  (n=4) 3 (0.4) 11(7.4) NA 
 
Sense of  incomplete 
Evacuation (%) 
Temporary (n=8) 94 (18) 30 (35) -64 (-99, -28) 0.004 
1 month (n=5) 90 (22) 10 (22) -80 (-100, -24) 0.02 
3 months (n=5) 90 (22) 28 (41) -62 (-100, 3) 0.06 
6 months (n=5) 90 (22) 35 (19) -55 (-100, 9) 0.07 
1 year  (n=4) 88 (25) 25(49) NA 
 
Straining  on 
Defaecation (%) 
Temporary (n=8) 81 (23) 44 (38) -38 (-71, -5) 0.03 
1 month (n=5) 80 (23) 38 (48) -43 (-100, 31) 0.17 
3 months (n=5) 80 (23) 38 (48) -43 (-100, 31) 0.17 
6 months (n=5) 80 (23) 44 (43) -36 (-100, 35) 0.21 
 
1 year  (n=4) 83 (28) 41 (14) NA 
Wexner score 
Temporary (n=8) 17 (3.2) 10 (4.5)  -7 (-10.9, -1.8) 0.01 
1 month (n=5) 17 (3.3) 9 (1.8) -8 (-13.4, -1.4) 0.03 
3 months (n=5) 17 (3.3) 10 (2.6) -7 (-12.4, -1.2) 0.03 
6 months (n=5) 17 (3.3) 11 (3.1) -6 (-12.9, 1.7) 0.10 
 
1 year  (n=4) 16 (1.7) 11 (2.1) NA 
 
Unsuccessful visits to 
lavatory / week 
Temporary (n=8) 25 (20) 9 (10) -16 (-33, 1) 0.07 
1 month (n=5) 22 (11) 3 (3) -19 (-35, -4) 0.02 
3 months (n=5) 22 (11) 2 (3) -20 (-36, -6) 0.02 
6 months (n=5) 22 (11) 3 (6) -19 (-38, -1) 0.04 
 
1 year  (n=4) 25 (12) 3 (7) NA 
Ability to defer 
Temporary (n=8) 1.8 (1.8) 7.8 (6.7) 6.0 (-1.2, 13.2) 0.08 
1 month (n=5) 2.0 (2.0) 11.5 (7.0) 9.5 (-1.0, 20.0) 0.06 
3 months (n=5) 2.0 (2.0) 9.0 (7.1) 7.0 (-2.9, 16.9) 0.11 
6 months (n=5) 2.0 (2.0) 10.0 (4.1) 8.0 (0.8, 15.2) 0.04 
 
1 year  (n=4) 2.3 (2.3) 11.6 (2.8) NA 
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Abdominal 
Pain 
Temporary (n=8) 58 (33) 22 (25) -36 (-60, -12) 0.01 
1 month (n=5) 57 (33) 8 (18) -49 (-79, -19) 0.01 
3 months (n=5) 57 (33) 10 (22) -47 (-76, -18) 0.01 
6 months (n=5) 57 (33) 12 (18) -45 (-77, -13) 0.02 
 
1 year  (n=4) 59 (38) 10 (20) NA 
 
Abdominal 
Bloating 
Temporary (n=8) 56 (50) 28 (40) -29 (-59, 2) 0.06 
1 month (n=5) 50 (50) 20 (45) -30 (-86, 25) 0.21 
3 months (n=5) 50 (50) 20 (45) -30 (-86, 25) 0.21 
6 months (n=5) 50 (50) 30 (45) -20 (-76, 35) 0.37 
 
1 year  (n=4) 62 (48) 20 (22) NA 
 
Time per toilet 
visit 
Temporary (n=8) 17.6 (7.1) 9 (4.2) -5.3 (12,- 1) 0.09 
1 month (n=5) 17.6 (6.2) 7.2 (3.1) -10.4 (17, 3) 0.01 
3 months (n=5) 17.6 (6.2) 7.6  (2.5) -10 (17, 2) 0.02 
6 months (n=5) 17.6 (6.2) 9 (4.1) -8.6 (18, -1) 0.06 
 
1 year  (n=4) 16.2 (6.2) 10.7 (6.9) NA 
* P-values calculated using the paired t-test 
 
 
5.8.5 - Use of Aids to Assist Evacuation 
 
 
Digital Assistance for Evacuation 
 
Seven out of the 8 patients recruited (which included 4 out of the 5 patients who 
proceeded to permanent neurostimulator implant) required digital assistance to 
aid evacuation. During the 3 week trial phase, four out of the seven patients 
stopped this practice. These were the same patients who showed more than 50% 
improvement in symptoms during the trial phase and proceeded to permanent 
implantation. The three patients who continued digital assistance during the trial 
phase did not show improvement in symptoms and did not proceed to permanent 
implantation. 
Two out of the five patients who had a permanent implant continued to use digital 
assistance to initiate evacuation during the latter part of the follow-up period. 
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Laxative Use 
 
Five out of the eight patients required daily laxatives at baseline. Three of the five 
patients who underwent permanent implantation experienced a reduction in 
laxative use. One was able to stop and two required laxatives once every two 
weeks.  
 
Use of Enemas 
 
Three of the eight patients required a weekly enema. Two of these had a 
permanent implantation and was able to stop the enemas completely. Both were 
able to defecate without the use of enemas at their latest follow-up. 
 
5.8.6 - Anorectal Physiology 
5.8.6.1 - Intraprocedure Anal Manometry  
 
 
Intra-operative anal manometry was performed using a stationary pull through 
technique with an eight-channel water-perfused system (MMS, Enschede, 
Netherlands).The resting and squeeze anal pressures generated during PNS with 
the electrode in the optimal position were recorded. The mean resting pressures 
(cm of water) during stimulation was 7.1 +/- 2.6 cm of water and the peak 
squeeze pressure was 27.1+/- 15.6 cm of water. 
 
5.8.6.2 - Pre and Post Stimulation Anal Manometry  
 
 
Anal manometry was performed before and during PNS and at 1, 3, 6 and 12 
months using the stationary pull through technique and an eight-channel water-
perfused system (MMS, Enschede,Netherlands). 
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The resting pressure showed only mild variation after permanent implantation. 
Improvements in squeeze, endurance squeeze and involuntary squeeze pressures 
following permanent neurostimulation were observed. 
No significant changes in any of measurements of rectal capacity or rectal or anal 
sensations were demonstrated (Table 8).  
 
 
 
Table 8: Pre and Post Stimulation Anorectal Physiology Assessments 
 
 
Variable Time 
Baseline     
Mean (SD) 
Subsequent 
Mean (SD) 
Change            
Mean (95% CI) 
P-value * 
Anorectal Manometry Assessments (cm of water) 
Resting Pressure 
1 month (n=5) 70 (38) 69 (9) -1.8 (-43, 39) 0.91 
3 months (n=5) 70 (38) 79 (25) 8.4 (-18, 35) 0.43 
6 months (n=5) 70 (38) 65 (21) -5.6 (-40, 29) 0.67 
1 year  (n=4) 81 (35) 91 (25) NA 
 
Peak Squeeze 
1 month (n=5) 34 (6) 57 (33) 23 (-17, 64) 0.19 
3 months (n=5) 34 (6) 64 (24) 30 (1, 59) 0.05 
6 months (n=5) 34 (6) 58 (34) 24 (-16, 63) 0.17 
1 year  (n=4) 33 (6) 79 (30) NA 
 
5 second Squeeze 
1 month (n=5) 13.0 (12) 28.8 (18) 15.8 (5, 26) 0.01** 
3 months (n=5) 13.0 (12) 43.8 (65) 30.8 (-40., 4) 0.35** 
6 months (n=5) 13.0 (12) 28.8 (34) 15.2 (-22, 52) 0.06** 
1 year  (n=4) 9.5 (9.8) 38.2 (45) NA 
Involuntary 
Squeeze Pressure 
1 month (n=5) 41 (29) 52 (30) 17 (-35, 57) 0.54 
3 months (n=5) 41 (29) 65 (15) 24 (-9, 57) 0.11 
6 months (n=5) 41 (29) 62 (22) 20 (-7, 48) 0.11 
1 year  (n=4) 50 (24) 70(18) NA 
Rectal Capacity Assessments (Ml of air) 
Threshold 
Volume 
1 month (n=5) 173 (93) 144 (48) -29 (-98, 40) 0.31 
3 months (n=5) 173 (93) 130 (45) -43 (-155, 69) 0.35 
6 months (n=5) 173 (93) 140 (76) -33 (-182, 116) 0.57 
1 year  (n=4) 195 (91) 148 (47) NA 
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Urge Volume 
1 month (n=5) 219 (87) 226 (76) 7 (-19, 33) 0.45 
3 months (n=5) 219 (87) 196 (63) -23 (-92, 46) 0.41 
6 months (n=5) 219 (87) 204 (83) -15 (-116, 86) 0.70 
1 year  (n=4) 246 (71) 225 (64) NA 
 
Maximal Tolerated 
Volumes 
1 month (n=5) 239 (72) 265 (49) 26 (-5, 57) 0.08 
3 months (n=5) 239 (72) 244 (36) 5 (-62, 72) 0.85 
6 months (n=5) 239 (72) 242 (78) 3 (-85, 91) 0.93 
1 year  (n=4) 262 (57) 296 (47) NA 
Anal and Rectal Electro sensation (mA) 
 
Anal 
sensation ** 
1 month (n=5) 20 (12) 19 (9) -1 (-17, 14) 0.83 
3 months (n=5) 20 (12) 15 (6) -5 (-18, 8) 0.34 
6 months (n=5) 20 (12) 14 (6) -6 (-24, 12) 0.41 
1 year  (n=4) 22 (13) 15 (11) NA 
Rectal 
sensation 
1 month (n=5) 54 (17) 40 (27) -14 (-42, 14) 0.24 
3 months (n=5) 54 (17) 42 (28) -11 (-49, 26) 0.45 
6 months (n=5) 54 (17) 40 (27) -15 (-38, 7) 0.13 
1 year  (n=4) 58 (16) 33 (19) NA 
* p value calculated using the paired t test 
** P-values calculated using Wilcoxon matched-pairs test 
 
5.8.7 - Quality of Life (QOL) Analysis 
 
Quality of life was estimated using the  general  SF-36 QOL questionnaire (202) 
and the PAC-QOL constipation specific(204) questionnaire.  
 
5.8.7.1 - The PAC Quality of Life Subset Scores 
 
The PAC-QOL constipation specific (204) questionnaire showed improvement in 
all four subsets after stimulation which was maintained into the permanent phase 
as well(Table 9). 
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Table 9: PAC-QOL constipation specific quality of life subsets mean scores  
 
Variable Time 
Baseline 
Mean (SD) 
Subsequent 
Mean (SD) 
Change 
Mean (95% CI) 
P-value* 
      
PAC QoL Temporary (n=8) 2.4 (0.8) 0.6 (0.6) -1.8 (-2.8, -0.8) 0.003 
Physical 1 month (n=5) 2.7 (0.8) 1.2 (0.5) -1.5 (-2.7, -0.3) 0.02 
 3 months (n=5) 2.7 (0.8) 1.0 (1.0) -1.7 (-3.5, 0.1) 0.06 
 
6 months (n=5) 
1 year (n=4) 
2.7 (0.8) 
2.7 (0.8) 
1.0 (1.2) 
1.6 (1) 
-1.4 (-2.6, -0.2) 
NA 
0.03 
NA 
      
PAC QoL Temporary (n=8) 2.4 (1.1) 1.0 (1.2) -1.4 (-2.6, -0.2) 0.03 
Psychosocial 1 month (n=5) 2.9 (0.7) 2.2 (0.8) -0.7 (-1.2, -0.2) 0.02 
 3 months (n=5) 2.9 (0.9) 1.4 (0.9) -1.5 (-2.8, -0.2) 0.03 
 
6 months (n=5) 
1 year (n=4) 
2.9 (0.9) 
2.9 (0.9) 
1.7 (0.9) 
1.6 (1.3) 
-1.2 (-2.6, 0.3) 
NA 
0.09 
NA 
      
PAC QoL Temporary (n=8) 2.9 (0.8) 1.3 (1.1) -1.6 (-2.5, -0.8) 0.003 
Worries 1 month (n=5) 2.8 (0.9) 2.3 (1.2) -0.6 (-1.3, 0.2) 0.11 
 3 months (n=5) 2.8 (0.9) 1.5 (0.8) -1.3 (-2.3, -0.3) 0.02 
 
6 months (n=5) 
1 year (n=4) 
2.8 (0.9) 
2.8 (0.9) 
1.8 (1.1) 
1.9 (1.1) 
-1.0 (-2.6, 0.5) 
NA 
0.14 
NA 
      
PAC QoL Temporary (n=8) 3.6 (0.3) 1.6 (1.2) -2.0 (-3.0, -1.0) 0.002 
Satisfaction 1 month (n=5) 3.5 (0.4) 2.2 (1.2) -1.4 (-2.5, -0.2) 0.03 
 3 months (n=5) 3.5 (0.4) 2.0 (1.5) -1.6 (-3.2, 0.1) 0.06 
 
6 months (n=5) 
1 year (n=4) 
3.5 (0.4) 
3.5 (0.4) 
2.5 (1.1) 
2.5 (1.1) 
-1.0 (-2.2, 0.1) 
NA 
0.07 
NA 
      
* P values calculated using paired t-test  
 
5.8.7.2 - Short Form 36 General Health Quality of Life Subset Scores 
 
 
The SF-36 questionnaire showed a small but sustained improvement in only three 
of the eight domains but these were not statistically significant (Table 10). 
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Table 10: Short Form 36 general health quality of life subsets mean scores  
 
Variable Time 
Baseline 
Mean (SD) 
Subsequent 
Mean (SD) 
Change 
Mean (95% CI) 
P-value * 
Physical function Temporary (n=8) 32 (25) 33 (22) 1 (-8, 10) 0.75 
 1 month (n=5) 31 (21) 24 (18) -7 (-15, 1) 0.08 
 3 months (n=5) 31 (21) 41 (32) 10 (-5, 25) 0.13 
 
6 months (n=5) 
1 year (n=4) 
31 (21) 
33 (23) 
35 (23) 
39 (34) 
4 (-1, 9) 
NA 
0.10 
NA 
      
Role physical Temporary (n=8) 13 (36) 19 (29) 6 (-12, 25) 0.45 
 1 month (n=5) 0 (0) 20 (21) 20 (-6, 46) 0.10 
 3 months (n=5) 0 (0) 25 (25) 25 (-6, 56) 0.09 
 
6 months (n=5) 
1 year (n=4) 
0 (0) 
0 (0) 
20 (21) 
6 (12) 
20 (-6, 46) 
NA 
0.10 
NA 
      
Bodily pain Temporary (n=8) 37 (30) 41 (29) 4 (-6, 14) 0.35 
 1 month (n=5) 28 (17) 25 (18) -4 (-22, 15) 0.62 
 3 months (n=5) 28 (17) 43 (14) 14 (1, 27) 0.04 
 
6 months (n=5) 
1 year (n=4) 
28 (17) 
35  (6) 
32 (20) 
38 (15) 
5 (-18, 24) 
NA 
0.68 
NA 
      
General health Temporary (n=8) 39 (22) 44 (27) 5 (-9, 20) 0.42 
 1 month (n=5) 33 (23) 38 (28) 5 (-13, 23) 0.49 
 3 months (n=5) 33 (23) 46 (26) 13 (2, 25) 0.03 
 
6 months (n=5) 
1 year (n=4) 
33 (23) 
33 (26) 
34 (24) 
44 (29) 
1 (-7, 10) 
NA 
0.67 
NA 
      
Vitality Temporary (n=8) 31 (25) 39 (25) 8 (2, 14) 0.02 
 1 month (n=5) 33 (17) 34 (13) 1 (-19, 21) 0.90 
 3 months (n=5) 33 (17) 29 (20) -4 (-37, 29) 0.75 
 
6 months (n=5) 
1 year (n=4) 
33 (17) 
38 (13) 
28 (13) 
34 (26) 
-5 (-32, 22) 
NA 
0.64 
NA 
      
Social function Temporary (n=8) 36 (36) 51 (34) 16 (-3, 37) 0.08 
 1 month (n=5) 27 (27) 47 (32) 20 (3, 37) 0.03 
 3 months (n=5) 27 (27) 60 (21) 33 (15, 50) 0.007 
 
6 months (n=5) 
1 year (n=4) 
27 (27) 
34 (25) 
42 (26) 
41 (31) 
15 (-5, 35) 
NA 
0.11 
NA 
      
Role emotional Temporary (n=8) 29 (45) 63 (52) 33 (-6, 73) 0.09 
 1 month (n=5) 27 (43) 67 (47) 40 (-28, 100) 0.18 
 3 months (n=5) 27 (43) 86 (19) 60 (6, 100) 0.04 
 
6 months (n=5) 
1 year (n=4) 
27 (43) 
33 (47) 
27 (43) 
33 (47) 
0 (-29, 29) 
NA 
1.00 
NA 
 
Mental health 
 
Temporary (n=8) 
 
56 (20) 
 
63 (24) 
 
8 (-5, 20) 
 
0.21 
 1 month (n=5) 59 (10) 62 (18) 3 (-14, 21) 0.64 
 3 months (n=5) 59 (10) 64 (13) 5 (-11, 21) 0.46 
 
6 months (n=5) 
1 year (n=4) 
59 (10) 
63 (6) 
53 (16) 
57 (11) 
-6 (-32, 19) 
NA 
0.52 
NA 
* P values calculated using paired t-test  
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5.8.8 - Urinary Function Assessments 
Patients had mainly urinary retention and used self-intermittent catheterisation 
(SIC). Six of the eight patients could not initiate voiding and required SIC for 
bladder emptying. Two were able to void without SIC but had daily urinary 
incontinence. Of the five patients who proceeded to permanent implantation, three 
required SIC and two could void but had urinary accidents. All three patients who 
required SIC reported improvements in that they could initiate voiding and required 
the use of SIC only to complete urination. 
 Both patients with episodes of urinary incontinence improved their ability to defer 
urination and became continent. 
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5.9 - Results of Pudendal Nerve Stimulation in patients who failed SNS 
 
5.9.1 - Vital Parameters 
Seven females (mean age: 60 +/- 10.7 years) who had previously failed to improve with 
SNS, underwent temporary PNE. The mean BMI was 25 +/- 2.9. The mean duration of 
FI was 11.6 +/- 4.2 years. All had urge and passive FI. 
All were multiparous. Three had had a third degree tear. Three patients had a defect in 
the external (EAS) and internal (IAS) sphincter.  Two had a previous sphincter repair. 
 
5.9.2 - Co-morbidities / Previous surgery 
 
One patient was a diabetic who had been on oral hypoglycaemics for 10 years. One 
patient had a history of cardiac arrhythmia. Two had had a hysterectomy and one 
had a laparoscopic cholecystectomy. Three patients had attempted temporary SNS 
but had not improved in symptoms. Four patients had successfully attempted 
temporary SNS and had had a permanent implant but had lost efficacy thereafter.  
 
5.9.3 - Efficacy of stimulation 
 
 Four (57%) of the seven patients showed a > 50% improvement in their episodes 
of incontinence per week and were considered eligible for the permanent implant. 
Out of these, two had failed previous temporary SNS testing and two had a 
permanent stimulator insitu but this was no longer effective. 
The remaining three patients showed an < 50% improvement in symptoms and 
hence did not qualify for a permanent implant. Two patients in this group had a 
second attempt at pudendal nerve stimulation on the opposite side which was 
successful in one who proceeded to permanent neurostimulator implantation. 
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5.9.4 - Follow up and complications 
The mean period of follow up was 10 +/- 2.8 months. One patient lost efficacy at 
three months and voluntarily withdrew from the study.  There were no reports of 
any further complications or loss of efficacy in the patients during the follow-up 
period.  
5.9.5 - Stimulation parameters 
The lowest voltage required for obtaining a motor response during the procedure was 
2.1 +/- 1.2 volts. The lowest voltage required for a sensory response when the 
temporary stimulator was switched on was 2.4 +/- 1.1 volts and 2.5 +/- 0.7 volts when 
the permanent stimulator was switched on. The permanent neurostimulator were set at 
a frequency of 14 Hz and a pulse width of 210 microseconds.  
 
5.9.6 - Continence  
 
 
When the baseline and temporary stimulation periods were compared, there was 
a significant reduction in the number of incontinent episodes of four/week. Though 
there was evidence of a sustained reduction of the episodes of FI into the 
permanent phase as well, this was not of statistical significance (Table 11). 
The ability to defer defaecation improved from baseline during the temporary 
phase with a median increase of 2 minutes. There was no statistically significant 
improvement that was sustained into the permanent phase. 
No significant sustained changes in the bowel movement/24 hour frequency was 
observed after temporary or permanent stimulation. 
The St Mark’s scores improved by four units following PNE with a sustained improvement 
into the permanent phase. 
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Table 11: Continence parameters 
 
Variable 
Time 
Point 
Baseline 
Median (Range) 
Subsequent 
Median (Range) 
Change Median 
(95% CI) 
P value* 
Incontinence 
episodes 
per week 
Temporary (n=7) 7 (2, 35) 1.5 (0.3, 20) -4 (-25, -1) 0.02 
1 month (n=4) 6 (2, 35) 0 (0) -5 (-35, -2) 0.07 
3 month(n=4) 6 (2, 35) 3 (0, 5) -3 (-30, -2) 0.07 
6 month(n=3) 5 (2,35) 1 (0,2) -4 (-33,-2) 
NA 
1 year(n=2) 18(2,35) 1 (0,2) NA 
St Mark’s 
Scores 
Temporary (n=7) 19 (17, 24) 15 (0, 18) -3 (-19, -1) 0.02 
1 month (n=4) 20 (17, 24) 13 (9 ,14) -6 (-15, -5) 0.07 
3 month(n=4) 20 (17, 24) 15 (13, 19) -4 (-11, -1) 0.07 
6 month(n=3) 19 (17,24) 11 (10,12) -8 (-12,-9) 
NA 
1 year(n=2) 20 (19,24) 13 (8,18) NA 
Ability to defer 
defaecation 
(Minutes) 
Temporary (n=7) 1 (1, 3) 3 (1, 15) 2 (0, 13) 0.05 
1 month (n=4) 1 (1, 3) 3 (3, 15) 2 (0, 14) 0.32 
3 month(n=4) 1 (1, 3) 3 (1, 13) 2 (0, 10) 0.16 
6 month(n=3) 1 (1, 3) 3(3,12) 2(2,9) 
NA 
1 year(n=2) 1 (1, 3) 7 (3, 12) NA 
Variable 
Time 
Point 
Baseline 
Mean (SD) 
Subsequent  
Mean (SD) 
Change Mean  
(95% CI) 
P value** 
Bowel 
movements/24 
hours 
Temporary (n=7) 1.7 (0.7) 2.1 (1.0) 0.4 (-0.2, 0.9) 0.18 
1 month (n=4) 1.4 (0.5) 2.0 (0.6) 0.6 (0.2, 1.0) 0.02 
3 month(n=4) 1.4 (0.5) 1.8 (0.6) 0.4 (0.0, 0.8) 0.06 
6 month(n=3) 1.2(0.3) 1.5 (0.5) 0.3 (0.3, 1.0) 
NA 
1 year(n=2) 1.3 (0.4) 1.3 (1) NA 
* P values calculated using Wilcoxon matched pair test  
** P values calculated using paired t-test  
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5.9.7 - Quality of Life (QOL) Assessments 
 
 
5.9.7.1 - Short Form 36 General Health QOL Scores  
 
 
The SF-36 questionnaire showed improvements in three out of the eight domains. 
There was no statistical significance in any of the domains before and after 
neurostimulation (Table 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
127 
 
Table 12: Short Form 36 General Health QOL Subset Scores 
Variable Time 
Baseline 
Mean (SD) 
Subsequent 
Mean (SD) 
Change 
Mean (95% CI) 
P-
value* 
Physical Temporary (n=7) 64 (37) 76 (31) 11 (-11, 34) 0.25 
function 1 month (n=4) 54 (47) 79 (39) 25 (-24, 74) 0.21 
 3 months(n=4) 54 (47) 75 (37) 21 (-22, 65) 0.22 
 
6 months(n=3) 
1 year(n=2) 
71 (37) 
58 (39) 
95 (9) 
92 (4) 
24 (-123, 77) 
NA 
NA 
NA 
      
Role physical Temporary (n=7) 57 (53) 71 (41) 14 (-45, 74) 0.58 
 1 month (n=4) 50 (58) 50 (58) 0 (-100, 100) 1.00 
 3 months(n=4) 50 (58) 63 (48) 13 (-27, 52) 0.39 
 
6 months(n=3) 
1 year(n=2) 
66 (58) 
50 (70) 
83 (29) 
25 (18) 
17 (-1, 55) 
NA 
NA 
NA 
      
Bodily pain Temporary (n=7) 59 (39) 68 (23) 9 (-33, 50) 0.62 
 1 month (n=4) 45 (45) 64 (18) 19 (-33, 100) 0.34 
 3 months(n=4) 45 (45) 64 (34) 19 (-4, 41) 0.08 
 
6 months(n=3) 
1 year(n=2) 
56 (48) 
42 (59) 
64 (6) 
66 (48) 
8 (-122, 106) 
NA 
NA 
NA 
      
General health Temporary (n=7) 65 (19) 56 (22) -10 (-30, 11) 0.30 
 1 month (n=4) 75 (16) 59 (24) -17 (-62, 29) 0.33 
 3 months(n=4) 75 (16) 61 (30) -15 (-61, 32) 0.39 
 
6 months(n=3) 
1 year(n=2) 
73 (18) 
68 (23) 
69 (10) 
62 (7) 
-4 (-15, 24) 
NA 
NA 
NA 
      
Vitality Temporary (n=7) 71 (31) 53 (27) -18 (-46, 10) 0.17 
 1 month (n=4) 55 (33) 44 (33) -11 (-44, 21) 0.35 
 3 months(n=4) 55 (33) 39 (23) -16 (-48, 15) 0.20 
 
6 months(n=3) 
1 year(n=2) 
60 (39) 
50 (49) 
47 (12) 
25 (7) 
-13 (-59, 86) 
NA 
NA 
NA 
      
Social function Temporary (n=7) 71 (31) 53 (27) -18 (-46, 10) 0.17 
 1 month (n=4) 59 (36) 62 (31) 3 (-31, 37) 0.78 
 3 months(n=4) 59 (36) 53 (28) -6 (-32, 20) 0.50 
 
6 months(n=3) 
1 year(n=2) 
58 (44) 
37 (35) 
83 (19) 
12 (0) 
25 (-87, 37) 
NA 
NA 
NA 
      
Role emotional Temporary (n=7) 71 (49) 36 (48) -35 (-100, 34) 0.26 
 1 month (n=4) 75 (50) 58 (20) -17 (-100, 75) 0.60 
 3 months(n=4) 75 (50) 25 (55) -50 (-100, 42) 0.18 
 
6 months(n=3) 
1 year(n=2) 
67 (58) 
50 (70) 
77 (20) 
16 (23) 
10 (-136, 115) 
NA 
NA 
NA 
      
Mental health Temporary (n=7) 64 (20) 61 (13) -3 (-19, 13) 0.67 
 1 month (n=4) 73 (22) 68 (19) -5 (-37, 27) 0.65 
 3 months(n=4) 73 (22) 60 (14) -13 (-48, 22) 0.32 
 
6 months(n=3) 
1 year(n=2) 
71 (27) 
62 (31) 
75 (10) 
46 (8) 
4 (-47, 39) 
NA 
NA 
NA 
* P values calculated using paired t-test  
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5.9.7.2 - Rockwood QOL Scores  
The FI specific Rockwood QOL (203)  showed an improvement (though not 
statistically significant) in all four domains post stimulation which was also 
maintained into the permanent phase (Table 13). 
 
Table 13: Rockwood Quality of Life subset scores  
 
Variable Time 
Baseline 
Mean (SD) 
Subsequent 
Mean (SD) 
 
Change 
Mean (95% CI) 
 
P-value* 
 
      
Lifestyle Temporary (n=7) 2.1 (1.0) 2.4 (0.9) 0.2 (-0.8, 1.2) 0.59 
 1 month (n=4) 1.8 (0.7) 2.6 (1.1) 0.8 (-0.8, 2.3) 0.21 
 3 months(n=4) 1.8 (0.7) 2.4 (1.2) 0.6 (-0.7, 1.8) 0.25 
 
6 months(n=3) 
1 year(n=2) 
2.1 (0.6) 
1.7 (0.2) 
2.7 (0.7) 
1.9 (0.6) 
0.6 (-0.4, 1.6) 
NA 
NA 
NA 
      
Coping/Behaviour Temporary (n=7) 1.6 (0.6) 1.9 (0.5) 0.3 (-0.3, 0.8) 0.32 
 1 month (n=4) 1.5 (0.4) 1.9 (0.6) 0.5 (-0.6, 1.5) 0.27 
 3 months(n=4) 1.5 (0.4) 2.1 (0.8) 0.6 (-0.4, 1.6) 0.14 
 
6 months(n=3) 
1 year(n=2) 
1.6 (0.4) 
1.4 (0.1) 
2.4 (0.5) 
1.8 (0.2) 
0.8 (0.5, 2.2) 
NA 
NA 
NA 
      
Depression/ Temporary (n=7) 2.5 (0.8) 2.6 (0.4) 0.1 (-0.4, 0.6) 0.74 
Self-Perception 1 month (n=4) 2.3 (0.7) 2.7 (0.6) 0.4 (-0.5, 1.3) 0.28 
 3 months(n=4) 2.3 (0.7) 2.7 (0.6) 0.4 (-0.5, 1.3) 0.24 
 
6 months(n=3) 
1 year(n=2) 
2.3 (0.9) 
1.8 (0) 
3.3 (0.8) 
2.0 (0.1) 
1.0 (1.8, 3.8) 
NA 
NA 
NA 
 
Embarrassment 
 
Temporary (n=7) 
 
1.7 (0.3) 
 
1.6 (0.4) 
 
-0.1 (-0.4, 0.3) 
 
0.73 
 1 month (n=4) 1.7 (0.3) 1.8 (0.6) 0.1 (-1.0, 1.2) 0.80 
 3 months(n=4) 1.7 (0.3) 1.8 (0.5) 0.1 (-0.8, 1.0) 0.74 
 
6 months(n=3) 
1 year(n=2) 
1.7 (0.4) 
1.7 (0.5) 
1.9 (0.5) 
1.6 (0.7) 
0.2 (-0.6, 1.1) 
NA 
NA 
NA 
      
* P values calculated using paired t-test  
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5.9.8 - Anorectal Physiology testing 
 
5.9.8.1 - Intra Procedure Anal Manometry 
 
Intra-operative anorectal manometry was performed to record contraction of the 
sphincter using a stationary pull through technique with an eight-channel water-
perfused system (MMS, Enschede, Netherlands). The resting and squeeze anal 
pressures generated during the pudendal nerve stimulation with the electrode in 
the optimal position were recorded. The mean resting pressure on ano-rectal 
manometry testing during stimulation was 4.5 +/- 4 cm of water and a peak 
squeeze of 20.2 +/- 15 cm of water during PNS. 
 
5.9.8.2 – Before and after PNS Anal Manometry Testing 
 
Routine pre-operative and post procedure anorectal physiology measurements were 
performed at the 1 month, 3 month, 6 month and 1 year follow-up patient visits using 
the stationary pull through technique using an eight-channel water-perfused system 
(MMS, Enschede,Netherlands). There were no statistically significant improvements in 
any of the anorectal manometry assessments post stimulation (Table 14). 
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Table 14: Pre and Post Stimulation Anorectal Physiology Assessments 
 
Variable Time 
Baseline     
Mean (SD) 
Subsequent 
Mean (SD) 
Change            
Mean (95% CI) 
P-value * 
Anorectal Manometry Assessments (cm of water) 
Resting Pressure 
1 month (n=4) 43 (31) 39 (18) -4(-21, 30) 0.61 
3 months (n=4) 43 (31) 49 (24) 6 (-7, 19) 0.22 
6 months (n=3) 42 (38) 53 (45) 11 (-28, 5) NA 
1 year  (n=2) 46 (53) 50 (45) NA 
 
Peak Squeeze 
1 month (n=4) 47 (17) 55 (41) 8 (-75, 60) 0.75 
3 months (n=4) 48 (17) 36 (22) -11 (-43, 20) 0.34 
6 months (n=3) 40 (10) 45 (23) 5 (-38, 28) NA 
1 year  (n=2) 45 (3) 62 (25) NA 
5 second Squeeze 
1 month (n=4) 21 (27) 25 (33) 4 (-19, 11) 0.50 
3 months (n=4) 21 (27) 17 (13) -4 (-28, 20) 0.63 
6 months (n=3) 28 (28) 12    (8) -16 (-65, 97) NA 
1 year  (n=2) 36 (20) 14 (51) NA 
Involuntary 
Squeeze Pressure 
1 month (n=4) 41 (17) 43 (25) 2 (-19, 15) 0.80 
3 months (n=4) 41 (17) 49 (13) 8 (-25, 9) 0.21 
6 months (n=3) 40 (21) 38 (7) -2 (-33, 37) NA 
1 year  (n=2) 31 (19) 34 (13) NA 
Rectal Capacity Assessments (Ml of air) 
Threshold 
Volume 
1 month (n=4) 56 (40) 69 (23) 13 (-61, 86) 0.62 
3 months (n=4) 56 (40) 74 (28) 18 (-4, 39) 0.08 
6 months (n=3) 
49 (44) 
 
72 (19) 
 
23 (-117,70) 
 
NA 
1 year  (n=2) 60 (56) 67 (25) NA 
Urge Volume 
1 month (n=4) 110 (59) 128 (24) 18 (-77, 112) 0.60 
3 months (n=4) 110 (59) 138 (25) 28 (-40, 95) 0.29 
6 months (n=3) 97 (45) 135 (41) 48(-216, 28) NA 
1 year  (n=2) 110 (28) 100 (0) NA 
Maximal Tolerated 
Volumes 
1 month (n=4) 139 (56) 175 (31) 36 (-75, 147) 0.38 
3 months (n=4) 139 (56) 180 (28) 41 (-26, 108) 0.14 
6 months (n=3) 118 (46) 180 (61) -62 (-218, 95) NA 
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1 year  (n=2) 145 (7) 195 (64) NA 
Anal and Rectal Electro sensation (mA) 
 
Anal 
sensation  
1 month (n=4) 11 (4) 8 (1) -2 (-9, 4) 0.32 
3 months (n=4) 11 (4) 13 (4) 2 (-6, 11) 0.45 
6 months (n=3) 10 (2) 12 (4) 2 (-4,9) NA 
1 year  (n=2) 10 (4) 11 (0) NA 
 
Rectal 
sensation 
1 month (n=4) 19 (3) 32 (11) 13 (-2, 29) 0.07 
3 months (n=4) 19 (3) 30 (12) 11 (-9, 31) 0.17 
6 months (n=3) 18 (2) 30 (11) 12(-19,22) NA 
1 year  (n=2) 19 (2) 30 (10) NA 
* p value calculated using the paired t test 
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5.10 - Discussion 
 
Published data suggest that pudendal neuromodulation may be superior to sacral 
neuromodulation for the treatment of voiding dysfunction in neurogenic and non-
neurogenic patients (101, 132). Our study demonstrates a beneficial effect in the short 
term from PNS with a successful stimulation in 10 (77%) out of the 13 patients with 
complete CES and four (57%) out of the seven patients who had previously failed SNS. 
Bowel dysfunction is a common feature for central neurological conditions including 
spinal cord injury and CES. Patients with CES represent only a small proportion of the 
patient population but they suffer from major  disturbances in bladder and bowel function 
(206). The sudden loss of  bowel control in patients who previously had normal bowel 
habits before the  CES  can severely damage confidence and self-esteem (207). Patients 
may present with FI, constipation or rarely both (141). CES lesions principally produce a 
lower motor neurone disturbance of the sacral outflow, from which the descending colon, 
rectum and anus derive their nerve supply. Damage to the cauda equina can produce a 
sensory, motor and parasympathetic denervation of the sigmoid colon, rectum and anus 
(142, 206, 208). The subsequent bowel atonia makes the patient more prone to 
developing severe and chronic constipation (208). Conversely, denervation of the anal 
sphincter can also cause patients to develop incontinence to flatus and faeces (208). 
The principal micturation centre lies in the sacral part of the spinal cord .Visceral and 
somatic afferent pathways enter the sacral spinal cord through the cauda equina and 
connect to the nucleus of Onuf (209). Disruption to these neuronal pathways could 
explain the bladder and bowel symptoms in patients with complete CES. Damage to the 
sacral nerve roots could result in a completely paralysed bladder causing urinary 
retention or involuntary detrusor contraction causing urinary incontinence. 
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The sacral neural pathways are only partially disrupted in incomplete CES lesions which 
may explain the success of SNS in such patients (145). A more complete injury to the 
sacral outflow would make stimulation of the sacral nerve root ineffective in such patients 
- as was the case in two patients in our series (201). 
Constipation is the predominant bowel symptom after spinal cord injury (210) and a 
similar pattern was observed in eight out of the 13 complete CES patients in our study. All 
constipation predominant complete CES patients had slow colonic transit especially in the 
left colon and rectum, a pattern similar to spinal cord injury patients (211). In the patients 
who used digital assistance to aid evacuation (7 out of the 8 constipation predominant 
patients recruited) the colonic transit was normal when digital assistance was used and 
prolonged when they were asked not to do so. This may imply that there is a major delay 
in the progression of faeces at the level of the rectal ampulla which affects transit more 
proximally.  
Another interesting observation was the similarity between the occurrence of bowel and 
bladder symptoms and their improvement. The predominant form of urinary dysfunction 
in the faecally incontinent CES patients was incontinence. In the CES patients with 
constipation it was urinary retention, with the requirement for self-catheterisation.. 
Improvements following PNS were also linked in that four out of the five patients in the 
FI group and all five in the constipation group showed also showed an improvement in 
their urinary dysfunction. No patient demonstrated urinary improvement on its own.   
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5.10.1 - PNS in failed SNS Patients 
The S 2, S3 and S4 nerve root origin of the pudendal nerve gives it an inherent 
anatomical and physiological advantage over the sacral nerve (94, 95). Stimulation of 
the pudendal nerve can provide afferent stimulation to all the three sacral nerve roots 
simultaneously (101). The neurophysiologic response following PNS should therefore be 
greater than following SNS. A blinded trial comparing these two routes of stimulation for 
voiding dysfunction showed that 80% of the patients preferred PNS to SNS (101). 
PNS is now the next logical progression for neurostimulation in patients who fail to 
improve following SNS for urinary dysfunction (132, 199). A similar rationale may 
indicate a role of PNS in treating patients with FI who have failed to respond to SNS. 
 
5.10.2 - Mechanism of Action 
The exact mechanism of action of PNS remains undetermined though PNS and 
urological assessment in intact and spinal animals have been studied and different 
mechanisms of actions suggested.  
The urological effects of PNS are  thought to be secondary to interactions between the 
somatic and autonomic pathways within the spinal cord and higher centres (102). Most 
of these pathways, which are inhibitory, have their afferent limb in the pudendal nerve. 
Intraurethral electrical stimulation in anaesthetised cats selectively evoked bladder 
responses by activating two distinct pudendal afferent pathways (212) and, depending 
on the stimulation frequency,  either inhibited the bladder and promoted continence or 
excited the bladder and caused mituration (213, 214). Recent studies suggest the 
presence of an excitatory pudendal-to-bladder spinal reflex in man (215, 216). Although 
the exact pathways of this reflex are yet to be identified, it could be that a similar 
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excitatory pudendal to bowel reflex pathway exists whereby bowel functions are 
modulated as well. 
Normal function of the sacral parasympathetic supply is crucial to the maintenance of 
colonic motility and function (210). In patients with complete CES, the loss of this 
parasympathetic activity could explain the constipation symptoms while the occurrence 
of spontaneous irregular colonic contractions (210) and  the loss of the tone of the EAS 
could explain the symptoms of FI. Pudendal pathway projections onto thoracolumbar 
sympathetic and sacral parasympathetic systems and a spinal interaction between 
pudendal afferents and sympathetic efferents have been demonstrated (102). The 
pudendal nerve has autonomic fibres enclosed within it (217). A common origin for the 
pudendal nerve fibres and parasympathetic fibres forming the pelvic splanchnic nerves 
point to the pudendal nerve being linked to both the somatic and the autonomic nervous 
systems.  
It could be possible that PNS may cause reactivation of the parasympathetic system 
supplying the bowel through neural connections yet unknown, which may in part explain 
the symptom improvement and the normalisation of the previously slow colonic transit. 
However this explanation fails to explain the  six month follow up findings of normal 
colonic transit in two and slow  transit in the other three  patients even though all the 
five  patients showed consistent symptom improvement. 
The function of the anal sphincter complex is one of the keys  to continence (218, 
219).The IAS contributes to 80% of the resting anorectal pressure (220, 221). The EAS 
on the other hand, contributes only to 20% of the resting pressure but to 100% of the 
squeeze and the endurance squeeze pressures (220, 221). The ability to sustain an 
anal squeeze for five seconds is more important than the peak squeeze (222) and an 
improvement in the five second endurance squeeze could help improve continence . 
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The loss of the EAS function along with the occurrence of spontaneous irregular colonic 
contractions (210) could explain FI symptoms in CES patients. Poor function of the EAS 
could also explain FI in patients who failed SNS. 
The EAS is innervated bilaterally by the pudendal nerve and the improved post PNS 
squeeze and endurance squeeze pressure measurements may provide a possible 
explanation for the improved continence shown by patients in both the CES and failed 
SNS groups. Although the IAS is also thought to be a major contributor to continence 
no improvement in IAS function could be identified in any group. Stimulation of the 
pudendal nerve also has been shown to increase the electromyographic activity of the 
pelvic floor muscles and this may also contribute to the improved continence in these 
patients (169).  
 
5.10.3 - Limitations of our study 
 
Our study has several limitations. 
 
Patient recruitment 
 
1) A complete neurological examination of all the recruited complete CES patients was 
not done though this would have indicated the completeness of the cauda equina 
lesion.  
2) No imaging was done at the time of patient recruitment to identify the level of the 
CES lesion.  
3) The heterogeneity of the patients is acknowledged as a confounding factor in the 
study group of patients who had failed SNS. 
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4) Patient numbers in all the study groups were small. 
 
Data collection 
 
1) The incontinence and constipation questionnaires used have not been validated for 
use in patients with neurological bowel dysfunction. 
2) The use of anorectal manometry under general anaesthesia has to be cautiously 
interpreted as there is no previously published data. The high squeeze pressures 
recorded in the patients should be viewed cautiously given the unknown effects of 
general anaesthesia on these patients and the small number of patients. The 
intraprocedure anorectal manometry data is therefore best viewed qualitatively and not 
quantitatively. 
 
Procedure Related Issues 
 
In our experience, although the success rates are similar, the short term complication 
rates are higher for PNS compared to SNS. All patients in our study had the quadripolar 
tined (barbed) lead electrode (Model 3889, Medtronic) placed adjacent to the pudendal 
nerve even for the temporary trial phase. 
For lead removal if the trial phase is unsuccessful, the patient requires a subsequent 
operative procedure to remove the lead with the possibility of minor complication. This 
is in contrast to SNS where a temporary stimulation electrode is placed during the trial 
phase which can be removed as an outpatient procedure with no patient morbidity. Our 
rationale for use of the quadripolar tined lead electrode (Model 3889, Medtronic), as in 
another similar study (34) ,was that the PNS techniques available to date were 
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cumbersome with the use of EMG (100) and the placement of second stimulation 
electrode at the same point would be technically difficult. Newer and easier PNS lead 
placement techniques (223) may in the future permit a temporary stimulation electrode 
placement similar to that used for SNS. 
 
 
5.11 - New Knowledge from this Study 
 
This study has shown the efficacy of pudendal nerve stimulation on bowel continence in 
patients with complete CES and in those who had failed sacral nerve stimulation 
Further prospective studies with larger patient numbers and longer follow-up are required 
to validate our findings. 
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Chapter  6 
 
 
A Single Blinded Placebo Controlled RCT of Percutaneous and Transcutaneous 
Posterior Tibial Nerve Stimulation in Faecal Incontinence 
 
6.1 - Overview of the chapter 
 
Posterior tibial nerve stimulation (PTNS) has gained prominence as a new approach to 
neuromodulation (224). In 1983, two studies (110, 169) showed that transcutaneous 
stimulation of the posterior tibial nerve using a surface electrode was effective in urinary 
urge incontinence and overactive bladder. This has since been confirmed by other 
studies (170, 171). The percutaneous route for PTNS was used by Stoller et al in 1999 
who described a new technique for needle placement (172). Percutaneous PTNS has 
been found to be more effective than the transcutaneous for bladder control and several 
studies have been published on the results of percutaneous PTNS for urological 
dysfunction (174, 175).  Shafik et al first reported the use of PTNS for fecal incontinence 
(FI) with a 78% improvement among 32 patients (35). Several subsequent studies 
including a multicentre study have demonstrated the efficacy of percutaneous and 
transcutaneous stimulation with improvements of 50 - 80% (35, 36, 111, 113, 176). 
Percutaneous stimulation may have a greater efficacy than transcutaneous stimulation 
as the stimulating electrode is closer to the posterior tibial nerve. To date, there have 
been no prospective studies comparing percutaneous and transcutaneous stimulation 
and studies relating to PTNS for FI have, so far, been uncontrolled.  
We describe a prospective, single-blinded placebo controlled study comparing 
percutaneous, transcutaneous and sham transcutaneous stimulation in FI. 
 
140 
 
6.2 - Percutaneous PTNS 
 
Stoller’s studies in monkeys,(225) based on research by McGuire et al who used direct 
electrical stimulation of the tibial nerve as an alternate route to SNS and to inhibit 
detrusor activity (110). This paved the way for the clinical application of percutaneous 
PTNS. The most commonly used technique for percutaneous PTNS is the Stoller 
technique, first described by Dr Marshall Stoller at the University of California, San 
Francisco Medical Centre in 1999 (172). The percutaneous approach requires placement 
of a small 34-gauge needle adjacent to the posterior tibial nerve along with a stimulating 
device (The Stoller Afferent Nerve Stimulator (SANS)) and a ground electrode on the 
ipsilateral limb. The posterior tibial nerve is stimulated at the SP-6 point (160, 161).  
 
6.3 - Transcutaneous PTNS 
 
Transcutaneous PTNS is stimulation of the posterior tibial nerve using surface electrodes 
placed on the skin over the nerve above and behind the medial malleolus  (160, 161). 
This is simpler to perform and less invasive and painful than percutaneous stimulation. It 
can be performed outside the hospital environment in the comfort of the patient’s own 
home. The technique that is commonly used for transcutaneous PTNS is the one 
described by Queralto et al (36). 
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6.4 - Hypothesis 
The working hypothesis was that percutaneous and transcutaneous PTNS would cause 
a clinically higher number of treatment responders compared to the sham group while the 
null hypothesis was that the responders in all three groups would be equal.  
6.5 - Study Protocol 
6.5.1 - Design  
The single blinded randomised controlled trial included three study arms: 
Group 1: Percutaneous tibial nerve stimulation 
Group 2: Transcutaneous tibial nerve stimulation 
Group 3: Sham trans-cutaneous tibial nerve stimulation 
A placebo group used was only for the transcutaneous stimulation as it was felt that a 
sham percutaneous group would be confounded by any acupuncture effects due to 
needle insertion (228-230). 
The study was carried out in a single center with the testing performed by one of five 
clinicians. The coded data were tabulated and analysed by one of the clinicians and a 
statistician, both of whom were blinded to the procedure used in any patient. 
 
6.5.2 - Evaluation 
Prior to consideration for enrolment in the study, all subjects underwent a thorough 
evaluation including clinical assessment, anorectal physiological testing and an endoanal 
ultrasound. At the time of recruitment, informed consent was obtained and all patients 
completed a detailed two-week bowel diary documenting bowel activity. Patients 
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recorded all episodes of incontinence to flatus, liquid and solid stool in addition to 
completing the St Mark’s Incontinence score (207), Rockwood quality of life in faecal 
incontinence questionnaires (203) and the SF-36 quality of life questionnaires (202).  
After the start of PTNS patients completed bowel diaries at the end of the 2nd, 4th and 
6th week recording all episodes of incontinence to flatus, liquid and solid stool.  
In addition, at the end of the 6 weeks, they entered details to allow computation of the St 
Mark’s Incontinence score (207).  The Rockwood quality of life of fecal incontinence 
questionnaires (203) and the SF-36 quality of life questionnaire (202) were also 
completed. Patients underwent anorectal manometry at 6 weeks. 
All patients who had a > 50% improvement in incontinence episodes at the end of the 
study period were followed up for a further 6 months at the end of which they exited the 
study. Those in groups 1 and 2 were given a top-up session of stimulation at the 1 month 
post study. As there was no accepted protocol for follow-up of either percutaneous or 
transcutaneous PTNS, regular top-up sessions of stimulation were arranged on an as-
required basis during the six months. Details of recurrence of symptoms and number of 
further top-up sessions were also recorded. 
 
6.5.3 - Patient Selection 
 
PTNS requires regular visits to the hospital over the stimulation period and there was a 
particular risk that any recorded improvement could in part be due to the extra attention 
the patient received or to lifestyle changes that occurred during treatment. To address 
this, the study was carried out on those patients who had attempted and failed 
conservative treatment and biofeedback therapy and were awaiting further treatment. 
Patients were selected after individual assessments from clinics based at St Mark’s 
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Hospital or identified from an existing database of such patients. All the recruited patients 
were asked to stop taking any constipating medications including loperamide before 
starting the trial. 
6.5.4 - Inclusion and Exclusion Criteria  
 Inclusion criteria  
The following were requirements for inclusion: 
1) Signed informed consent 
2) Age > 18 years 
3) FI defined as at least two episodes per week of involuntary loss to either solid or liquid 
stool as demonstrated by means of a baseline bowel habit diary 
4) Patients who have completed biofeedback awaiting further treatment 
5) Willing to consent to participate in clinical trial 
6) Willing to travel frequently to the study centre for investigation over the six-week 
duration of the stimulation 
7) Willing and competent to fill out diary cards and undergo physiological investigations 
during the study 
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Exclusion criteria 
The following patients were excluded from the study: 
1) Previous congenital or acquired spinal injury, spinal tumour or spinal surgery 
2) Neurological diseases, such as diabetic neuropathy, multiple sclerosis and 
Parkinson’s disease, 
3) Peripheral vascular disease / uncontrolled diabetes mellitus 
4) Congenital anorectal malformations 
5) Previous rectal surgery (rectopexy / resection) done < 12 months ago  
6) Present evidence of external full thickness rectal prolapse 
7) Chronic bowel diseases such as inflammatory bowel disease 
8) Chronic diarrhoea, uncontrolled by drugs or diet 
9) Alternating bowel habit, associated with abdominal pain such as severe constipation 
which requires daily medical treatment with suppositories, enemas and/or laxatives 
10) Anatomical limitations that would prevent successful placement of an electrode 
11) Previous use of transcutaneous or percutaneous electrical nerve stimulation 
12) Stoma in-situ 
13) Bleeding disorders 
14) Psychiatric or physical inability to comply with the study protocol 
15) Pregnancy or attempting to become pregnant 
 
6.5.5 - Primary and Secondary Endpoints 
The primary end point of this trial was to assess the efficacy of percutaneous and 
transcutaneous PTNS compared to the sham intervention in subjects with FI on an 
intention to treat basis. Response was defined as a ≥50% reduction in number of 
incontinence episodes per week at the end of the study period. 
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Secondary end points included changes in continence, urgency and quality of life scores 
as recorded by the Rockwood (203) and SF36 (202) QOL questionnaires at week 6 
compared to baseline. 
 
 6.5.6 - Technique 
6.5.6.1 - Percutaneous Stimulation 
 
Patients in the percutaneous stimulation group were treated with twice weekly sessions for 
6 weeks, each session lasting for 30 minutes. Percutaneous stimulation was  performed 
using the technique used by Stoller et al (172). The Urgent PC neuromodulation system 
(Uroplasty, Berkshire, UK) uses a 34-gauge inert stainless steel needle (Urgent1 PC 
catalogue #250-12) and a neutral surface electrode (Figure 24). The needle diameter was 
about the width of a hair. The patient was placed in the supine position with the soles of 
the feet together and the knees abducted and flexed. Palpation of the medial malleolus 
was performed and the 34-gauge stainless steel needle was introduced one finger breadth 
posterior and three finger breadths superior to the medial malleolus between the posterior 
margin of the tibia and soleus muscle (Figure 25). An adhesive electrode was placed on 
the same leg near the arch of the foot. The needle and electrode were connected to a 9V 
stimulator (Urgent PC®, Uroplasty Inc., US) with an adjustable pulse intensity of 0 - 20mA, 
a fixed pulse width of 200 microseconds and a frequency of 20Hz. 
A sensation of stimulation was experienced in the foot that travelled towards the big toe 
with increasing amplitude of stimulation and the amplitude was slowly increased until a 
motor and a sensory response was elicited. The motor response included the big toe 
starting to curl or the other toes starting to fan out. The sensory response was a tingling 
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sensation radiating to all the toes. If the big toe did not curl or pain occurred near the 
insertion site, the stimulation device was switched off and the procedure repeated after the 
position of the needle was readjusted. The current was set at the highest level that was 
tolerable to the patient. 
Stimulation was continued for thirty minutes before the needle electrode was simply 
removed and gentle pressure applied if any bleeding occurred. 
 
Figure 24: Percutaneous PTNS stimulation kit 
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Figure 25: Position for needle placement 
 
 
 
 
6.5.6.2 - Transcutaneous Stimulation 
Patients in the transcutaneous stimulation group were also treated with twice a week 
sessions for 6 weeks, with each session lasting for 30 minutes.  
Transcutaneous stimulation was applied using the technique described by Queralto et 
al (36). Two 50 mm x 50 mm self-adhesive surface electrodes (Model VS.5050, Premier 
Medical Products, Bedford) (Figure 26) were used with the negative contact electrode 
being placed on the skin behind the medial malleolus and the positive electrode being 
placed 10 cm above it. The electrodes were connected to a NeuroTrac Continence 
Neurostimulator (NeuroTrac Continence, Premier Medical Products, Bedford, UK) 
(Figure 27). The settings described by Queralto et al (36) of a pulse width of 200 
microseconds and a frequency of 10 Hz were modified to retain the same pulse width 
but the frequency increased to 20 Hz to mirror that of percutaneous PTNS. Stimulation 
current (0 to 60mA) was increased until a motor and a sensory response (as described 
Point of 
insertion of the 
needle 
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for percutaneous PTNS) was obtained. If no satisfactory response was obtained, the 
positive electrode was repositioned. The current was again set at the highest level that 
was tolerable to the patient. 
 
Figure 26: NeuroTrac Continence Neurostimulator   
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Figure  27: 50 mm x 50 mm electrodes for transcutaneous stimulation 
 
 
 
 
6.5.6.3 - Sham Transcutaneous Stimulation 
Patients in the sham transcutaneous group also had twice a week 30 minute sessions for 
6 weeks. The same kit used for the transcutaneous group was also used here with the 
electrodes being placed in similar positions. 
The stimulator was briefly switched on for 30 seconds to induce only a minor electrical 
sensation in the skin and was then turned off during the rest of the treatment. This short 
duration was given for only for a few seconds to avoid lower limb stimulation as reported 
in animal models (226). Patients in all three groups were told that they may not have any 
perception of the electrical sensation. Without prior knowledge about what to expect from 
treatment this enabled the sham group to act as a control. In order to improve on the 
blinding effect of the study the electronic display window of the stimulators was shielded 
for all patients in all the three groups. Treatments were provided for all patients in 
individual screened cubicles to prevent patient comparisons of the treatment given. This 
formed part of the strong visual and verbal suggestions that we used to validate the 
sham group (227). 
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To test the validity of the different groups, at the end of the trial, subjects in each group 
were also asked to identify which intervention they believed they received during the 
study and this was compared to the actual received. Concordance between believed 
treatment and administered treatment was then analysed.  
6.6 - Randomisation 
 
The sealed envelope technique for randomising patients was used (228). Predetermined 
codes (A- percutaneous PTNS, B- Transcutaneous PTNS and C- Sham transcutaneous 
PTNS) were used to identify each group and the papers with the codes were sealed in 
windowless envelopes with all the envelopes mixed together. Patients were asked to pick 
an envelope which was given to a named investigator who recorded the group that the 
patient had chosen. As codes were used in all documentation there was no possibility 
that the patients could inadvertently identify which group they belonged to. 
 
6.7 - Power Calculation for the Study 
 
The efficacy of percutaneous and transcutaneous PTNS compared with sham treatment 
was evaluated. Accordingly the working hypothesis was that percutaneous and 
transcutaneous PTNS would cause a clinically higher number of treatment responders 
compared to the sham group while the null hypothesis was that the responders in both 
groups would be equal.  
Sham transcutaneous PTNS has not been attempted previously either for urinary or for 
bowel dysfunction and there are therefore few data on the likely response rate. There are 
however data on sham percutaneous stimulation for urinary dysfunction reporting 
responses of 0 to 33% (229, 230).  For the purposes of this study, we therefore took a 
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10% response rate for the purpose of calculating the power. We took the  80% response 
rate reported by  Queralto et al as the expected figure in the treatment group (36). With 
these proportions and with the criterion for significance (alpha) was set at 0.050 (2 tails) 
and at a 5% significance level and 80% power, 10 patients were required in each group. 
To account for a dropout rate of 10%, 11 patients were required for each group.  
 
6.8 - Statistical Analysis 
The aim of the analyses was to compare between the three treatment groups at the end 
of the 6 week treatment phase. The patients were also measured at baseline, and 
baseline differences between groups were also considered in the analysis. All outcomes 
were measured on a continuous scale. The distribution of the change in values from 
baseline to subsequent times was found to be approximately normally distributed for 
most endpoints. The exception was for the ability to defer, anal sensitivity and the 5-
second endurance squeeze pressures, which were found to be highly skewed in 
distribution. As a result, these variables were analysed on the log scale.  
Analyses were performed by analysis of covariance (ANCOVA). These compared the 
groups at the end of the 6 week treatment phase adjusting for the baseline values for 
each outcome. Additionally the overall difference in outcome between the three groups 
and the individual difference between each pair of groups was also assessed using the 
Fisher's exact test. Whenever multiple comparisons between groups for the same 
outcome were performed, the increased risk to find a significant result due to chance 
alone was compensated by allowing the p-values to be corrected upwards using the 
Bonferroni adjustment. Consistently, to allow for multiple testing, 98.3% confidence 
intervals are presented with the differences rather than 95% confidence intervals. P 
values of 0.05 and less were considered significant.  
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6.9 - Results 
 
  
 Thirty patients (28 female, 2 male, mean age: 57 +/- 13.5 years) were recruited. The 
mean duration of incontinence was 55 +/- 22.3 months. Twenty three patients had 
both urge and passive FI, six had only urge while one patient had passive FI only. 
The mean BMI was 27.2 +/- 3.7. All 28 women were multiparous. Eleven had had 
normal vaginal deliveries and 17 had a documented third or fourth degree tear. On 
endoanal ultrasound eleven (37%) patients had an intact external (EAS) and internal 
anal sphincter (IAS) muscles, three (10%) had an isolated EAS defect, 2 (7%) had 
only an IAS defect and 14 (46%) had damage to both the EAS and IAS.  
Eighteen patients had had a previous surgical procedure including sphincter repair, 
repeat sphincter repair, post anal repair, bladder surgery, stapled 
haemorrhoidectomy and an abdominal hysterectomy. Two patients had hypertension, 
two had asthma and two had well controlled diabetes mellitus. Six patients were 
healthy with no co-morbidity or previous surgery.   
Of the 30 patients, 11 were randomised to group 1 (percutaneous group), 11 to group 2 
(transcutaneous group) and 8 to group 3 (sham transcutaneous group). One patient in 
group 2 withdrew from the study after one week for personal reasons. All the remaining 
29 patients successfully completed the 6 weeks treatment. 
 
6.9.1 - Complications 
 
During stimulation, two patients reported two episodes each of mild self-limiting 
cramping abdominal pain which settled with paracetamol. One patient developed 
minor bleeding from the needle insertion site, which stopped with pressure. No 
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patient reported pain, swelling, evidence of infection or any other complication 
during the study period.  
Successful stimulation was denoted by the presence of both a sensory and a motor 
response in the foot in both group 1 and group 2. In one patient in group 1 (who was not 
a known diabetic patient), no sensory response was elicited despite multiple attempts at 
repositioning the electrode.  The mean intensity of stimulation required for obtaining a 
successful response in the group 1 was 8.7 +/- 3.7 mA while the same for the group 2 
was 28.2 +/- 12 mA. 
 
6.9.2 - Responders in Each Group 
 
All the patients who responded became fully continent with no episodes of FI at the end 
of the 6 week assessment. 
On an intention to treat basis, the number of responders who reported a greater than 
50% reduction in the number of incontinence episodes/week at the end of the 6 weeks of 
the study were 9 (82%) of the 11 patients in group 1, 5 (45%) of the 11 in group 2 and 1 
(12.5%) of the 8 patients in group 3. Analysing these proportions using the Fisher’s exact 
test with Bonferroni correction, the differences between these groups were statistically 
significant (p = 0.01) (Table 15).   
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Table 15: Patients with > 50% reduction in incontinence episodes/week 
 
Groups 
> 50% reduction 
in incontinent 
episodes/week   
(%) 
Overall 
P-value * 
Group 1 to 
Group 2 * 
Group 1 to 
Group 3 * 
Group 2 to 
Group 3 * 
Group 1 
(n=11) 
9 (82%) 
0.01 0.55 0.02 0.53 
Group 2 
(n=11) 
5 (45%) 
Group 3 
(n=8) 
1 (12.5%) 
* Data analysed using Fisher's exact test (with Bonferroni correction to allow for multiple testing) 
 
6.9.3 - Other Continence Parameters 
 
After 6 weeks of the treatment phase, the number of incontinence episodes per 
week (mean +/-S: D) in groups 1, 2 and 3 were 1.8 +/-2.0, 5.1 +/- 5.5 and 4.7 +/- 
3.5. The differences between groups were significant overall (p=0.04). Groups 2 
and 3 had significantly more incontinent episodes per week than group 1(Table 16). 
Patients in groups 1, 2 and 3 showed improvement in the ability to defer defecation 
(minutes +/-S: D) at 6 weeks as follows: 6.7 +/- 5.2 minutes, 4.4 +/- 5.4 minutes 
and 2.6 +/- 1.5 minutes. The differences between groups were statistically 
significant (p=0.01) with group 1 having a 2 to 3 times better ability to defer 
defecation compared to group 2 and group 3.  
There were no significant differences between the  groups  in the St Mark’s 
continence Score (231) (p=0.20) or in the daily bowel movements (p=0.27) at the 
end of the 6 week phase. 
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Table 16: Faecal incontinence assessment parameters between groups 
Variable    Group Mean (SD) Adj. Difference 
Mean (98.3% CI) 
Overall   
P-value ** 
Incontinent 
Episodes / week 
Group 1 1.8 (2.0) 0 
0.04 Group 2 5.1 (5.5) 3.6 (-0.1, 7.4) 
Group 3 4.7 (3.5) 3.5 (-0.5, 7.6) 
Ability to Defer *  
(minutes) 
Group 1 6.7 (5.2) 1 
0.01 Group 2 4.4 (5.4) 0.43 (0.18, 1.05) 
Group 3 2.6 (1.5) 0.32 (0.12, 0.82) 
St. Marks Score 
(0-24) 
Group 1 12.7 (2.1) 0 
0.20 Group 2 14.7 (6.7) 2.3 (-1.9, 6.5) 
Group 3 14.1 (2.4) 3.1 (-1.6, 7.9) 
 
 Bowel Movements/24 
hours 
Group 1 2.3 (1.0) 0 
0.27 Group 2 2.4 (1.3) 0.5 (-0.4, 1.5) 
Group 3 2.6 (1.1) 0.5 (-0.5, 1.5) 
*data analysed on a log scale 
** Data analysed using analysis of covariance (ANCOVA) 
 
6.9.4 - Quality of Life Assessment  
 
The Rockwood FI specific QOL and the SF-36 QOL scores showed no significant 
improvements between groups at the end of the 6 week study phase except for the 
vitality subset in the SF-36 analysis.  (Table 17) 
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Table 17: Rockwood and SF-36 Quality of Life assessment  
 
Variable Group Mean (SD) 
Adj. Difference 
Mean (98.3% CI) 
Overall 
P-value * 
Rockwood Fecal Incontinence Quality of Life Scores 
Lifestyle 
Group 1 2.7 (0.8) 0  
0.17 Group 2 2.4 (1.2) -0.5 (-1.2, 0.2) 
Group 3 2.7 (1.2) 0.0 (-0.8, 0.8) 
Coping / Behaviour 
Group 1 2.2 (0.5) 0  
0.54 Group 2 2.0 (1.1) -0.2 (-0.8, 0.5) 
Group 3 2.1 (0.9) -0.3 (-1.0, 0.4) 
Depression 
/ Self-perception 
Group 1 3.0 (0.5) 0  
0.45 Group 2 2.7 (0.7) -0.2 (-0.9, 0.3) 
Group 3 2.9 (0.9) -0.2 (-0.9, 0.4) 
Embarrassment 
Group 1 2.0 (0.9) 0  
0.83 Group 2 1.8 (0.7) -0.1 (-0.8, 0.7) 
Group 3 2.7 (1.1) 0.2 (-0.7, 1.1) 
Short Form 36 Quality of Life Scores 
Physical Function 
Group 1 57 (33) 0  
0.67 Group 2 65 (27) 5 (-9, 19) 
Group 3 76 (25)         1 (-14, 17) 
Role Physical 
Group 1 61 (47) 0  
0.98 Group 2 65 (47) -2 (-44, 39) 
Group 3 56 (48) -3 (-47, 41)        
Body Pain 
Group 1 53 (26) 0  
0.88 Group 2 61 (29) 4 (-18, 28) 
Group 3 62 (33) 1 (-24, 26)      
General Health 
Group 1 57 (14)          0  
0.25 Group 2 63 (25) 10 (-5, 25) 
Group 3 54 (29) 3 (-13, 19) 
Vitality 
Group 1 46 (18) 0  
0.008 Group 2 54 (26) -4 (-21, 14) 
Group 3 37 (31)    -24 (-42, -5)     
Social Function 
Group 1 77 (21) 0  
0.51 Group 2 64 (32) -12 (-39, 15) 
Group 3 67 (40) -2 (-32, 27)       
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Role Emotional 
Group 1 76 (37) 0  
0.41 Group 2 57 (47) -24 (-70, 23) 
Group 3 62 (45) -18 (-67, 31)         
Mental Health 
Group 1 76 (15) 0  
0.44 Group 2 75 (24) -7 (-25, 11) 
Group 3 72 (22) -9 (-28, 10)         
   * Data analysed using analysis of covariance (ANCOVA) 
 
6.9.5 - Anorectal Physiology Assessment 
 
There was no statistical change of anorectal physiology assessments in the groups 
at the end of the 6 week study phase except for squeeze pressures (Table 18). 
 The squeeze pressures improved in all the three groups following the 6 weeks of 
treatment. In group 1, the mean squeeze pressure increment +/- SD improved from 
a baseline  of  50 +/- 29 cm of water to 68 +/- 34cm of water at the end of the 6 
weeks (p=0.042). The same for group 2 and 3 was 27 +/- 14 and 31 +/- 20 at 
baseline compared to 35 +/- 22 and 40 +/- 25 at the end of the 6 weeks (p=0.046 
and p=0.037) respectively. 
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Table 18: Anorectal Physiology Parameters 
 
Variable Group Mean (SD) Adj. Difference 
Mean (98.3% CI) 
Overall   
P-value ** 
Resting  Pressure 
 
Group 1 46 (23) 0  
0.61 Group 2 61 (27) 7 (-14, 28) 
Group 3 65 (28) 8 (-15, 31) 
Peak squeeze 
Pressure 
 
Group 1 68 (34) 0  
0.44 Group 2 35 (22) -10 (-32, 12) 
Group 3 41 (25) -9 (-32, 13) 
5 second Squeeze 
Pressure * 
 
Group 1 20 (16) 1  
0.75 Group 2 13 (11) 0.82 (0.29, 2.30) 
Group 3 21 (21) 1.13 (0.38, 3.36) 
Involuntary Squeeze 
Pressure 
 
Group 1 74 (36) 0  
0.28 Group 2 51 (20) -16 (-47, 15) 
Group 3 49 (16) -19 (-51, 13) 
Threshold Volume 
 
Group 1 54 (17) 0  
0.07 Group 2 60 (24) 5 (-21, 31) 
Group 3 78 (33) 25 (-2, 53) 
Urge Volume 
 
Group 1 107 (39) 0  
0.45 Group 2 99 (42) -7 (-44, 29) 
Group 3 118 (46) 13 (-26, 52) 
Maximal Volume 
 
Group 1 149 (43) 0  
0.23 Group 2 136 (53) -21 (-58, 15) 
Group 3 154 (54) 3 (-35, 41) 
Rectal Sensitivity 
 
Group 1 26 (9) 0  
0.11 Group 2 18 (4) -8 (-16, 1) 
Group 3 22 (8) -4 (-13, 5) 
Anal Sensitivity * 
 
Group 1 9.1 (3.0) 1  
0.56 Group 2 8.7 (2.7) 0.95 (0.65, 1.38) 
Group 3 10.4 (3.7) 1.12 (0.76, 1.42) 
Anal Canal Length 
 
Group 1 2.9 (0.3) 0  
0.43 Group 2 2.9 (0.2) 0.0 (-0.3, 0.3) 
Group 3 
2.8 (0.4) -0.2 (-0.5, 0.2) 
*data analysed on a log scale 
** Data analysed using analysis of covariance (ANCOVA) 
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6.9.6 - Patient Perspectives 
 
Six (75%) of eight patients in group 3 thought that they were receiving active 
treatment while five (45%) of eleven patients in group 2 thought that they were in 
the placebo group. Nine (82%) of the 11 patients in group 1 felt that their 
incontinence had improved following treatment. Five (45%) of the 11 patients in 
group 2 also felt that their symptoms had improved. Only one (12.5%) of the eight 
patients in group 3 felt that their symptoms had improved.  
 
6.9.7 - Follow-up 
 
Patients who had > 50% improvement in symptoms were followed for a further six 
months. No patient in any of the groups was lost during the follow-up period. 
Seven out of the nine patients in group 1 remained asymptomatic and required no 
top-up sessions. The remaining two patients had a loss of efficacy after 3 months. 
This was regained after monthly top-up sessions of percutaneous PTNS.. All the 
five patients in group 2 and the single patient in group 3 remained asymptomatic 
until the end of the six month follow-up period. 
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6.10 – Discussion 
 
Different studies have highlighted the efficacy of percutaneous and  transcutaneous 
PTNS in FI (232). Our study is, however, the first to compare these by a controlled 
randomised study. The findings confirm the efficacy of percutaneous over 
transcutaneous with a higher proportion of patients responding to treatment (82% 
compared with 45%). The response in the transcutaneous group (45%) was lower than in 
other studies (60-85%) (36).  
Our approach to sham transcutaneous PTNS is, to our knowledge, the first attempt at a 
sham percutaneous PTNS approach for FI. Percutaneous needle insertion was not used 
for the sham group due to concerns about a possible stimulatory effect associated with 
needle insertion (233). Even a brief period of stimulation may be sufficient to produce a 
neuromodulatory effect (233). The placebo effect associated with pad application and 
transcutaneous PTNS may be lower than that reported with percutaneous PTNS (229, 
230).  
In order to improve on the blinding effect of the study the electronic display window of the 
transcutaneous stimulator was shielded for all patients. Treatments were provided for all 
patients in individual screened cubicles to prevent patient comparisons of the treatment 
given. This formed part of the strong visual and verbal input  that we used to validate the 
sham group (227) . 
Currently SNS is the next treatment option for some patients who fail conservative 
measures (16). The patients recruited to this study had been offered this procedure. 
Following improvement in symptoms, 8 patients withdrew from the waiting list for SNS.  
SNS is an effective treatment for FI in selected patients but it is expensive and can be 
associated with some morbidity and limited adaptability once in situ (178). PTNS is 
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simpler, less invasive and has the additional benefit that it can be safely administered in 
a nurse-led outpatient clinic(179). All the patients in the present study had PTNS on an 
outpatient basis with no discomfort or other complications. Outside the context of a 
clinical trial, PTNS may offer a possibility of treatment being self-administered though 
some patients may have difficulty with or reluctance to perform needle insertion.  
PTNS is thought to work through  sensory and motor neuromodulation (232) but the 
exact mechanism is unclear. Neurostimulation has been reported to cause improvement 
in afferent rectal sensory perception (77, 234) and striated sphincter muscle function (35, 
77, 235). In contrast, the present study shows that although significant improvement in 
squeeze pressure was observed in the percutaneous and transcutaneous group, an 
equally significant change was also observed in the sham group. In addition there was no 
appreciable difference between rectal sensory perceptions in the three groups.  These 
findings suggest that the previously observed differences may not in fact be true 
differences, as such findings were also observed in the placebo group. 
For percutaneous PTNS, reduction in urgency has been described as the first indication 
that the treatment is effective (179). We did not observe this in our study group and a 
reduction in urgency was seen only towards the latter half of the treatment period. 
 
6.10.1 - Limitations of the Study  
 
Our study has several limitations. The patient numbers in our study are small. Although 
the patient numbers were sufficient to identify overall differences between groups, this 
study was underpowered for specific comparison between groups. The absence of a 
comparative percutaneous sham group makes it difficult to exclude bias towards 
favourable outcome in the percutaneous PTNS group. The patients selected were those 
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from a tertiary center who had failed conservative treatment. There was therefore a 
possibility of a Hawthorne effect confounding our findings. The fact that we had only 8 
subjects in the sham group (instead of the 11 required) may conceal a higher 
improvement rate in the sham group. A larger study with more patients in each study arm 
may show the true response for the placebo treatment. A longer follow-up of the patients 
who showed a > 50% improvement in FI may have demonstrated whether the improved 
continence was sustained over a longer term as well as in evaluating the top-up 
maintaince required.   
 
6.10.2 - Alteration of Stimulation Settings for Uniformity 
 
The pulse width stimulation settings for the transcutaneous PTNS were modified 
compared to settings as described by Queralto et al (36) in order to provide an uniform 
and comparable setting for both the percutaneous and the transcutaneous PTNS. The 
pulse width of 10 Hz was increased to 20 Hz as a pulse width at 20 Hz was suggested to 
cause effect through two mechanisms - conversion of fast twitch fibres into slow twitch 
fibres (166) and a reflex inhibition (167). Chung et al demonstrated that increasing 
frequencies (upto a maximum of 20 Hz) showed a linear relationship with increasing 
nerve inhibition (163). 
 
6.11 - New Knowledge from this Study 
 
This randomised placebo controlled study shows PTNS to have a short-term 
improvement on bowel continence as well as a superior efficacy for percutaneous PTNS 
compared to the transcutaneous route of stimulation. 
163 
 
Our results may also contradict previous study findings that PTNS may exert its action 
through improved afferent rectal sensory perceptions (77, 234) and improved striated 
sphincter muscle function (35, 77, 235) as there was a  similarity of findings in the 
placebo group. 
 
6.12 - Scope for Further Research 
 
Further prospective studies are required to evaluate the response of both percutaneous 
and transcutaneous PTNS in a larger population of patients including studies to assess 
the optimal frequency and duration of treatment as well as the parameters of stimulation 
that gives best effect 
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Chapter  7 
 
Double Blinded Crossover of Sacral Nerve Stimulation in Constipation 
    
7.1 - Overview of the Chapter 
 
Constipation can be a distressing problem which can drastically affect the quality of life of 
the affected individual. This condition can have an overwhelming impact on psychosocial 
behaviour with diminished self-esteem and social isolation. Sacral nerve stimulation (SNS) 
for constipation is a relatively new treatment (88). The long term effects of 
neurostimulation on bowel function in constipation are not known. 
This double blinded crossover study assessed whether implanted SNS devices could be 
safely switched off without loss of efficacy. 
 
7.2 - Hypothesis 
The hypothesis for this study was that patients would have a demonstrable difference in 
constipation symptoms when the implanted neurostimulator was in the ON and OFF 
phases while the null hypothesis was that there would be no demonstrable differences 
between the two phases.  
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7.3 - Study Protocol 
 
7.3.1 - Details of the Sample Group 
 
Patients who had an SNS implanted for slow transit constipation were identified from an 
existing database of patients at St Mark’s Hospital.  
 
7.3.2 - Study Design   
 
Once the eligibility of the patient for the study was confirmed informed consent was 
obtained after a detailed discussion with the patient. 
The study had 3 phases: 
 
 -- Base-line phase 
 -- Cross-over phase 1  
 -- Cross-over phase 2 
 
Phase 1 (Study Baseline Phase – Month 1) 
 
During the baseline phase the severity of constipation of each patient was recorded, by 
the patient, using a continuous detailed bowel diary documenting their daily bowel activity. 
The patients also completed the Wexner Constipation Score (206), the PAC-QOL 
Constipation Quality of Life assessment Questionnaire (204), and the SF-36 Quality of Life 
Questionnaire (202) once at the end of Phase 1.The patient also had ano-rectal 
physiological testing and a colonic transit study done at the end of this phase. 
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Phase 2 (Cross-Over Phase 1 – Month 2) 
 
 Both the patients and the investigator were blinded when the patients were randomised 
using a sealed envelope technique, to one of 2 groups – the first group having their SNS 
implant left switched ON and the second group having their implant switched OFF.  
This was done by an independent research nurse with experience of SNS programming. 
During this phase, the severity of the bowel symptoms was recorded by the patient, using 
a continuous detailed 1 month bowel diary, documenting their daily bowel activity. The 
patients also completed the Wexner Constipation Score(206), the PAC-QOL Constipation 
Quality of Life assessment Questionnaire(204) and the SF-36 Quality of Life 
Questionnaire(202) at the end of month 2. The patients also had ano-rectal physiological 
testing and a colonic transit study done at the end of this phase. 
 
Phase 3 (Cross-over Phase 2 – Month 3) 
 
During this phase both the patients and the investigator remained blinded and the patients 
crossed over to the opposite study arm. Switching ON or switching OFF of the stimulators 
was performed by the same independent research nurse as in Phase 1. During this phase 
the severity of the bowel symptoms was also recorded by the patient using a continuous 
detailed 1 month bowel diary, documenting their daily bowel activity. The patients also 
completed the Wexner Constipation Score(206), the PAC-QOL Constipation Quality of Life 
assessment Questionnaire(204) and the SF-36 Quality of Life Questionnaire(202) at the 
end of month 3. The patients also had ano-rectal physiological testing and a colonic transit 
study done at the end of this phase. 
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At the end of the study patients were unblinded and all the stimulators were switched on to 
the pre- study settings. The original baseline data, i.e. - the baseline data that patients had 
provided before they had the neurostimulator implanted for their constipation – was also 
looked at and compared. 
 
 
7.3.3 - Flow chart of the study  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Original Baseline         
(Prior to SNS implant) 
Study Baseline         
(6 years post SNS) 
ON 
 
OFF 
 
Post Study 
assessment 
Blinded and Randomised 
ON 
 
OFF 
 
1 month 1 month 
Unblinded 
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7.3.4 - ON and OFF Neurostimulator settings 
 
All the patients had the stimulators turned up to a level at which they could detect the 
impulse. In the active group this was then turned down to a sub sensory level. In the 
inactive group, the stimulators were switched off. 
Throughout the study and for ethical reasons, the patient retained their handheld 
programmers (Medtronic, Interstim model 3031) which could be used to start stimulation 
or alter the stimulation voltage. The patients were asked not to use it except in case of an 
emergency and to report any such usage to the investigator. In addition the independent 
research nurse checked that the stimulator was switched ON or OFF at the end of each 
trial period. The stimulation parameters were also checked to ensure that they were the 
same as the pre-trial parameters. 
 
 7.3.5 - Colonic Transit Study 
 
A colonic transit study was obtained at study baseline and at the end of each of the study 
arms and compared to the original baseline. The transit study was done using radiopaque 
markers which were ingested over five consecutive days, followed by a plain abdominal 
radiograph taken 120 hours after ingestion of the first set of markers. Retention of an 
excessive proportion of any one of the sets of markers (more than 80%) was regarded as 
diagnostic for slow transit constipation. 
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7.3.6 - Inclusion and Exclusion Criteria 
 
Inclusion Criteria  
 
1) Age of 18years or older. 
2) Patients who had previously undergone a successful 3 week trial for SNS and then had 
the permanent neurostimulator implanted. 
3) Patients who had successfully completed at least five years from having the permanent 
neurostimulator implanted for their constipation 
4) Competent to and willing to fill in questionnaires and attend clinics throughout the study. 
5) Patient must be able to comprehend and fully understand the meaning of his/her 
participation in the study and sign on the informed consent form. 
 
Exclusion Criteria 
 
1) Patients who are unable to consent 
2) Patients with spinal cord injury or other neurological diseases 
3) Known Immune deficiency states 
4) Pregnancy / Breastfeeding 
5) Patients who are mentally or physically unable to comply with the protocol of the study. 
 
7.3.7 - Primary and Secondary End Points 
 
Primary Endpoint 
 
The primary endpoint of the study was to assess the improvement in bowel function   
measured objectively though a detailed 21 day bowel diary and assessment of the Wexner 
Constipation Score (205). 
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Secondary Endpoints 
  
The secondary endpoints included assessments in the quality of life changes which were  
measured using the PAC-QOL Constipation Quality of Life assessment Questionnaire(204) 
and the SF-36 Quality of Life Questionnaire(202) and assessment of safety as measured by 
the presence of any device related adverse events. 
 
7.4 - Ethical Permission 
 
Ethical permission to proceed with the study of pudendal nerve stimulation was granted by 
the Outer Northeast London Research Ethics Committee. Written informed consent was 
obtained from all patients after a detailed discussion of the procedure involved and before 
any investigation and treatment. 
 
7.5 - Power of the Study 
 
The study was powered to detect a difference of seven units on the Wexner Constipation 
Scale, between the ON and the OFF phase. The difference of seven units was based on the 
original Wexner Score publication where a score of 15 or more was defined as constipation 
and patients who improved in their symptoms were required to show a 50% improvement 
(have a score of 8 or less i.e. a difference of at least 7 units) (205). The criterion for 
significance (alpha) was set at 0.050 (2 tails). With a 5% significance level and 90% power, a 
minimum of 6 patients were required for the study.  
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7.6 - Statistics 
 
Two sets of comparisons were made. The first set was a comparison between the ON and 
OFF phase to the study baseline. The baseline assessment had been made following a 
mean of 6 years of having a working neurostimulator insitu. Several outcomes were 
measured as part of the study, the majority of which were measured on a continuous 
scale. There were three exceptions - digital assistance, enemas assistance and laxative 
use, which were categorical in nature. As these outcomes were relatively rare, no formal 
analysis was performed for these outcomes. The analysis from both phases was analysed 
using linear regression. The explanatory variables used were patient id, time period and 
device on or off. The main focus of the analysis was the effect of the device on the 
outcome, but the other two factors were included to allow for differences in outcomes 
between patients, and also for statistical validation for the order effect. The analyses of the 
majority of outcomes met the assumptions for linear regression. The exception was for the 
number of unsuccessful visits to the toilet, which had a highly skewed distribution, hence 
was given a log transformation before analysis. 
The second set of comparisons was between the original baseline (before patients had the 
neurostimulator implanted) and the study baseline (following a mean of 6 years of working 
neurostimulator insitu). All outcomes were measured on a continuous scale. Analyses of 
the differences in outcomes over time found were found to be normally distributed and 
hence a paired t-test was used for the second set analyses. 
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7.7 - Results 
 
Six female patients (mean age: 45 +/- 11.1 years) participated in the study. 
All six patients had a > 50% improvement in constipation symptoms following a temporary 
testing phase and had the permanent neurostimulator implanted. The median duration of 
time since permanent neurostimulator implant was 6 years (5 - 9 years). All six patients 
had been on regular follow up as part of the multicentre trial of SNS for constipation (88) 
and had come off the study at the end of the five year follow up period. 
All six were healthy with no co-morbidities. 
 
7.7.1 - Follow up and Complications 
 
No patient reported any complications during the study period. Although all had a 
hand held programmer, none reported using the programmer during the entire 
duration of the study.  
 
7.7.2 - Colonic Transit Studies 
All patients recruited into the crossover study had slow transit before they had the 
neurostimulator implanted. Four of the six patients showed a change to normal transit 
at the 6 year follow-up baseline. During the ON and OFF phases only 2 of the 6 
patients showed any change in colonic transit times – both patients showed a slowing 
of transit with the SNS switched OFF and a normalisation of transit with the device 
switched ON. (Table 19)  
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Table 19: Colonic Transit studies in the patients  
 
Patient ID 
Original 
baseline 
Study 
Baseline 
ON OFF 
Pt 1 slow normal normal normal 
Pt 2 slow normal normal slow 
Pt 3 slow slow slow slow 
Pt 4 slow slow slow slow 
Pt 5 slow normal normal normal 
Pt 6 slow normal normal slow 
 
 
 
 
7.7.3 - Continence Parameters  
 
 
 
Baseline to OFF/ON Phase Comparison 
 
 
Nine parameters used to assess constipation were measured during the OFF and ON 
phase and compared to the study baseline (Table 20).  
The analyses suggested that there was no significant difference in outcomes between when 
the device was OFF and ON for the majority of outcomes. 
However, significant differences were observed for two outcomes, the urge to defecate and 
the number of unsuccessful visits to the toilet. The urge to defecate was increased when 
the device was on, with an increase of 3 minutes with the device on compared to having the 
device off. The number of unsuccessful visits to the toilet was decreased with the device on 
with around 10 times less unsuccessful visits with the device on compared to having the 
device off. 
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Table 20: Constipation symptoms between Study Baseline and OFF/ON Phases  
 
Variable 
 
Study Baseline 
Mean (SD) 
OFF 
Mean (SD) 
ON 
Mean (SD) 
Mean 
(95% CI) 
P-value** 
 
Wexner score 
 
10.3 (3.8) 
 
15.7 (5.4) 
 
10.8 (5.3) 
 
-5.3 (-17.2, 6.7) 
 
0.29 
Bowel 
movements/week 
5.7 (2.2) 2.1 (1.5) 6.5 (4.8) 4.4 (-3.3, 12.0) 0.18 
Urge to defecate 
(mins) 
5.4 (4.6) 6 (4) 9 (5) 3.2 (0.5, 5.9) 0.03 
Time in lavatory 
(mins) 
6.7 (2.6) 14.3 (8.4) 7.3 (2.9) -7.3 (-17.9, 3.4) 0.13 
Unsuccessful  
lavatory visits/week * 
0.5 (1.2) 14.0 (11.7) 0.5 (0.8) 
 
0.11 (0.02, 0.79) 
 
0.04 
Sense of incomplete 
evacuation (%) 
4 (8) 51 (30) 23 (34) 
-34 (-100, 39) 
 
0.27 
Abdominal Pain 
 (%) 
3 (4) 45 (29) 8 (20) 
-36 (-98, 27) 
 
0.19 
Abdominal Bloating 
(%) 
5 (12) 48 (29) 17 (36) 
 
-35 (-100, 48) 
 
0.32 
Straining on 
defaecation (%) 
0(0) 31 (19) 8 (20) -27 (-75, 21) 0.20 
* Value given a log transformation before analysis 
** P value calculated using linear regression 
 
 
Original Baseline to Study Baseline Comparison 
 
 
All nine parameters used above to assess constipation were measured and compared 
between the Original Baseline and the Study Baseline phases (Table 21).  
The results suggested that there were significant differences between the two phases for 
the Wexner score, weekly bowel movements, time in the lavatory, incomplete evacuation, 
straining on evacuation, and unsuccessful visits to the lavatory, abdominal pain and 
abdominal bloating. There was a significant decrease in values for all of these outcomes, 
with the exception of the number of bowel movements, which increased over time. The 
Wexner score was found to have reduced by a mean of 14 units between the two time 
periods. 
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Table 21: Constipation symptoms between Original Baseline and Study Baseline Phases  
 
Variable 
 
Original 
Baseline 
Mean (SD) 
Study 
Baseline 
Mean (SD) 
Difference 
 (Original – Study Baseline) 
Mean (95% CI) 
P-value * 
 
Wexner score 
24.2 (3.4) 10.3 (3.8) -13.8 (-20.5, -7.2) 0.003 
Bowel 
movements/week 
0.9 (0.4) 5.7 (2.2) 4.8 (2.2, 7.3) 0.005 
Urge to defecate 
(mins) 
2.7 (2.0) 7.0 (5.7) 4.4 (-1.0, 9.7) 0.09 
Time in lavatory 
(mins) 
28.3 (16.6) 6.7 (2.6) -21.7 (-40.3, -3.0) 0.03 
Unsuccessful  
lavatory visits/week  
23.0 (6.8) 0.5 (1.2) -22.5 (-29.7, -15.3) <0.001 
Sense of incomplete 
evacuation (%) 
94 (7) 4 (8) -90 (-103, -77) <0.001 
Abdominal Pain 
 (%) 
89 (12) 3 (4) -86 (-98, -75) <0.001 
Abdominal Bloating 
(%) 
85 (7) 5 (5) -80 (-97, -63) <0.001 
Straining on 
defaecation (%) 
95 (5) 0 (0) -95 (-99, -90) <0.001 
* P value calculated using linear regression 
 
 
7.7.4 - Anorectal Physiology  
 
Comparison between Study Baseline and OFF/ON Phases  
  
Anorectal manometric assessments using nine parameters were used to compare 
between the study baseline and the OFF/ON Phases (Table 22).  
The analyses suggested that there was no significant difference in outcomes between when 
the device was OFF and ON for anorectal manometric assessments. 
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Table 22: Anorectal Manometry Comparison between Study Baseline and OFF/ON Phases  
 
Variable 
 
Study Baseline 
Mean (SD) 
OFF 
Mean (SD) 
ON 
Mean (SD) 
Mean 
(95% CI) 
P-value* 
 
Resting pressure 
94 (36) 83 (50) 88 (36) 13 (-28, 54) 0.43 
 
Peak Squeeze pressure 
84 (32) 77 (46) 102 (43) 27 (-12, 66) 0.12 
 
5 sec squeeze pressure 
35 (28) 20 (24) 38 (33) 27 (-17, 71) 0.16 
 
Involuntary squeeze 
pressure 
58 (24) 53 (27) 62 (38) 8 (-33, 49) 0.61 
 
Threshold volume 
77 (23) 56 (24) 70 (26) 18 (-26, 63) 0.32 
 
Urge volume 
117 (27) 107 (22) 111 (36) 9 (-49, 67) 0.70 
 
Maximum volume 
162 (37) 152 (20) 153 (41) 2 (-60, 64) 0.94 
  
Anal Sensitivity 
12.0 (8.7) 8.1 (1.6) 7.4 (1.7) -0.3 (-1.9, 1.3) 0.62 
 
Rectal Sensitivity  
20.0 (1.7) 17.4 (7.6) 16.1 (5.5) -0.6 (-8.4, 7.3) 0.86 
* P value calculated using linear regression 
 
Original Baseline to Study Baseline Comparison 
 
All nine parameters used in anorectal manometric assessments were used to compare 
between the original baseline and the study baseline as well (Table 23). 
Although there was evidence of a slight increase in threshold volume and in the resting 
pressure following six years of the working neurostimulator being in-situ, these results were 
not statistically significant. No other significant improvements in other anorectal manometric 
assessments between the original baseline and the study baseline were seen. 
 
 
 
 
 
177 
 
Table 23: Anorectal Manometry Comparison between Original Baseline and Study Baseline  
 
Variable 
 
Original 
Baseline 
Mean (SD) 
Study 
Baseline 
Mean (SD) 
Difference 
 (Original – Study Baseline) 
Mean (95% CI) 
P-value * 
 
Resting pressure 
81 (10) 94 (36) 12 (-2, 27) 0.08 
 
Peak Squeeze 
pressure 
90 (68) 84 (32) -7 (-55, 42) 0.73 
 
5 sec squeeze 
pressure 
33 (24) 35 (28) 2 (-28, 32) 0.89 
 
Involuntary squeeze 
pressure 
68 (31) 58 (24) -10 (-35, 15) 0.34 
 
Threshold volume 
50 (27) 77 (23) 27 (0, 53) 0.05 
 
Urge volume 
118 (50) 117 (27) -2 (-37, 34) 0.92 
 
Maximum volume 
198 (55) 162 (37) -36 (-81, 9) 0.09 
 
Anal Sensitivity 
9.8 (4.6) 12.0 (8.7) 2.2 (-6.9, 11.3) 0.56 
 
Rectal Sensitivity 
28.5 (17.4) 20.0 (1.7) -8.6 (-26.4, 9.3) 0.27 
* P value calculated using paired t-test 
 
 
7.7.5 - Quality of Life (QOL) Comparisons 
 
 
 Comparison between Study Baseline and OFF/ON Phases 
 
Quality of Life assessments were carried out using the generic  SF-36 quality of life 
questionnaires (202) and the constipation specific PACQOL constipation questionnaire (204). 
Although changes were observed between the ON and OFF phases, no significance could 
be inferred. (Table 24)  
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Table 24: Quality of Life Assessments between Study Baseline and OFF/ON Phases   
 
Variable 
 
Study Baseline 
Mean (SD) 
OFF 
Mean (SD) 
ON 
Mean (SD) 
Mean 
(95% CI) 
P-
value* 
SF-36 Scores 
Physical Function 77 (32) 70 (33) 81 (24) 12 (-25, 49) 0.42 
Role Physical 54 (51) 38 (49) 58 (49) 28 (-68, 124) 0.46 
Bodily Pain 59 (32) 43 (31) 68 (32) 33 (-14, 79) 0.12 
General Health 59 (25) 59 (25) 51 (15) -11 (-39, 18) 0.36 
Vitality 59 (24) 48 (25) 62 (24) 19 (-19, 57) 0.23 
Social Function 67 (35) 58 (35) 81 (13) 23 (-21, 67) 0.21 
Role Emotional 50 (55) 33 (52) 67 (42) 37 (-63, 138) 0.36 
Mental health 59 (28) 62 (26) 82 (18) 20 (-16, 55) 0.20 
PAC-QOL Assessment 
 
Physical discomfort 0.5 (0.5) 2.0 (1.3) 0.9 (1.1) -1.2 (-3.9, 1.6) 0.31 
Psychosocial discomfort 0.4 (0.5) 1.5 (1.0) 0.5 (0.8) -1.1 (-3.3, 1.1) 0.24 
Worries & concerns 0.5 (0.3) 0.6 (0.9) 0.6 (0.9) -1.1 (-3.2, 1.1) 0.24 
Satisfaction 0.8 (0.9) 2.5 (1.0) 1.0 (1.3) -1.6 (-4.3, 1.2) 0.20 
* P value calculated using linear regression 
 
 
Comparison between Original Baseline and Study Baseline Phases 
 
Only the generic  SF-36 quality of life questionnaires (202) were available for quality of life 
assessments at Original Baseline and comparisons were done between both of these 
phases. No evidence of any significant improvements in any of the parameters were 
observed.  (Table 25)  
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Table 25: Quality of Life Assessments between Original Baseline and Study Baseline   
Variable 
 
Study Baseline 
Mean (SD) 
OFF 
Mean (SD) 
ON 
Mean (SD) 
Mean 
(95% CI) 
P-value* 
SF-36 Scores 
Physical Function 56 (29) 77 (32) 21 (-13, 55) 0.18 56 (29) 
Role Physical 63 (34) 54 (51) -8 (-70, 53) 0.74 63 (34) 
Bodily Pain 34 (11) 59 (32) 25 (-12, 61) 0.15 34 (11) 
General Health 60 (19) 59 (25) -1 (-28, 26) 0.94 60 (19) 
Vitality 38 (14) 59 (24) 22 (-1, 44) 0.06 38 (14) 
Social Function 54 (26) 67 (35) 13 (-27, 52) 0.46 54 (26) 
Role Emotional 89 (27) 50 (55) -39 (-90, 13) 0.11 89 (27) 
Mental health 71 (23) 59 (28) -12 (-29, 5) 0.13 71 (23) 
* P value calculated using the paired t-test 
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7.8 - Discussion 
 
SNS for constipation is relatively new with only a few studies reported so far (88, 114, 116, 
236, 237) . The majority of these studies having have included only a few patients. 
Reported success rates for the temporary testing phase vary from 25 to 85% (88, 114-
116, 238) - lower than that for faecal incontinence. Reports of complications following 
permanent neurostimulator implant for constipation are scarce but one study suggested 
that 60% of patients experienced at least one reportable adverse event and that more than 
one-third of patients implanted required further surgical interventions or required  
discontinuation of therapy (92).Concerns have been raised regarding a placebo effect in 
constipation (90, 115). 
Our study highlights two observations: 
1) Patients had an improvement in symptoms of constipation when comparing the study 
baseline at a mean of six years post SNS implant to the original baseline prior to SNS 
implantation. This is the first report of long term data on SNS for constipation. 
2) Switching the device off for one month caused no appreciable loss of efficacy without 
any deterioration in patient symptoms compared to the on phase. All patients returned to 
study baseline symptoms when their devices were switched back on.  
Our study findings contrast to that of a similar but smaller crossover study for constipation 
done in 2002 in the same institution  by Kenefick et al  (118). However, there were only 2 
patients in that study and the patients were randomised to each arm of the study only for 2 
weeks. Furthermore these patients had only had the neurostimulator in place for a median 
of 12 months. Both patients involved in this study were also included in our crossover 
study as well. Kenefick et al showed that SNS had a strong positive impact on  improving 
constipation symptoms compared to both baseline and 1 year post permanent SNS with 
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the patients having a total loss of efficacy during the on phase (118). None of our study 
patients experienced a total loss of efficacy with return to original baseline constipation 
symptoms even after 1 month of having the neurostimulator switched off.  
Our study confirms the positive effect of SNS in constipation – shown by the improvement 
in the 6 year baseline symptoms compared to the original baseline and also by the change 
from slow to normal colonic transit studies in four of the six patients involved. This 
contrasts to Malouf et al who demonstrated no change in colonic transit even after 
successful neurostimulation(115). However, this study was done immediately post implant 
in comparison to our study which was done at a mean of 6 years post SNS implant.  
Possible explanations for our findings could be: 
1) The prolonged periods of neurostimulation in these patients may have precipitated 
chronic changes which may explain the change of slow colonic transit to normal transit in 
four of the six patients.  
2) It could be that continuous neurostimulation over a long duration may have “re-trained” 
the bowel to maintain normal motility even when the neurostimulator was switched off. 
This would explain why patients did not experience any significant symptom deterioration 
in the off phase compared to the on phase. This is further evidenced by the normal colonic 
transit studies in two study patients where no loss of motility was seen even with the SNS 
switched off. This contrasts to the available knowledge of neurostimulation and 
constipation which suggests that patient symptoms return to baseline immediately after 
removal of the temporary stimulation lead (115). 
3) SNS  for constipation may produce  a residual effect similar to that of tibial nerve 
stimulation and long periods of continuous neurostimulation may induce learning changes 
through neural plasticity (224). No such effect was observed at 1 year post implant by 
Kenefick et al in his study where both the patients became immediately constipated 
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following the device being switched off (118). It may be possible that periods of 
neurostimulation greater than 1 year could produce such an effect. 
4) A placebo effect for SNS in patients with constipation though unlikely also needs to be 
considered - this possibility has previously been raised (118). 
There is no doubt that a subgroup of patients with constipation may benefit from SNS. Our 
results also confirm the long term efficacy of this treatment. However, the lack of 
significant symptom differences between the on and off phases raises the possibility as to 
whether the SNS could in fact be safely switched off without any significant drop in patient 
symptoms. The same may hold true for SNS and faecal incontinence as there have been 
no double blinded crossover studies for SNS and FI on patients who have had the 
neurostimulator implant for more than 5 years. This contrasts to existing knowledge which 
suggests an immediate loss of efficacy once the neurostimulator is switched off (42, 118). 
Questioning the need for lifelong stimulation could have implications on the cost benefit for 
the device as leaving the device switched off for short periods of time can prolong the 
battery life of the implant. 
Whether the patients could gain permanent benefit (so the device will not be required) or 
whether our findings showed a residual carryover effect into the off phase where the 
patients would deteriorate with the neurostimulator device switched of over a prolonged 
period requires a much more detailed, larger study. 
 Our study has several strengths: 
1) All the patients recruited had undergone a successful 3 week trial phase for SNS 
followed by a functioning SNS for 6 consecutive years.  
2) Although the number of patients recruited was only six, this number was calculated on a 
50% improvement in score corresponding to a  seven unit change on the Wexner scale - 
as was required in the original score calculations by Agachan et al (205). 
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3) We used a period of one month for each arm in our study as previous studies 
suggested  no apparent delay in  patient response to having the neurostimulator switched 
on or off and thus would indicate a lack of residual effect on the bowel (42, 118).  
 
7.9 - Limitations of the Study  
 
Our study also had several limitations.  
1) The patient number in our study was small. Our study number calculation was based on 
a 50% improvement in Wexner scores for clinical significance - which required a change of 
seven units. It may be possible that a smaller reduction in the score may be sufficient to 
be clinically significant.  
2) Study of a larger parallel patient group where in one set of patients the device is on and 
another set it is off with a longer follow-up period to allow any possible carryover to wear 
off may be required before the true efficacy of this procedure is confirmed.  
 
7.10 - New knowledge this study had created 
 
This study has, for the first time shown that there was no loss of efficacy in the short term 
when the SNS was switched off in patients who have had the device for longer than five  
years. Our findings raise the possibility of long term neurostimulation causing bowel 
“retraining” or leaving a residual effect on the bowel – the exact duration of which remains 
to be identified. 
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7.11 - Scope for further research 
 
A similar study with a larger patient group could provide more evidence on what we have 
observed in our study.  A parallel patient group study with the neurostimulator device 
switched on in one group and off in the other group with a longer follow-up period could 
also shed more light on our observations.  
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Chapter 8 
 
Sacral nerve stimulation in the Elderly 
 
8.1 - Overview of the Chapter 
 
 
Several studies have reported the long term safety and efficacy of sacral nerve 
stimulation (SNS) (59, 76, 121) in faecal incontinence (FI) in the adult  population. FI 
in the elderly population (> 65 year age group) is underreported and can affect up to 
10% of people over the age of 65 years living at home and approximately 50% of 
nursing home residents over 65 years (11). There are no reports on the use of SNS 
for FI in the elderly.  In this chapter we present the findings of our study into the 
effects of SNS for FI in patients over 65 years. 
 
 
8.2 - Materials and Methods 
 
An analysis of prospectively collected data was performed on all patients over 65 
years who had undergone a three week peripheral nerve evaluation (PNE) for faecal 
incontinence, between January 1996 and December 2009. 
Eligible patients were asked to enter details of their bowel function before and after 
PNE in a bowel diary which was maintained for two consecutive weeks.  The  St 
Mark’s incontinence score (231), ability to defer defaecation (in minutes),  daily 
bowel movements and number of incontinent episodes per week were recorded. 
The Short Form 36 (SF-36) health survey questionnaire was given to  patients 
before and after treatment (202).  Anal manometry was performed using a stationary 
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pull-through technique with an eight channel water-perfused system (MMS, 
Enschede, Netherlands). Anal and rectal electrical sensation to electrical stimulation 
was recorded using a 1 cm bipolar ring electrode mounted on a 10 French catheter 
(Dantec 21L10, Neuromatic 2000 M/C current stimulator; Dantec Dynamics, Bristol, 
UK). 
Data were obtained at baseline and following PNE (45). Patients who had a greater than 
50% reduction in incontinent episodes during the PNE phase had a permanent 
neurostimulator implanted. They were assessed at 1, 3, 6 and 12 months following 
surgery and yearly thereafter. All adverse events were recorded. 
 
 
8.3 - Inclusion and Exclusion Criteria 
 
Inclusion criteria 
1) Signed informed consent  
2) Age 65 years or older  
3) Faecal incontinence of two or more episodes a week assessed by a three-week diary 
card.  
4) Failed biofeedback and medical therapy  
5) Competent and willing to fill in questionnaires  
 
Exclusion criteria 
1) Inflammatory bowel disease 
2) Chronic diarrhoea 
3) Rectal prolapse 
4) Stoma 
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5) Pilonidal sepsis 
6) A cloacal defect and other anatomical deformities which would prevent the 
successful insertion of an SNS electrode.  
 
8.4 - Ethical Permission 
 
Ethical permission to proceed with the study was granted by the Harrow Research 
Ethics Committee. Written informed consent was obtained from all patients after a 
detailed discussion of the procedure involved and before any investigation and 
treatment.  
 
8.5 - Statistical Analyses 
 
The first set of analyses compared the difference in outcomes between baseline and post-
temporary SNS. Normality of data was assessed using a histogram.   The paired t-test 
was used to compare the St. Marks score and the ability to defer defaecation – which 
were normally distributed.  
The Wilcoxon test was used to compare the number of incontinent episodes per week and 
the daily bowel movements- both of which were not normally distributed. 
The correlation between various factors and a successful SNS was assessed using the 
Chi2 and the Mann-Whitney U tests.  
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8.6 - Results 
 
Thirty (28 females) patients aged 65 years or more underwent PNE. Seventeen were 
between 65 and 70 years and 13 were over 70 years. 
The median duration of incontinence was 8 (2 -26) years. Three patients had urge 
incontinence only, seven had passive incontinence and 20 patients had both. Anal 
ultrasound showed 12 (40%) patients to have an external anal sphincter (EAS) defect 
and 10 (33%) an internal anal sphincter (IAS) defect. Eleven (37%) had had a 
previous sphincter repair. Nine had had other pelvic or perineal procedures within the 
previous 10 years including haemorrhoidectomy, sphincterotomy, transanal excision 
of a tumour and Delorme’s procedure. 
 
8.6.1 - Co-morbidities 
 
 
Three patients had associated asthma or bronchestiaisis and six had a history of 
cardiac disease including myocardial infarction, atrial fibrillation and other forms of 
arrhythmia. One patient was on anticoagulation treatment. Seven had a history of a 
previously malignancy. One had sarcoidosis and two had scleroderma. Only nine 
(39%) patients were healthy with no associated co morbidity. 
All 30 patients underwent temporary screening for three weeks. Seven (23%) showed 
no improvement and did not proceed to a permanent stimulation. Three (10%) had 
more than one temporary lead insertion due to lead displacement during the 
temporary testing phase. Twenty three patients underwent insertion of a permanent 
neurostimulator with no peri-operative complications in any case.  These included 13 
out of the 17 patients aged 65-70 years and 10 out of the 13 patients over 70 years. 
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8.6.2 - Complications and Follow up 
 
 
The median period of follow up was 44 (20 – 150) months. 
One patient required repositioning of the electrode at 36 months post permanent 
implant due to ipsilateral leg pain. Three patients lost efficacy and required re-
insertion of the permanent stimulating lead. Two of the three patients lost efficacy due 
to damage sustained to the permanent stimulating lead following use of monopolar 
diathermy during surgery for abdominal pathologies. The third patient lost efficacy due 
to an anterior migration of the stimulating lead. 
Two patients developed metastases from a previous malignancy; one of whom 
underwent surgical resection of an isolated liver lesion during which damage to the 
permanent stimulating electrode occurred (see above). The second patient was on 
palliative chemotherapy at the time of follow-up.  
One patient died of natural causes eight years after permanent lead insertion. Another 
experienced loss of efficacy four years after insertion and underwent contra lateral 
insertion of another electrode. This failed to improve symptoms and the device was 
removed one year later.  
Two patients had replacement of the battery at 82 and 42 months.  
 
8.6.3 - Continence Data 
 
 
Weekly Incontinence Episodes and Daily Bowel Movements 
 
 
Patients reported an improvement in the number of weekly episodes of faecal incontinence 
to solid or liquid stool and a reduction in the number of daily bowel movements during the 
duration of the temporary testing phase. This improvement was sustained post permanent 
implant and also at the latest follow-up (Table 26).  
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Table 26: Faecal Incontinence Episodes Pre and Post SNS 
Variable 
Baseline 
Median (IQR) 
Subsequent 
Median (IQR) 
Difference 
Median (95% CI) 
P-value* 
     
Incontinent Episodes     
     
Post-temporary SNS 10 (7, 14) 1 (0, 5) -8 (-10, -6) <0.001 
Post-permanent SNS (3 month) 10 (8, 14) 2 (0, 5) -8 (-10, -5) <0.001 
Latest Follow-up 10 (8, 14) 0 (0, 6) -8 (-12, -4) <0.001 
     
Daily Bowel Movements     
     
Post-temporary SNS 3 (2, 6) 2 (2, 3) -1 (-3, -1) <0.001 
Post-permanent SNS (3 month) 4 (2, 6) 2 (2, 3) -2 (-3, -1) <0.001 
Latest Follow-up 4 (2, 6) 2 (2, 3) -2 (-3, -1) <0.001 
     
*P value calculated using the Wilcoxon matched-pairs test 
 
 
 
St Mark’s Scores and Ability to Defer Defaecation (minutes) 
 
 
Patients reported an improvement in their ability to defer defaecation during the 3 week 
trial phase and this improvement was sustained into the permanent implant phase and 
also at the latest follow-up as well. The St Mark’s continence scores also reflected a 
similar improvement (Table 27).  
 
Table 27: St Mark’s Scores and Ability to defer defaecation Pre and Post SNS 
Variable 
Baseline 
Mean (SD) 
Subsequent 
Mean (SD) 
Difference 
Mean (95% CI) 
P-value* 
     
St Mark’s Scores     
     
Post-temporary SNS 19.1 (3.2) 8.5 (3.4) -10.6 (-12.6, -8.7) <0.001 
Post-permanent SNS (3 month) 18.9 (3.1) 9.4 (3.4) -9.6 (-11.5, -7.6) <0.001 
Latest Follow-up 19.3 (3.3) 9.7 (3.7) -9.6 (-11.8, -7.3) <0.001 
     
Ability to Defer Defaecation(mts)     
     
Post-temporary SNS 1.3 (1.4) 7.5 (5.2) 6.2 (4.1, 8.2) <0.001 
Post-permanent SNS (3 month) 1.4 (1.5) 8.3 (5.0) 7.0 (5.0, 8.9) <0.001 
Latest Follow-up 1.4 (1.5) 7.9 (5.4) 6.6 (4.2, 8.9) <0.001 
     
*P value calculated using the paired t-test 
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Association of St Mark’s Scores with other Variables 
 
 
Additional analyses examined the association between the changes in St. Marks 
score from baseline to subsequent time points, with the equivalent change in other 
variables (Table 28).  
Results indicated a significant association between the changes in St. Mark’s score and 
the ability to defer during the time period between baseline and post temporary. There was 
a negative association between the two variables, suggesting that a decrease in St. Mark's 
score was associated with an increase in the ability to defer. There was no significant 
association between the change in St. Mark’s score and the number of incontinent 
episodes or the number of bowel movements during the same time period. There was no 
significant association between the change in the St. Mark's score and the change in other 
variables between baseline and post definite, or between baseline and latest follow-up. 
 
Table 28: Correlation of St Mark’s Scores with other variables Pre and Post SNS 
Time Variable Correlation Coefficient P-value* 
    
Baseline to Incontinent Episodes -0.07 0.75 
Post temporary Bowel Movements  0.18 0.43 
 Ability to defer -0.47 0.03 
    
Baseline to Incontinent Episodes  0.17 0.48 
Post permanent Bowel Movements  0.32 0.16 
 Ability to defer -0.09 0.72 
    
Baseline to Incontinent Episodes -0.17 0.48 
Latest follow-up Bowel Movements  0.40 0.08 
 Ability to defer  0.00 0.98 
    
*P value calculated using the Pearson correlation 
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8.6.4 - Anorectal Physiology Assessment 
Anorectal physiology assessments were carried out at baseline, post permanent SNS and 
at the latest follow-up period. 
 
Comparison of Assessments at Baseline and Post Permanent SNS  
Analysis of the results indicated a statistically significant change from baseline to post-
SNS for both urge and maximal tolerated volumes. For both variables there was a 
significant decrease from baseline to post-SNS. There was a mean reduction of 43 units 
over time for urge and a mean reduction of 39 units over time for maximal tolerated 
volumes. There was also non-significant tendency towards a reduction in the 5-second 
pressure from baseline to post-SNS.  No other significant changes over time were 
observed for the other outcomes (Table 29). 
 
Table 29: Anorectal Physiology assessments at Baseline and Post Permanent SNS 
Variable Baseline 
Mean (SD) 
Post-SNS 
Mean (SD) 
Difference 
Mean (95% CI) 
P-value* 
     
Resting pressure 25.2 (12.4) 29.8 (15.6) 4.5 (-2.3, 11.3) 0.17 
Peak squeeze pressure 45.9 (47.1) 48.7 (41.1) 2.8 (-21.3, 26.8) 0.81 
5 second Squeeze Pressure 34.2 (50.3) 16.5 (25.2) -17.8 (-35.7, 0.2) 0.05 
Involuntary Squeeze Pressure 45.8 (32.2) 50.5 (31.5) 4.8 (-18.6, 28.1) 0.66 
Anal canal length 3.04 (1.28) 2.42 (0.45) -0.62 (-1.33, 0.09) 0.08 
Threshold Volumes 46.1 (29.8) 32.2 (11.9) -13.9 (-31.7, 3.8) 0.11 
Urge Volumes 106 (38) 63 (24) -43 (-67, -19)   0.002 
Maximal tolerated  Volumes 156 (44) 118 (82) -39 (-73, -4) 0.03 
Variable Baseline 
Median (IQR) 
Post-SNS 
Median (IQR) 
Difference 
Median (95% CI) 
P-
value** 
     
Anal electro sensitivity 8.9 (6.8, 12.2) 7.0 (5.4, 16.0) -1.8 (-4.5, 5.9) 0.94 
Rectal electro sensitivity 11.8 (9.5, 30.8) 16.5 (14.1, 35.0) 3.4 (-13.7, 23.6) 0.16 
*   p value calculated using paired T test 
** p value calculated using the Wilcoxon matched-pairs test 
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Comparison of Assessments at Baseline and at the Latest Follow-up  
The results showed a similar pattern to those from the baseline to post-SNS. There was a 
significant reduction in both urge volumes and the maximal tolerated volumes from 
baseline to the latest follow-up. There were no other significant differences between 
baseline the latest follow-up point (Table 30). 
 
Table 30: Anorectal Physiology assessments at Baseline and Latest Follow-up 
Variable Baseline 
Mean (SD) 
Latest FU 
Mean (SD) 
Difference 
Mean (95% CI) 
P-value* 
Resting pressure 29.7 (14.3) 31.2 (17.1) 1.5 (-12.6, 15.6) 0.81 
Peak squeeze pressure 49.7 (47.1) 48.4 (40.7) -1.3 (-16.2, 13.6) 0.85 
5 second Squeeze Pressure 37.5 (56.7) 34.9 (40.4) -2.6 (-31.0, 25.8) 0.84 
Involuntary Squeeze Pressure 48.9 (32.7) 47.9 (27.8) -1.0 (-19.9, 17.9) 0.91 
Anal canal length 2.95 (0.37) 2.80 (0.63) -0.15 (-0.56, 0.26) 0.43 
Threshold Volumes 56.7 (44.2) 54.7 (47.5) -2.0 (-14.9, 10.9) 0.73 
Urge Volumes 122 (56) 90 (67) -33 (-60, -5) 0.03 
Maximal tolerated  Volumes 178 (62) 123 (68) -55 (-90, -19)   0.007 
Variable Baseline 
Median (IQR) 
Post-SNS 
Median (IQR) 
Difference 
Median (95% CI) 
P-value** 
Anal electro sensitivity 8.9 (7.0, 10.7) 8.9 (6.7, 12.1) -0.5 (-4.1, 6.3) 0.96 
Rectal electro sensitivity 16.2 (9.9, 31.0) 16.0 (11.4, 30.0) 2.0 (-4.4, 4.0) 0.77 
* p value calculated using paired T test 
** p value calculated using the Wilcoxon matched-pairs test 
 
 
8.6.5 - Short Form-36 Quality of Life (QOL) Analysis 
The SF-36 (202) QOL questionnaire showed improvement in seven out of the eight 
subsets when the latest visits were compared to baseline although these changes were 
not statistically significant (Table 31). 
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          Table 31: Short Form 36 General Health Quality of Life Subset Mean Scores  
 
Variable Time 
Baseline 
Mean (SD) 
Subsequent 
Mean (SD) 
Change 
Mean (95% CI) 
P-value * 
Physical function Post perm SNS 61 (27) 66 (24)  -5 (-20, 30) 0.60 
 Latest  visit 76 (27) 70 (30) -6 (-23, 11) 0.41 
      
Role physical Post perm SNS 45 (37) 45 (51) 0 (-38, 38) 1.00 
 Latest  visit 61 (35) 79 (37) 18 (-8, 44) 0.14 
      
Bodily pain Post perm SNS 75 (30) 71 (21) 4 (-20, 28) 0.63 
 Latest  visit 63 (22) 76 (31) 13 (-8, 35) 0.17 
      
General health Post perm SNS 62 (35) 62 (35) 0 (-8, 8) 1.00 
 Latest  visit 61 (29) 63 (30) 2 (-8, 12) 0.63 
      
Vitality Post perm SNS 37 (38) 53 (28) 16 (-10, 42) 0.16 
 Latest  visit 51 (36) 57 (30) 6 (-18, 31) 0.55 
      
Social function Post perm SNS 52 (32) 75 (27) 23 (-5, 39) 0.02 
 Latest  visit 78 (25) 80 (27) 2 (-17, 21) 0.82 
      
Role emotional Post perm SNS 53 (50) 47 (50) -6 (-38, 51) 0.70 
 Latest  visit 76 (42) 81 (26) 5 (-41, 50) 0.81 
      
Mental health Post perm SNS 42 (40) 62 (37) 20 (-1 , 23) 0.27 
 Latest  visit 62 (41) 73 (31) 11 (-25, 48) 0.47 
* P values calculated using paired t-test  
 
 
8.6.6 - Predictive Factors for a Successful Stimulation 
 
 
Assessments of the various study parameters were done to identify any positive 
predictive factors for a successful stimulation though the numbers studied were 
small. A lower stimulation voltage to obtain stimulation response was not associated 
with improved outcome (p=0.081).Interestingly, more than 1 attempt at PNE was not 
associated with a risk of failure (p=0.51). Evidence of anal sphincter trauma was not 
associated with a greater risk of failure (p=0.093). A longer duration of symptoms 
(p=0.19) or older age at presentation were not associated with a greater risk of 
failure.   
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8.7 - Discussion 
 
Over the next half century the proportion of the population aged more than 65 years 
worldwide is expected to double (193). With one out of every seven people over 65 
years projected to have some degree of faecal incontinence (194) the additional cost 
involved of their care will also increase. The cost of managing combined urinary and 
faecal incontinence has been estimated to be around AU$ 50 per 24 hours in a  
sub-acute care facility in an Australian study(239).  
The causes of incontinence in the elderly are multifactorial and are not clearly defined 
whereas in younger patients obstetric trauma accounts for many cases. Causes for FI 
in the elderly include medical conditions which can cause diminution in the muscular 
and neural control of the anus and rectum (240)  and a weakened external anal 
sphincter secondary to ageing . Chronic constipation and faecal impaction also can 
cause incontinence as can dementia. The presence of such non-gender related 
causes has been interpreted by some authors to explain a narrowing gender ratio of 
faecal incontinence with increasing age (241) although in the present study there was 
still a high predominance of females. This may have been due to the fact that the 
present series did not include institutionalized patients.  
Conservative treatments including biofeedback, help to improve sphincter strength and 
reduce incontinence episodes by up to 75% (242), but there will still be patients who do 
not respond to this treatment. For such patients, SNS should be the next available 
treatment option. The opportunity of rapid assessment by PNE should encourage the 
use of this treatment in the older patient who has not responded to conservative therapy 
allowing those unlikely to benefit to be rapidly excluded (186). Although a study had 
pointed to the success of PNE being less in the elderly population compared to the 
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younger age group (159), we have found a 77% success for PNE in our study- 
comparable to results of PNE from other published series of SNS. 
The absence of any significant short term or long term complications and the maintained 
long term effectiveness as evidenced in our study further support its effectiveness. 
Fracture and dislodgement of the stimulating lead is a known complication following 
SNS (55, 63, 100) and occurred in 4 (17%) of the patients in our study group. 
Damage to the stimulating lead during unrelated surgery is a potential risk following 
SNS (243). Surgical procedures are more likely to be carried out on older patients 
compared to the younger population for unrelated pathologies and care should be taken 
during patient handling as well as during surgical procedures and using diathermy to 
avoid inadvertent damage to the permanent stimulating lead (243).  
All the patients in our study were motivated, mobile and mentally capable. The role of 
SNS in elderly patients with dementia or those who are wheel chair bound has not 
been defined as SNS depends largely on the ability of the patient to regulate the 
settings to achieve optimal continence. This study deals with a selected group of 
elderly patients and SNS may not therefore be applicable to those in institutions. 
 
8.8 - New knowledge this study has created 
For the first time the effectiveness and long term outcomes of SNS as a treatment for 
FI in patients older than 65 years is described in this study. Despite the fact that over 
half of the patients in our study had some associated co morbidity, the complication 
rate following SNS was similar to that seen in younger patients. 
These results should pave the way for SNS being offered as a routine treatment for FI 
in the elderly patients who fail to improve with conservative measures and 
biofeedback. 
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Chapter 9 
 
Scope for Further Research 
 
9.1 - Pudendal Nerve Stimulation 
 
Our study explores the role of PNS in two groups of patients with bowel dysfunction 
(complete CES and failed SNS) in whom SNS in unlikely to work or has failed to work. 
The results that we have found are encouraging and could hold promise as a new 
treatment for such patients. 
Our study has been a pilot study with few patient numbers and a relatively short follow-up 
to date. There exists the need for a larger multicentre study with a longer patient follow-
up to confirm our findings. 
 
9.2 - New Technique of Pudendal Nerve Stimulation 
 
The new technique for stimulating the pudendal nerve has been effective in all our 
patients with complication rates comparable to SNS. An independent assessment will be 
needed to further validate our new approach to PNS. 
 
9.3 - Tibial nerve stimulation in Faecal Incontinence 
 
The randomised controlled study that we carried out was adequately powered and robust 
though the numbers of patients involved were relatively small. Our findings suggest that 
the efficacy of the percutaneous approach to PTNS is more effective than the 
transcutaneous approach. The efficacy of PTNS which we found comparable to SNS in 
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the short term raises the possibility of PTNS being offered as an alternative to SNS in a 
selected group of patients. 
We highlight the need for a larger multicentre randomised trial to further support our 
findings.  
 
9.4 - Sacral Nerve Stimulation in Constipation 
 
Our double blinded study of SNS in constipation raises the possibility of a residual effect 
of SNS as we could not find any significant deterioration in symptoms even with the 
neurostimulator switched off. The number of patients that we recruited into our study was 
small though sufficiently powered.  
There exists the need for a larger study with more patient numbers and a longer OFF 
interval to see whether the residual effects of neurostimulation that we found does last for 
a longer period of time.  
 
9.5 - Sacral Nerve Stimulation in the Elderly 
 
Our study into the safety and efficacy of SNS in the elderly population suggests that SNS 
has a good long term efficacy with complication rates comparable to other age groups.  
This may further substantiate the regular use of SNS as a treatment for FI in the elderly 
who fail to respond to conservative measures. 
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Chapter 10 
 
Study Device Descriptions 
 
10.1 - General Description  
All Medtronic devices that were used in this clinical study had the CE mark and are 
commercially available throughout Europe. Implantable devices used included:   
                                  Medtronic model 3550-18 Lead Introducer Kit  
                                  Medtronic model 3023 implantable pulse generator (IPG) 
                                  Medtronic model 3057 extension cable 
                                  Medtronic model 3093 tined quadripolar electrode lead 
 
Each of these devices is discussed in the following sections. 
 
 
10.2 - Test Stimulation Devices  
 
 
10.2.1 - Model 3550-18 Lead Introducer Kit  
 
The model 3550-18 lead introducer kit contains the equipment required to insert the 
model 3093 lead correctly. It includes the lead introducer which can be divided into two 
components - a plastic introducer sheath in which is placed a rigid dilator that is 
secured in place using a locking mechanism at the proximal end of the device (Figure 
28). This has a central lumen that can be passed over a bi-directional guide wire. The 
guide wire is positioned in proximity to the nerve by being passed through a model 
041828 foramen needle after percutaneous evaluation.   
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Figure 28: Lead introducer with plastic sheath and rigid metal dilator 
 
 
 
 
 
The introducer kit includes two 9cm foramen needles (Model 041828) (Figure 29) 
which is covered in a parylene coating over a portion of the cannula for electrical 
isolation. Depth markers at one centimetre graduations allow depth of insertion to be 
ascertained. 12.5cm needles are also available separately for use in larger patients.  
Other items in the kit include two (Model 041826) ground pads used to return the 
electrical path during unipolar stimulation and a (Model 041831) patient cable which 
terminates at one end to a pin socket which mates with a long auxiliary screener cable 
and at the other end to a spring-actuated clip used for attaching the cable to the 
foramen needle or quadripolar lead (Figure 30). 
The power is supplied by an external pulse generator-Medtronic external 
neurostimulator (Model 3625).                                                                                     
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Figure 29: Model 041828 20 G Foramen Needle 
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Figure 30: Test Stimulation Kit 
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10.3 - Permanent Stimulation Devices  
 
 
10.3.1 - Permanent Stimulation Leads (Model 3889 and 3093)                 
  
There are two commercially available Medtronic stimulation lead kits- model 3889 and 
3093. However, in our study the lead used was only the model 3093 lead for reasons 
described below. 
These two leads are indicated for the management of chronic intractable disorders of 
the pelvis and lower urinary or intestinal tract. No changes to these leads were required 
for their use in these clinical investigations. Both lead models are provided sterile and 
are manufactured by Medtronic. Both leads are quadripolar in-line leads. The Model 
3889 lead contains four cylindrical electrodes equal in length and spaced equidistantly 
(3 mm each spaced 3mm apart) (Figure 3).  
The Model 3093 lead is the same as the Model 3889 lead except that electrode 1 (the 
electrode second from the distal end) is a coiled electrode approximately three times 
longer (10 mm) than the other three cylindrical electrodes which are 3 mm each. The 
electrodes on the 3093 lead lie in closer proximity with reduced spacing (1.5 mm apart) 
allowing greater surface contact with the nerve being stimulated (Figure 31). 
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Figure 31: Model 3093 stimulation lead 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marker bands       
C & D 
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Both leads have small barbs (tines) and marker bands A - D. The tines anchor the lead, 
and the marker bands indicate lead depth and tine deployment during percutaneous 
implantation with a Medtronic lead introducer (Model 3550). Marker bands C and D can 
be seen visually, while marker bands A and B can be seen under fluoroscopy.                                                                                            
The leads are designed to be connected via a percutaneous extension to a Medtronic 
external neurostimulator (Model 3625) or with an in-line connector (Model 3057) to an 
implantable pulse generator- the Interstim I (Model 3023) or the smaller new generation 
Interstim II (Model 3058).                                                                                                                              
The sterile package contains:  
One quadripolar lead (with inserted long stylet)  
One hex wrench 
One stylet: short (snaps onto lead)   
One silicone rubber connecting boot  
One stainless-steel tunnelling tool, tunnelling tip and fluoropolymer tube  
One twist-lock screening cable  
One percutaneous extension (and tunnelling tubing)  
The lead and accessories contained in the lead kit are intended for single use only. 
  
10.3.2 - Model 3095 Extension Cable  
 
A model 3095 extension is used to connect the lead to the Interstim Model 3023 IPG. 
One end of the extension terminates to an in-line connector for connection to the 
proximal end of either the 3889 or 3093 tined quadripolar electrode lead. The remaining 
end terminates in a two-pin connector for connection to the Interstim IPG. The 
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extension is comprised of four separate MP35N conductors, covered with medical 
grade silicone rubber. Though several extension lengths are available, in our study the 
10cm length was used. The extension kit includes the accessories needed for 
implanting the extension and for connection to the lead and IPG. The physician manual 
packaged with the extension explains the implantation procedures. 
 
 
10.3.3 - Interstim Model 3023 Implantable Pulse Generator (IPG)  
 
 
The Interstim Model 3023 IPG (Figure 32) or the smaller new generation Interstim II 
(Model 3058) (Figure 33) is the electrical power source for neurostimulation therapy. 
The IPG is implanted in the ipsilateral buttock to the implanted quadripolar lead, either 
on the left or right. The IPG is capable of delivering electrical stimulation pulses with a 
variety of parameters, modes and polarities. The IPG is powered by a hermetically 
sealed lithium chloride single cell-battery and utilizes a hermetically sealed, integrated 
circuit. To further protect the neurostimulator components from bodily fluids, the 
electronics and power source are hermetically sealed within an oval-shaped titanium 
shield. The IPG case has an external insulating coating to prevent skeletal muscle 
stimulation at the implant site. An un-insulated area on the etched side can be used as 
an indifferent anode and should be positioned away from muscle tissue.  
The Interstim IPG is commercially available in Europe and is identical to the Medtronic 
Model 7425 Itrel 3 IPG which is FDA approved for spinal cord stimulation for pain. The 
Interstim 3023 fully complies with the European Directive AIMD 90/385/EEC bearing the 
CE mark reference I7971217834282.  
The stimulation parameters of the implanted Interstim IPG can be non-invasively set 
and adjusted to optimize the therapy outcome for each patient. Initial parameters and 
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adjustments are made by radiofrequency (RF) telemetry from the Model 8840 physician 
programmer. The programmer’s programming head is placed over the site of the IPG, 
and can send and receive information by RF to and from the IPG. Model 3023 IPGs, 
when properly reviewed by the programmer, are capable of providing telemetry data 
transmissions such as model and serial number identification, total stimulation time, 
number of patient activations and lead impedance. The Interstim IPG can be 
programmed to provide stimulation with a wide range of parameters. The stimulation 
parameters that were used in this study were as follows:  
Pulse amplitude :  0-10 volts ( < 5 volts expected) 
Pulse frequency : 5-30 Hz (expected 14 Hz) 
Pulse width : 90-450µsec (expected 210µsec) 
Pulse mode : Continuous (with soft start) 
Daily usage : A maximum of 24 hours per 24 hour period 
The precise parameters need to be adjusted for each patient to optimize the response 
to stimulation.  
Because the Interstim IPG is battery powered, it has a finite life and must be surgically 
replaced when the battery becomes depleted. The implant time before replacement is 
determined by the stimulation parameters used and the number of hour it is used daily. 
It is expected that the Interstim IPG system used in this study will have an implant life of 
around 6-8 years based on expected stimulation parameters and estimated daily usage.  
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Figure 32: Model 3023 Interstim I Neurostimulator 
 
 
 
 
 
 
 
 
 
 
Figure 33: Model 3058 Interstim II Neurostimulator 
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10.3.4 - 3031 Patient Programmer  
 
 
The Interstim model 3031 patient programmer is a handheld, battery operated 
programmer used by patients to non-invasively monitor and control their implanted 
Interstim IPG. When the programmer is placed over the implanted IPG, patients can 
turn the IPG ON or OFF, increase/decrease the amplitude of stimulation within 
physician-set limits, or check the battery status of the IPG via RF telemetry. An optional 
antenna (Model 7440) can be used with the patient programmer when the IPG is in a 
location that is difficult for the patient to reach. Patients use four control buttons located 
on the top of the programmer to monitor and control their implanted IPG. Light 
indicators on the bottom of the programmer provide visual feedback on whether the IPG 
has received the transmission and an audible beep can also be enabled to confirm 
communication. The programmer has a unique access code so that it can be used to 
program only an Interstim Model 3023 IPG.  
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